<SEC-DOCUMENT>0001193125-21-328795.txt : 20211115
<SEC-HEADER>0001193125-21-328795.hdr.sgml : 20211115
<ACCEPTANCE-DATETIME>20211115061022
ACCESSION NUMBER:		0001193125-21-328795
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211115
DATE AS OF CHANGE:		20211115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Benitec Biopharma Inc.
		CENTRAL INDEX KEY:			0001808898
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39267
		FILM NUMBER:		211406074

	BUSINESS ADDRESS:	
		STREET 1:		3940 TRUST WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 780-0819

	MAIL ADDRESS:	
		STREET 1:		3940 TRUST WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d230065d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:bntc="http://www.benitecbiopharmainc.com/20210930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form 10-Q</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P07_01_2021To09_30_2021">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="hidden29143025" contextRef="P07_01_2021To09_30_2021">84-4620206</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P07_01_2021To09_30_2021">2022</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P07_01_2021To09_30_2021">Q1</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P07_01_2021To09_30_2021">0001808898</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P07_01_2021To09_30_2021">--06-30</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="bntc-20210930.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_15_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2021To08_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-01</xbrli:startDate> <xbrli:endDate>2021-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecBiopharmaProprietaryLimitedBblMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_BenitecBiopharmaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecBiopharmaProprietaryLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >bntc:LabEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >bntc:LabEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_LicenseMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis" >us-gaap:TransferredOverTimeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_06_2020To10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-06</xbrli:startDate> <xbrli:endDate>2020-10-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_06_2020To10_06_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-06</xbrli:startDate> <xbrli:endDate>2020-10-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_06_2020To10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-06</xbrli:startDate> <xbrli:endDate>2020-10-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-10-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_06_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-10-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-10-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2021To04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-30</xbrli:startDate> <xbrli:endDate>2021-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2021To04_30_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-30</xbrli:startDate> <xbrli:endDate>2021-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div><div style="background-color:white;display: inline;"><div style="margin-top: 0pt; font-weight: bold; font-size: .83em; margin-bottom: 1.67em"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">WASHINGTON, D.C. 20549 </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P07_01_2021To09_30_2021">10-Q</ix:nonNumeric></div> </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">(Mark One) </div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="P07_01_2021To09_30_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P07_01_2021To09_30_2021" format="ixt:datemonthdayyearen">September 30, 2021</ix:nonNumeric> </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P07_01_2021To09_30_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></td></tr></table><div style="margin-top: 24pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the transition period from <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div> to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;</div><div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"> </div></div> </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Commission File Number <ix:nonNumeric name="dei:EntityFileNumber" contextRef="P07_01_2021To09_30_2021"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-39267</div></ix:nonNumeric> </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 24pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P07_01_2021To09_30_2021">BENITEC BIOPHARMA INC.</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Exact name of registrant as specified in its charter) </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2021To09_30_2021" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden29143025">84-462</span>-0206</div></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">incorporation or organization)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(IRS Employer</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Identification No.)</div></div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P07_01_2021To09_30_2021">3940 Trust Way</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P07_01_2021To09_30_2021">Hayward</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P07_01_2021To09_30_2021" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P07_01_2021To09_30_2021">94545</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices&#160;&amp; zip code) </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P07_01_2021To09_30_2021">510</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P07_01_2021To09_30_2021">780-0819</ix:nonNumeric></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Registrant&#8217;s telephone number including area code) </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:33%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Title of each class</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Trading</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Symbol(s)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Name of each exchange</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">on which registered</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P07_01_2021To09_30_2021">Common Stock, par value $0.0001</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P07_01_2021To09_30_2021">BNTC</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P07_01_2021To09_30_2021" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></div></div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 <div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">days.&#160; &#160;&#160;</div></div><ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P07_01_2021To09_30_2021">Yes</ix:nonNumeric><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P07_01_2021To09_30_2021">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:20%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:20%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:2%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;white-space:nowrap">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#9744;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#9744;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;white-space:nowrap"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P07_01_2021To09_30_2021" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">&#9746;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P07_01_2021To09_30_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;white-space:nowrap">Emerging&#160;growth&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P07_01_2021To09_30_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744; or&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P07_01_2021To09_30_2021" format="ixt:booleanfalse">&#9746;</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We had <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn11_15_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,171,690</ix:nonFraction> shares of our common stock outstanding as of the close of business on November 15, 2021. </div><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div><div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">BENITEC BIOPHARMA INC. </div><div id="toc" style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">INDEX TO FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:8%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:88%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#tx230065_1">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#tx230065_2">PART I-FINANCIAL INFORMATION</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ITEM&#160;1.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><a href="#tx230065_3">Financial Statements (unaudited)</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#tx230065_4">Consolidated Balance Sheets as of September&#160;30, 2021 (Unaudited) and June&#160;30, 2021</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#tx230065_5">Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended September&#160;30, 2021 and 2020 (Unaudited)</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#tx230065_6">Consolidated Statements of Stockholders&#8217; Equity for the Three Months Ended September&#160;30, 2021 and 2020 (Unaudited)</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#tx230065_7">Consolidated Statements of Cash Flows for the Three Months Ended September&#160;30, 2021 and 2020 (Unaudited)</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#tx230065_8">Notes to Consolidated Financial Statements (Unaudited)</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ITEM&#160;2.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><a href="#tx230065_9">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ITEM&#160;3.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><a href="#tx230065_10">Quantitative and Qualitative Disclosures About Market Risk</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ITEM&#160;4.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><a href="#tx230065_11">Controls and Procedures</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#tx230065_12">PART <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">II-OTHER</span> INFORMATION</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ITEM&#160;1.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><a href="#tx230065_13">Legal Proceedings</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ITEM&#160;1A.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><a href="#tx230065_14">Risk Factors</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ITEM&#160;2.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><a href="#tx230065_15">Unregistered Sales of Equity Securities and Use of Proceeds</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ITEM&#160;3.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><a href="#tx230065_16">Defaults Upon Senior Securities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ITEM&#160;4.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><a href="#tx230065_17">Mine Safety Disclosures</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ITEM&#160;5.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><a href="#tx230065_18">Other Information</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ITEM&#160;6.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><a href="#tx230065_19">Exhibits</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="3" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#tx230065_20">SIGNATURES</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="tx230065_1" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Report contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. Our forward-looking statements relate to future events or our future performance and include, but are not limited to, statements concerning our business strategy, future commercial revenues, market growth, capital requirements, new product introductions, expansion plans and the adequacy of our funding. All statements, other than statements of historical fact included in this Report, are forward-looking statements. When used in this Report, the words &#8220;could,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;continue,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; or the negative of these terms, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the risks and uncertainties that may cause our actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements include the following: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the success of our plans to develop and potentially commercialize our product candidates; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the timing of the initiation and completion of preclinical studies and clinical trials; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the timing and sufficiency of patient enrollment and dosing in any future clinical trials; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the timing of the availability of data from clinical trials; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the timing and outcome of regulatory filings and approvals; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">unanticipated delays; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">sales, marketing, manufacturing and distribution requirements; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">market competition and the acceptance of our products in the marketplace; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">regulatory developments in the United States of America; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the development of novel AAV vectors; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the plans of licensees of our technology; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a &#8220;one shot&#8221; cure; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">our dependence on our relationships with collaborators and other third parties; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors, including our capital structure; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">our intellectual property position and the duration of our patent portfolio; </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the impact of local, regional, and national and international economic conditions and events; and </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">current&#160;COVID-19&#160;pandemic,</div> the disease caused by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;SARS-CoV-2&#160;virus,</div></div> which may adversely impact our business and preclinical and future clinical trials; </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as well as other risks detailed under the caption &#8220;Risk Factors&#8221; in this Report and in other reports filed with the SEC. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Report, we caution you that these statements are based on a combination of facts and important factors currently known by us and our expectations of the future, about which we cannot be certain. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have based the forward-looking statements included in this Report on information available to us on the date of this Report or on the date thereof. Except as required by law we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including annual reports on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K,&#160;quarterly</div> reports <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on&#160;Form&#160;10-Q&#160;and</div> current reports <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on&#160;Form&#160;8-K.</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All forward-looking statements included herein or in documents incorporated herein by reference are expressly qualified in their entirety by the cautionary statements contained or referred to elsewhere in this Report. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="tx230065_2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I &#8211; FINANCIAL INFORMATION </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx230065_3" style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Statements </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENITEC BIOPHARMA INC. </div></div></div></div><div id="tx230065_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except par value and share amounts) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,727</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,769</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other receivables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid and other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">642</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">814</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,372</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,608</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deposits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">169</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">185</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">947</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">202</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,836</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,379</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities and Stockholders&#8217; Equity</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,106</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">880</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">276</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,601</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,369</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, less current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">760</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,361</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,369</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and contingencies (Note 12)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; equity:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn06_30_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value&#8212;<ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,171,690</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2021 and June&#160;30, 2021, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">151,854</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">151,583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">135,164</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">130,119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,455</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,010</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders&#8217; equit<div style="display:inline;">y</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,836</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,379</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div></div><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc"></a></div></div></div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENITEC BIOPHARMA INC. </div></div></div></div> <div id="tx230065_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations and Comprehensive Loss </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share and per share amounts) </div></div></div></div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenues from customers</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total revenues</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Royalties and license fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:RoyaltiesAndLicenseFees" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:RoyaltiesAndLicenseFees" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">134</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,780</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">774</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,042</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,822</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,745</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,822</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (loss):</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency transaction loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">240</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gain on investment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other loss, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">223</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,045</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,718</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized foreign currency translation gain</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total comprehensive loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,806</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,540</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,045</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,718</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares outstanding:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,171,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,108,374</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div> </div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENITEC BIOPHARMA INC. </div></div></div></div> <div id="tx230065_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Stockholders&#8217; Equity </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share amounts) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217;</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loss</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at June&#160;30, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,108,374</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">128,826</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">116,636</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,953</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of share-based payments</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P07_01_2020To09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation gain</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2020To09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,718</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,718</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at September&#160;30, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,108,374</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">128,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">119,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,775</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,736</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENITEC BIOPHARMA INC. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Stockholders&#8217; Equity </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share amounts) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217;</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loss</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at June&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,171,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">151,583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">130,119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,455</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,010</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation gain</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2021To09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,045</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,045</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,171,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">151,854</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">135,164</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </div> </div> </div> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div> </div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENITEC BIOPHARMA INC. </div></div></div></div> <div id="tx230065_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities:</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,045</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,718</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AmortizationOfRightOfUseAssets" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AmortizationOfRightOfUseAssets" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on investment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">374</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IncreasedecreaseInAccountsAndOtherPayables" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="bntc:IncreasedecreaseInAccountsAndOtherPayables" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="bntc:IncreaseDecreaseInLeaseLiabilities" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="bntc:IncreaseDecreaseInLeaseLiabilities" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">46</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,278</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,360</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from investing activities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">173</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in investing activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">173</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effects of exchange rate changes on cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net decrease in cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,042</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,351</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents, beginning of period</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,769</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents, end of period</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,727</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental disclosure of cash flow information:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of operating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lease&#160;right-of-use&#160;assets</div></div> and liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div> </div> </div> </div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div id="tx230065_8" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> <ix:nonNumeric name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Business </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (the &#8220;Company&#8221;) is a corporation formed under the laws of Delaware, United States of America, on November&#160;22, 2019 and listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;BNTC&#8221;. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#8220;BBL&#8221;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April&#160;15, 2020. On August&#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&#8217;s business focuses on the development of novel genetic medicines. Our proprietary platform, called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DNA-directed</div> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with<div style="display:inline;">&#160;</div>gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended June&#160;30, 2021, the Company completed an organization res<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div>ructuring as part of the commercial desire to provide a more efficient structure for the future as the Company continues to transition its operations to the US. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s fiscal year end is June 30. References to a particular &#8220;fiscal year&#8221; are to our fiscal year end June&#160;30 of that calendar year. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="bntc:ScheduleOfEntitiesInControlTableTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principal&#160;place&#160;of</div></div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">business/country&#160;of</div></div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">incorporation</div></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2021To09_30_2021_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">Australia</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Australia Proprietary Limited</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2021To09_30_2021_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">Australia</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Limited</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2021To09_30_2021_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">United Kingdom</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2021To09_30_2021_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec LLC</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2021To09_30_2021_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">RNAi Therapeutics, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2021To09_30_2021_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tacere Therapeutics, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2021To09_30_2021_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec IP Holdings, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2021To09_30_2021_BenitecBiopharmaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true" continuedAt="TextSelection_29131176"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Basis of Presentation and Summary of Significant Accounting Policies </div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s consolidated financial statements contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with generally accepted accounting principles in the U.S. (&#8220;GAAP&#8221;)&#160;for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of U.S. Securities and Exchange Commission &#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended June&#160;30, 2021. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. </div></ix:nonNumeric> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><ix:continuation id="TextSelection_29131176" continuedAt="TextSelectionAppend_29131176_1"> <ix:nonNumeric name="bntc:RisksAndUncertainitiesPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with<div style="display:inline;">&#160;</div>government regulations and the need to obtain additional financing to fund operations. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;current&#160;COVID-19&#160;pandemic,&#160;which</div> is impacting worldwide economic activity, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented or inhibited from conducting business activities for an indefinite period of time which may <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">delay&#160;the&#160;start-up&#160;and&#160;conduct</div> of the Company&#8217;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#8217;s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company&#8217;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s functional currency and reporting currency is the United States dollar. BBL&#8217;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive loss.&#8221; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other comprehensive income for all periods presented includes only foreign currency translation gains. </div></ix:nonNumeric> </ix:continuation> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><ix:continuation id="TextSelectionAppend_29131176_1" continuedAt="TextSelectionAppend_29131176_2"> <ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures its financial assets and liabilities in accordance with US&#160;GAAP using ASC 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements.</div></div> For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:6%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</td></tr></table></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2021, and June&#160;30, 2021, the Company had <ix:nonFraction name="bntc:FinancialAssetsAtFairValue" contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="bntc:FinancialAssetsAtFairValue" contextRef="PAsOn09_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> financial assets or liabilities measured at fair value on a recurring basis. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade and Other Receivables </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </div></ix:nonNumeric> </ix:continuation> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:continuation id="TextSelectionAppend_29131176_2" continuedAt="TextSelectionAppend_29131176_3"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective<div style="display:inline;">&#160;</div>accounts, and any gain or loss is included in operations. <ix:nonNumeric name="bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true" continuedAt="TextSelection_29131278">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives:</ix:nonNumeric> </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelection_29131278"> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 85%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 28%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 71%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Software</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2021To09_30_2021_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2021To09_30_2021_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">4</ix:nonNumeric></div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2021To09_30_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2021To09_30_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">7</ix:nonNumeric></div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2021To09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P07_01_2021To09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P07_01_2021To09_30_2021_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">shorter of the lease term or estimated useful lives</ix:nonNumeric></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div></div> </ix:continuation></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div></ix:nonNumeric> <ix:nonNumeric name="bntc:TradeAndOtherPayablesPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade and other payables </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </div></ix:nonNumeric> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:continuation id="TextSelectionAppend_29131176_3" continuedAt="TextSelectionAppend_29131176_4"> <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and Diluted Net Loss Per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of September&#160;30, 2021, and June&#160;30, 2021, there were <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">809,159</ix:nonFraction></ix:nonFraction> potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true" continuedAt="TextSelection_29131191"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue in accordance with that core principle by applying the following steps: </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606 &#8211; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (&#8220;ASC 606&#8221;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing revenues </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div></ix:nonNumeric> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div></div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:continuation id="TextSelectionAppend_29131176_4" continuedAt="TextSelectionAppend_29131176_5"><ix:continuation id="TextSelection_29131191"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of products occur. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Services revenue </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expense </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being that the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. </div></div></ix:nonNumeric> </ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a><br/></div><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div></div></div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><ix:continuation id="TextSelectionAppend_29131176_5"> <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based Compensation Expense </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Compensation</div></div>. ASC 718 requires the fair value of all share-based compensation awarded to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation at fair value using the Black-Scholes Option Pricing Model. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to Australia and United States income tax laws. The Company follows ASC 740 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Income Taxes</div></div>, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13:</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments &#8211; Credit Losses</div></div> (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November&#160;15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates</div></div> amended the effective date for the Company to be for reporting periods beginning after December&#160;15, 2022. The Company will adopt this ASU effective July&#160;1, 2023. </div></ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="bntc:GoingConcernDisclosureTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true" continuedAt="TextSelection_29131168"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Going Concern </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the three months ended September&#160;30, 2021, and 2020, the Company incurred a net loss of $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.0</ix:nonFraction>&#160;million and&#160;$<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.7</ix:nonFraction>&#160;million and used net cash of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.4</ix:nonFraction>&#160;million in operations, respectively. The Company expects to continue to incur additional operating losses in the foreseeable future. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2021, the Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">15.7</ix:nonFraction>&#160;million in cash and cash equivalents. The Company has performed a review of the cash flow forecasts and believes that the current funding will be sufficient for a period of at least twelve months from the date of this Report. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a>&#160;</div></div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div><ix:continuation id="TextSelection_29131168"> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s ability to continue as a going concern is dependent upon its ability to generate revenue and obtain adequate financing. While the Company believes in its ability to generate revenue and raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>going concern due to unsuccessful product development or commercialization, or the inability to obtain adequate financing in the future. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Revenue </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div> <ix:nonNumeric name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:73%">&#160;</td>
<td style="vertical-align:bottom;width:11%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:11%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenues from customers (US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Months</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ended<br/> September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Months</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ended<br/> September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing revenue from services transferred overtime</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2020To09_30_2020_LicenseMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Cash and Cash equivalents </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:76%">&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash at Bank</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DueFromBanks" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,727</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DueFromBanks" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,769</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,727</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,769</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:OtherAssetsDisclosureTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Prepaid and other assets </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:77%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">763</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">967</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Security deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Market value of listed shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:MarketValueOfListedShares" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:MarketValueOfListedShares" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">811</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">169</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">185</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">642</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">814</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Property and equipment, net </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,328</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,329</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer hardware</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, gross</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,392</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,393</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated depreciation and amortization</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,069</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,018</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, net</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense was $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>&#160;million for the three months ended September&#160;30, 2021, and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P07_01_2019To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">45</ix:nonFraction>&#160;thousand, respectively, for the <div style="letter-spacing: 0px; top: 0px;;display:inline;">same</div> period in 2020. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Trade and other payables </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade payable</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued license fees</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedLicenceFeesCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedLicenceFeesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">99</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued&#160;<div style="text-indent: 0px;;display:inline;">OPMD project costs</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedOpmdProjectCostsCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">351</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedOpmdProjectCostsCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">279</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accrued bonuses</div></div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="text-align: right;">&#160;<div style="display:inline;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">112</ix:nonFraction></div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right;"><div style="white-space: nowrap;;display:inline;">&#160;&#8212;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; width: 76%; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other payables</div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">174</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,106</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">880</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true" continuedAt="TextSelection_29131248"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Leases </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into an operating lease for office space under an agreement that expires in 2022. The lease requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company&#8217;s lease does not contain any residual value guarantees or material restrictive covenants. During August 2021, the Company extended the lease thr<div style="letter-spacing: 0px; top: 0px;;display:inline;">o</div>ugh <ix:nonNumeric name="bntc:OperatingLeaseMonthOfMaturityRevised" contextRef="P08_01_2021To08_31_2021" format="ixt:datemonthyearen">June 2025</ix:nonNumeric>. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables below show the changes during the three months ended September&#160;30, 2021: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true" continuedAt="TextSelection_29131249">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-</div></div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">use assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2021</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">202</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">49</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 88%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset at September&#160;30, 2021</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">947</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 88%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div></div></div></div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <ix:continuation id="TextSelection_29131248"><ix:continuation id="TextSelection_29131249">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:RemeasurementOfLeaseLiabilitiesDuringThePeriod" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">954</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">760</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2021, the Company&#8217;s operating lease has a<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>remaining lease term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn09_30_2021" format="ixt-sec:duryear">3.71</ix:nonNumeric> years and a discount rate of <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="PAsOn09_30_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">4.67</ix:nonFraction>%. The maturities of the operating lease liabilities are as follows: &#160;</div> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:85%">&#160;</td>
<td style="vertical-align:bottom;width:11%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2021</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">235</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">287</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">297</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">228</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease payment<div style="display:inline;">s</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">954</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded lease liabilities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease assets for the lease based on the present value of lease payments over the expected lease term, discounted using the Company&#8217;s incremental borrowing rate. Rent expense was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction>&#160;million for the three months ended September&#160;30, 2021 and 2020, respectively, of which $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2020To09_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></ix:nonFraction>&#160;thousand was recorded in the general and administrative expense and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2020To09_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">45</ix:nonFraction></ix:nonFraction>&#160;thousand was record in research and development expenses. </div> </ix:continuation></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true" continuedAt="TextSelection_29131292"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Stockholders&#8217; equity </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;6, 2020, the Company announced the closing of an underwritten public offering of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P10_06_2020To10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,666,644</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">3.10</ix:nonFraction> per share. The Company also announced that the underwriter fully exercised its over-allotment option to purchase <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P10_06_2020To10_06_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">483,870</ix:nonFraction> additional shares of its common stock at the offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn10_06_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">3.10</ix:nonFraction> per share. The gross and net proceeds were $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P10_06_2020To10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P10_06_2020To10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">9.9</ix:nonFraction>&#160;million, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;30, 2021, the Company announced the closing of an underwritten public offering of&#160;<ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P04_30_2021To04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,036,366</ix:nonFraction>&#160;shares of its common stock at a price to the public of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">4.25</ix:nonFraction>&#160;per share. The Company also announced that the underwriter exercised the over-allotment option to purchase&#160;<ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P04_30_2021To04_30_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">317,274</ix:nonFraction>&#160;additional shares of its common stock at the offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn04_30_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">4.25</ix:nonFraction>&#160;per share. The gross and net proceeds were $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P04_30_2021To04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">14.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P04_30_2021To04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">12.7</ix:nonFraction>&#160;million, respectively. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;6, 2020, the Company announced the closing of an underwritten public offering of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P10_06_2020To10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">559,162</ix:nonFraction> shares of common stock underlying <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants initially purchased for $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">3.09</ix:nonFraction> per share and immediately exercisable at $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction> per share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Pre-Funded</div> Warrants&#8221;). All <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn06_30_2021_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">559,162</ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants issued had been exercised as of June&#160;30, 2021. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activity related to warrants during for the three months ended&#160;September 30, 2021,&#160;is summarized as follows: </div> <ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><br/>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Common&#160;Stock<br/> from Warrants</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted-<br/> average<br/> Exercise&#160;Price<br/> (per share)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding-top: 0pt; line-height: normal;">Outstanding at July&#160;1, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">107,095</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" contextRef="PAsOn06_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">10.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding-top: 0pt; line-height: normal;">Outstanding and exercisable at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">107,095</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" contextRef="PAsOn09_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">10.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div> </div> </div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <ix:continuation id="TextSelection_29131292" continuedAt="TextSelectionAppend_29131292_1"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Incentive Plan </div></div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Employee Share Option Plan </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> the Company assumed BBL&#8217;s obligations with respect to the settlement of options that were issued by BBL prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> pursuant to the Benitec Officers&#8217; and Employees&#8217; Share Option Plan (the &#8220;Share Option Plan&#8221;). This includes the Company&#8217;s assumption of the Share Option Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>exercise their options or the options are cancelled. After the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> no new options have been or will be issued under the Share Option Plan. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Equity and Incentive Compensation Plan </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;9, 2020, the Company&#8217;s stockholders approved the Company&#8217;s 2020 Equity and Incentive Compensation Plan (the &#8220;2020 Plan&#8221;). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are outstanding under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company&#8217;s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on each anniversary of the applicable grant date for three years. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> director options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on the day prior to each of the Company&#8217;s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 12 months to exercise their options or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 90 days to exercise their options or the options are cancelled. Any future equity grants will be made under the 2020 Plan. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Equity Awards </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to equity awards, which are comprised of stock options during the three months&#160;ended September&#160;30, 2021,&#160;is summarized as follows: </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px;"></div> <ix:nonNumeric name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 92%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:59%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Stock<br/> Options</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted-<br/> average<br/> Exercise<br/> Price</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted-<br/> average<br/> Remaining<br/> Contractual&#160;Term</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Aggregate<br/> Intrinsic&#160;Value</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">702,064</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">7.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P07_01_2020To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">8.07</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">702,064</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">7.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P07_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">7.82</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">54,158</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">47.90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P07_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.84</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Unaudited) </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <ix:continuation id="TextSelectionAppend_29131292_1"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Share-Based Compensation Expense </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The classification of share-based compensation expense is summarized as follows:</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"></div> <ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:83%">&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">81</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2020To09_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">190</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2020To09_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of&#160;September 30, 2021, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>&#160;million of unrecognized share-based compensation expense related to stock options issued under the Share Option Plan and the 2020 Plan. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Income taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three months ended September&#160;30, 2021, and 2020, the Company did not recognize a provision or benefit for income taxes as it has incurred net losses. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is more likely than not that the benefit will not be realized. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Commitments and contingencies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract commitments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Related party transactions </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended September&#160;30, 2021, the Company had entered into a related party transaction with Francis Abourizk Lightowlers for legal fees totaling $<ix:nonFraction name="us-gaap:LegalFees" contextRef="P07_01_2021To09_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction>&#160;thousand. Peter Francis, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> director of the Company is a partner at Francis Abourizk Lightowlers. As of September&#160;30, 2021 and June&#160;30, 2021 there were amounts due to this related party of $<ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction> thousand and $<ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction> thousand, respectively, included in trade and other payables on the accompanying consolidated balance sheet. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P07_01_2021To09_30_2021" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Subsequent events </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through the filing of this Quarterly Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-Q,</div> and determined that there have been no events that have occurred that would require adjustments or disclosures in the consolidated financial statements.</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"></div> </div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="tx230065_9" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">You should read the following discussion and analysis of financial condition and operating results together with our consolidated financial statements and the related notes and other financial information included elsewhere in this document. </div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Overview </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We endeavor to become the leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet medical need via the application of the silence and replace approach to the treatment of genetic disorders. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (&#8220;Benitec&#8221; or the &#8220;Company&#8221; or in the third person, &#8220;we&#8221; or &#8220;our&#8221;) is a development-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DNA-directed</div> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and life-threatening clinical indications including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> is the most advanced ddRNAi-based genetic medicine currently under development by Benitec. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> is an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AAV-based</div> gene therapy designed to both silence the expression of mutated, disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and simultaneously replace the mutant genes with normal, &#8220;wild type&#8221; genes (to drive restoration of function in diseased cells). This fundamental therapeutic approach to disease management is called &#8220;silence and replace&#8221; and this biological mechanism offers the potential to restore the underlying physiology of the treated tissues and, in the process, improve treatment outcomes for patients suffering from the chronic and, potentially, fatal effects of Oculopharyngeal Muscular Dystrophy (OPMD). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> has been granted Orphan Drug Designation in the United States and the European Union. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through the combination of the targeted gene silencing effects of RNAi and the durable transgene expression achievable via the use of modified viral vectors, the silence and replace approach has the potential to produce long-term silencing of disease-causing genes along with simultaneous replacement of wild type gene function following a single administration of the proprietary genetic medicine. We believe this novel attribute of the investigational agents under development by Benitec may facilitate the achievement of robust clinical activity while greatly reducing the dosing frequencies traditionally expected for medicines employed for the management of chronic diseases. Additionally, the achievement of long-term gene silencing and gene replacement may significantly reduce the risk of patient <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> during the course of medical management of potentially fatal clinical disorders. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation</div> </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;15, 2020, (the &#8220;Implementation Date&#8221;), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;re-domiciliation&#160;of</div> Benitec Biopharma Limited (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Re-domiciliation&#8221;),</div> a public company incorporated under the laws of the State of Western Australia, or BBL, was completed in accordance with the Scheme Implementation Agreement, as amended and restated as of January&#160;30, 2020, between BBL and us. As a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;Re-domiciliation,&#160;the</div> jurisdiction of incorporation was changed from Australia to Delaware, and BBL became our wholly owned subsidiary. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">The&#160;Re-domiciliation&#160;was</div> effected pursuant to a statutory scheme of arrangement under Australian law, or the Scheme, whereby on the Implementation Date, all of the issued and outstanding ordinary shares of BBL were exchanged for newly issued shares of our common stock, on the basis of one share of our common stock, par value $0.0001 per share, for every 300 ordinary shares of BBL issued and outstanding. Holders of BBL&#8217;s American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of our common stock for every three ADSs held. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19&#160;has</div> been declared a pandemic by the World Health Organization and has spread to nearly every country, including Australia and the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to businesses and capital markets around the world. The extent to which the coronavirus impacts us will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and its variants, and the actions to contain the coronavirus or treat its impact, including the effectiveness and adoption of vaccines for the virus, among others. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our research and development efforts are conducted globally, including the ongoing development of our silence and replace therapeutic for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), and will be dependent upon our ability to initiate preclinical and clinical studies despite the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ongoing&#160;COVID-19&#160;pandemic.</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we continue to actively advance our preclinical programs, including our ongoing Toxicology and Biodistribution study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for&#160;BB-301,&#160;we</div> are in close contact with our principal investigators and preclinical trial sites, which are primarily located in France, and are assessing the impact <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;COVID-19&#160;on</div> our studies and the expected development timelines and costs, on an ongoing basis. In light of developments relating to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;global</div> pandemic since the beginning of the outbreak, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s industry guidance for conducting clinical trials, we have experienced delays to the original timeline regarding the initiation and anticipated completion of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ongoing&#160;BB-301</div> Clinical Trial Application (CTA)-enabling and Investigational New Drug Application (IND)-enabling&#160;development work. The initiation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;BB-301&#160;Pilot</div> Dosing Study in Beagle dogs, which represents a key component of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CTA-enabling</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;IND-enabling&#160;work,</div> was delayed by several months, however, the study has been completed without incident. The acquisition of chemical reagents, biological reagents and laboratory supplies which are essential for the conduct of basic laboratory research, nonclinical studies and GMP manufacturing of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301,</div> has also become challenging due to the disruption of global supply chains inherent to the production of these materials. We will continue to evaluate the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic</div> on our business and expect to reevaluate the timing of our anticipated preclinical and clinical milestones as we learn more and the impact <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;COVID-19&#160;on</div> our industry becomes clearer. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also implemented a rotation system whereby staff work from home and attend the laboratory on designated days which may result in a reduction of laboratory work and a halt <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;non-essential&#160;business</div> travel. As we transition our employees back to our premises, there is a risk <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">that&#160;COVID-19&#160;infections</div> occur at our offices or laboratory facilities and significantly affect our operations. Additionally, if any of our critical vendors are impacted, our business could be affected if we become unable to timely procure essential equipment, supplies or services in adequate quantities and at acceptable prices. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Nonclinical Programs </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Our Pipeline </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our current product candidates and their development status: </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Table 1. Pipeline: Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B Virus Infection </div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g230065g1103070755124.jpg"/> </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> is under development for the treatment of Oculopharyngeal Muscular Dystrophy and is currently undergoing evaluation in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CTA-enabling</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-enabling</div> studies. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> is the lead pipeline program for Benitec, and the key attributes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> are outlined in in Figure 3. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Figure 3. Overview of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Program </div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g230065g1103070755608.jpg"/> </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-class</div></div> genetic medicine employing the &#8220;silence and replace&#8221; approach for the treatment of OPMD. OPMD is an insidious, autosomal-dominant, late-onset, degenerative muscle disorder that typically presents in patients at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">40-to-50</div></div> years of age. The disease is characterized by progressive swallowing difficulties (dysphagia) and eyelid drooping (ptosis). OPMD is caused by a specific mutation in the poly(A)-binding protein nuclear 1 gene (PABPN1). OPMD is a rare disease, however, patients have been diagnosed with OPMD in at least 33 countries. Patient populations suffering from OPMD are well-identified, and significant geographical clustering has been noted for patients with this disorder, which could simplify clinical development and global commercialization efforts. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PABPN1 is a ubiquitous factor that promotes the interaction between the poly(A) polymerase and CPSF (cleavage and polyadenylation specificity factor) and, thus, controls the length of mRNA poly(A) tails, mRNA export from the nucleus, and alternative poly(A) site usage. The characteristic genetic mutation underlying OPMD results in trinucleotide repeat expansion(s) within exon 1 of PABPN1 and results in an expanded poly-alanine tract at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">N-terminal</div> end of PABPN1. The mutation generates a protein with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">N-terminal</div> expanded poly-alanine tract of up to 18 contiguous alanine residues, and the mutant protein is prone to the formation of aggregates called intranuclear inclusions (INIs). The INIs that sequester wildtype PABPN1 could also contribute to loss of the function phenotype associated with OPMD. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, no therapeutic agents are approved for the treatment of OPMD. Additionally, no surgical interventions capable of altering the long-term natural history of OPMD are available. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> has received Orphan Drug Designation in the United States and the European Union which provides commercial exclusivity independent of intellectual property protection. While OPMD is a rare disorder, we believe the commercial opportunity for a safe and efficacious therapeutic agent in this clinical indication exceeds $1&#160;billion over the course of the commercial life of the product. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec has previously outlined the core <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CTA-enabling</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-enabling</div> studies required by global regulatory agencies to support the initiation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> clinical trials in OPMD patients, and these studies include a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Pilot Dosing Study (the &#8220;Pilot Dosing Study&#8221;) in large animals and a classical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> GLP Toxicology and Biodistribution Study. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> is directly injected into the pharyngeal muscles known to underlie the morbidity and mortality characterizing the natural history of OPMD. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Pilot Dosing Study is the first of two planned <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CTA-enabling</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-enabling</div> studies that were designed to be conducted in large animals. These studies continue to be carried out under the guidance of the scientific team at Benitec, with key elements of the study design and execution conducted in close collaboration with a team of leading experts in both medicine and surgery that have been deeply engaged in the treatment of OPMD patients for several decades. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Pilot Dosing Study, along with the subsequent GLP Toxicology and Biodistribution Study, will be conducted in canine subjects and will support the validation and optimization of the newly designed method of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> administration, confirm the efficiency of vector transduction and transgene expression in the key tissue compartments underlying the natural history of OPMD, confirm the optimal drug doses in advance of initiation of human clinical studies, and facilitate observation of key toxicological data-points. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Pilot Dosing Study was designed as an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-week</div> study in Beagle dogs to confirm the transduction efficiency of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> upon administration via direct intramuscular injection into specific anatomical regions of the pharynx through the use of an open surgical procedure. This new route of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> administration was developed in collaboration with key surgical experts in the field of Otolaryngology, and this novel method of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> dosing will significantly enhance the ability of a treating physician to accurately administer the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AAV-based</div> investigational agent to the muscles that underlie the characteristic deficits associated with the progression of OPMD. It is important to note that prior <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> have reproducibly validated the robust biological activity achieved following direct intramuscular injection. As an example, direct injection of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> into the tibialis anterior muscles of A17 mice facilitated robust transduction of the targeted skeletal muscle cells and supported complete remission of the OPMD disease phenotype in this animal model. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </div> </div> </div> </div> <div style="background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec conducted the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Pilot Dosing Study in Beagle dog subjects to demonstrate that direct intramuscular injection of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> via the use of a proprietary dosing device in an open surgical procedure could safely achieve the following goals: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Biologically significant and dose-dependent levels of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> tissue transduction (i.e., delivery of the multi-functional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> genetic construct into the target pharyngeal muscle cells); </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Broad-based and dose-dependent expression of the three distinct genes comprising the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> gene construct within the pharyngeal muscle cells; and </div> </td> </tr> </table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Durable and biologically significant levels of target gene knock-down (i.e., inhibition of the expression of the gene of interest) within the pharyngeal muscle cells. </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Pilot Dosing Study evaluated the safety and biological activity of two concentrations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> (1.0+E13 vg/mL and 3.0+E13 vg/mL) across three distinct doses (1.0+E13 vg/mL and 3.0+E13 vg/mL with a low injection volume, and 3.0+E13 vg/mL with a high injection volume) following direct intramuscular injection into the Hypopharyngeus (HP) muscles and the Thyropharyngeus (TP) muscles of Beagle dogs via the use of a proprietary delivery device employed in an open surgical procedure. The HP muscle in Beagle dogs corresponds to the Middle Pharyngeal Constrictor muscle in human subjects, and the TP muscle in Beagle dogs corresponds to the Inferior Pharyngeal Constrictor muscle in human subjects. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> was injected only on Day 1 of the Pilot Dosing Study, and the corresponding canine pharyngeal muscles were harvested for analysis after 8 weeks of observation post-dosing. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> dosing was carried out by both a veterinary surgeon and a practicing Otolaryngologist who has extensive experience with the provision of palliative surgical care for OPMD patients. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further data analyses are ongoing for the canine subjects treated in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Pilot Dosing Study, and the interim data-points highlighted here are derived from completed analyses of pharyngeal muscle tissues isolated from 16 Beagle dog subjects (of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-subject</div> study population). The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">data-set</div> derived from the Pilot Dosing Study and the formal conclusions will be updated as additional study subjects are analyzed. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key preliminary results are summarized here: </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Figure 4. Pharyngeal Muscle Tissue Transduction Levels for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> </div></div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g230065g1103070758718.jpg"/> </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regarding Gene Expression Levels Observed for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Within the Pharyngeal Muscle Tissues (Figure 5, Figure 6, Figure 7): </div></div></div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> encodes two distinct siRNA species (i.e., siRNA13 and siRNA17) which are each, independently, capable of inhibiting (i.e., &#8220;silencing&#8221;) the expression of the mutant form of the PABPN1 protein and the wildtype (i.e., endogenous) form of the PABPN1 protein (importantly, the mutant form of the PABPN1 protein underlies the development and progression of OPMD). </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> also codes for a wildtype version of the PABPN1 protein whose intracellular expression is unaffected by the inhibitory activities of siRNA13 and siRNA17, and this codon optimized PABPN1 protein (i.e., coPABPN1) serves to replenish the endogenous form of the PABPN1 protein and to replace the mutant form of PABPN1 that underlies the development and progression of OPMD in diseased tissues. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">For comparative purposes, is should be noted that the average range of expression for wild type PABPN1 within the pharyngeal muscle cells of Beagle dogs is 4.5 copies per <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cell-to-7.8</div></div> copies per cell. </div> </td> </tr> </table> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Figure 5. siRNA13 Expression Levels for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> within Pharyngeal Muscle Tissues </div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g230065g1103070759171.jpg"/> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Figure 6. siRNA17 Expression Levels for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> within Pharyngeal Muscle Tissues </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g230065g1103070759608.jpg"/> </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Figure 7. coPABPN1 Expression Levels for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> within Pharyngeal Muscle Tissues </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g230065g1103070800124.jpg"/> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Regarding WildType PABPN1 Silencing (i.e. target &#8220;knock-down&#8221;) Observed for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Within the Pharyngeal Muscle Tissues (Figure 8): </div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">As noted above, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> encodes two distinct siRNA species (i.e. siRNA13 and siRNA17) which are each, independently, capable of inhibiting (i.e., &#8220;silencing&#8221;) the expression of all forms of the PABPN1 protein (siRNA13 and siRNA17 silence the expression of both wildtype PABPN1 [wtPABPN1] and mutant PABPN1). </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal; text-indent: 0px;">While the Beagle dog subjects treated in the current BB-301 Pilot Dosing Study do not express mutant PABPN1, the level of BB-301-driven gene silencing for the PABPN1 target can be indirectly assessed due to the equivalent inhibitory effects of siRNA13 and siRNA17 on both wtPABPN1 and mutant PABPN1.&#160;<br/></div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Thus, the wtPABPN1 silencing activity observed in the current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Pilot Dosing Study serves as a surrogate for the activity that would be anticipated in the presence of mutant PABPN1. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> has been evaluated in prior <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies in animals that express mutant PABPN1 and, as a consequence, manifest the key signs and symptoms of OPMD; in these animal models of OPMD, the achievement of PABPN1 silencing levels of 31% inhibition or higher led to complete resolution of OPMD disease symptoms and correction of the histological hallmarks of OPMD. </div> </td> </tr> </table> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Figure 8. PABPN1 Silencing (i.e. &#8220;target knock-down&#8221;) within Pharyngeal Muscle Tissues </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g230065g1103070800546.jpg"/> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, it is critical to highlight the key methodological distinctions between the current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Pilot Dosing Study conducted by Benitec as compared to the prior <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Beagle dog dosing study carried out independently by the previous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> licensee. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> dosing study conducted by the prior <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> licensee employed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-ideal</div> routes and methods of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> administration to the target pharyngeal muscle tissues and employed similarly limited analytical methods at the completion of the dosing phase of the study. The Benitec team worked to optimize the route and method of administration of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> and to refine the core analytical methods employed following the completion of dosing. </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;">The newly developed proprietary methods of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> delivery, as well as the analytical methods developed to assay the key target tissues of the Beagle dog subjects, led to the observation of broad-based transduction of the pharyngeal muscle target tissues (<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Figure 9</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">individual sections of the TP muscle following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> dosing</div></div>) and demonstrated a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">228-fold</div> improvement (+22,647%) in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> transduction of the HP muscle and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">113-fold</div> improvement (+11,163%) in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> transduction of the TP muscle relative to the levels of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> transduction observed by the previous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> licensee (<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Figure 10</div></div>). </div> </div> </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Figure 9. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Transduction Levels Achieved for Individual Sections of the TP Muscle Following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> dosing </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g230065g1103070800905.jpg"/> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Figure 10. Impact of Benitec-Initiated Methodological Improvements to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Large Animal Study Design on the Relative Pharyngeal Muscle Tissue Transduction Levels Achieved </div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt;margin-bottom:0pt;text-align:center">
<img alt="LOGO" src="g230065g1103070801374.jpg"/> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the disclosure of the positive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Pilot Dosing Study data, Benitec completed a Scientific Advice meeting with The National Agency for the Safety of Medicines and Health Products in France (L&#8217;Agence nationale de s&#233;curit&#233; du m&#233;dicament et des produits de sant&#233; or &#8220;ANSM&#8221;) in the first half of 2021. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">The Scientific Advice meeting was conducted to review and confirm the adequacy of: </div></div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> data derived from the evaluation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> in both the murine <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">proof-of</div> concept studies and the Pilot Dosing study in Beagle dogs </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The experimental, analytical, and statistical methods comprising the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> GLP Toxicology and Biodistribution study in Beagle dogs </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The large-scale manufacturing plan for clinical grade <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> drug product for use in the Phase 1b/2a clinical study in OPMD patients </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The design of the Phase 1b/2a clinical study slated for initiation in 2022 </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Pilot Dosing Study was viewed as an appropriate dose range finding study. The preliminary data derived from the Pilot Dosing Study regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> pharyngeal muscle tissue transduction, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> transgene expression, and the resulting knock-down of wild type PABPN1 supported the adequacy of the data derived from this study to inform the choice of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> doses for use in the GLP Toxicology and Biodistribution Study. The design of the GLP Toxicology and Biodistribution study was viewed as appropriate to support <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-human</div></div> testing of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301.</div> Pending the final results of the ongoing GLP Toxicology and Biodistribution study, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Pilot Dosing Study data and the murine <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">proof-of-concept</div></div> study data are sufficient to inform the choice of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> drug doses employed in the upcoming Phase 1b/2a study. As <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> drug product has been reproducibly manufactured at large-scale in the past, the manufacturing plan for clinical grade <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> drug product can be conducted under GMP conditions with a production process analogous to that that employed in prior large-scale production runs. Finally, the design of the Phase 1b/2a clinical trial can support the evaluation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> safety and clinical efficacy in key populations of OPMD patients. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding our regulatory interactions with the FDA, Benitec has been granted a Type C meeting in the fourth quarter of 2021. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding our regulatory interactions with Health Canada, Benitec has been granted a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-CTA</div> meeting in the fourth quarter of 2021. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec continues to plan for the initiation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">First-in-Human</div></div> clinical study of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> in OPMD patients in 2022. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-103</div> </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-103</div> has demonstrated robust nonclinical activity during the evaluation of this agent for the treatment of Chronic Hepatitis B Virus infection. Benitec is currently seeking strategic partners to advance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-103</div> through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-enabling</div> studies. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Royalties, milestone payments and other license fees </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are required to pay royalties, milestone payments and other license fees in connection with our licensing of intellectual property from third parties, including as discussed below. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have collaborated with Biomics Biotechnologies Co., Ltd., or Biomics, pursuant to several collaboration agreements in relation to single-stranded RNA and shRNA sequences for treatment of hepatitis B. In July 2015, we entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">an&#160;earn-out&#160;agreement</div> with Biomics which confirmed Benitec&#8217;s ownership of certain patents resulting from the collaboration in exchange for an upfront payment and equity issuance to Biomics and a share of certain future licensing revenue received by Benitec. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s functional currency and reporting currency is the United States dollar. BBL&#8217;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive loss.&#8221; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income for all periods presented includes only foreign currency translation gains. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">October 2020 Capital Raise </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;6, 2020, the Company announced the closing of an underwritten public offering of common stock and common stock equivalents. The Company received gross proceeds of approximately $11.5&#160;million and net proceeds of approximately $9.9&#160;million from the offering. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">April 2021 Capital Raise </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;30, 2021, the Company announced the closing of an underwritten public offering of common stock and common stock equivalents. The Company received gross proceeds of approximately $14.3&#160;million and net proceeds of approximately $12.7&#160;million from the offering. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Results of Operations </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has not generated any revenues from the sales of products. Revenues from licensing fees and interest income are included in the revenue from customers line item on our statements of operations and comprehensive loss. Our licensing fees have been generated through the licensing of our ddRNAi technology to biopharmaceutical companies. The following table sets forth a summary of our revenues for each of the periods set forth below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Three&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues from customers</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues from customers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended September&#160;30, 2021 and 2020, respectively, the Company recognized $0 and $0.1&#160;million in customer revenues. The decrease in revenues from customers is due to the decrease in licensing and royalty revenues in the current period. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties and License Fees </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Royalties and license fees consist primarily of payments we are required to remit for royalties and other payments related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to&#160;in-licensed&#160;intellectual</div> property. Under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">our&#160;in-license&#160;agreements,</div> we may <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pay&#160;up-front&#160;fees</div> and milestone payments and be subject to future royalties. We cannot precisely predict the amount, if any, of royalties we will owe in the future, and if our calculations of royalty payments are incorrect, we may owe additional royalties, which could negatively affect our results of operations. As our product sales increase, we may, from time to time, disagree with our third-party collaborators as to the appropriate royalties owed, and the resolution of such disputes may be costly, may consume management&#8217;s time, and may damage our relationship with our collaborators. Furthermore, we may enter into additional license agreements in the future, which may also include royalty, milestone and other payments. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expenses relate primarily to the cost of conducting clinical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;pre-clinical&#160;trials.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical&#160;and</div> clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and Administrative Expenses </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses consist primarily of salaries, related benefits, travel, and equity-based compensation expense. General and administrative expenses also include facility expenses, professional fees for legal, consulting, accounting and audit services and other related costs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We anticipate that our general and administrative expenses may increase as the Company focuses on the continued development of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> OPMD program. The Company also anticipates an increase in expenses relating to accounting, legal and regulatory-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and other costs associated with being a domestic public company after the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables set forth a summary of our expenses for each of the periods set forth below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Three&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Expenses:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalties and license fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">774</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,837</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,822</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended September&#160;30, 2021 and 2020, respectively, we incurred $0 and $0.1&#160;million in royalties and license fees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the three months ended September&#160;30, 2021 and 2020, respectively, we incurred $2.8&#160;million and $0.8&#160;million in research and development expenses. The increase in research and development expenses is primarily related to the commencement of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> Regulatory Toxicology Study in Beagles at Charles River Laboratories in Evreux, France. As planned, the Company began incurring more costs related to the execution of two large nonclinical studies in Beagles, along with the commercial-scale <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GMP-grade</div> manufacturing of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301,</div> all of which is required to facilitate the CTA filing and the IND filing for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> in 2022. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expense was $2.0&#160;million and $1.8&#160;million for the three months ended September&#160;30, 2021 and 2020. The increase for the three month period was due to the small increases in insurance, consultants, legal and accounting fees. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Income (Expense) </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables set forth a summary of our other income (loss) for each of the periods set forth below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Three&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Income (Loss):</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency transaction loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(240</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(54</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other loss, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(223</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The other loss, net during the three months ended September&#160;30, 2021 and 2020, respectively, totaled $0.2&#160;million and $28&#160;thousand, which consists of foreign currency transaction loss, interest expense, other income, and unrealized gain on investment. Foreign currency transaction gain has increased due to a change in foreign exchange rates. Other income, net decreased due to&#160;no longer receiving <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19&#160;stimulus</div> incentives from the Australian government in 2021. Unrealized gain on investment had a minor increase for the three months ended September&#160;30, 2021, compared to the three months ended September&#160;30, 2020. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has incurred cumulative losses and negative cash flows from operations since our predecessor&#8217;s inception in 1995. The Company had accumulated losses of $135.2&#160;million as of September&#160;30, 2021. We expect that our research and development expenses may increase due to the continued development of the OPMD program. It is also likely that there will be an increase in the general and administrative expenses due to the obligations of being a domestic public company in the United States as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;Re-domiciliation.</div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We had no borrowings as at September&#160;30, 2021 and do not currently have a credit facility. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2021, we had cash and cash equivalents of approximately $15.7&#160;million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our cash and cash equivalents are held in bank accounts. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of the net cash flow activity for each of the periods set forth below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Three&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(173</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effects of exchange rate changes on cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">236</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net decrease in cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,351</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating activities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities for the three months ended September&#160;30, 2021 and 2020 was $4.3&#160;million and $2.4&#160;million, respectively. Net cash used in operating activities was primarily the result of our net loss and change in working capital and a decrease in payables. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing activities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities for the three months ended September&#160;30, 2021 and 2020 was $0 and $0.2&#160;million, respectively. The change was primarily related to a decrease in purchases of equipment in 2021 as there were none compared to purchases of $0.2&#160;million in the same period of 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The future of the Company as an operating business will depend on its ability to manage operating costs and budgeted amounts and obtain adequate financing. While we continue to progress discussions and advance opportunities to engage with pharmaceutical companies and continue to seek licensing partners for ddRNAi in disease areas that are not our focus, there can be no assurance as to whether we will enter into such arrangements or what the terms of any such arrangement could be. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While we have established some licensing arrangements, we do not have any products approved for sale and have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize one of our current or future product candidates. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless and until we establish significant revenues from licensing programs, strategic alliances or collaboration arrangements with pharmaceutical companies, or from product sales, we anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of product candidates and begin to prepare to commercialize any product that receives regulatory approval. We are subject to the risks inherent in the development of new gene therapy products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We estimate that our cash and cash equivalents will be sufficient to fund the Company&#8217;s operations at least for the next twelve months. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing and costs of our planned clinical trials for our ddRNAi and silence and replace product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing and costs of our planned preclinical studies for our ddRNAi and silence and replace product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the number and characteristics of product candidates that we pursue; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the outcome, timing and costs of seeking regulatory approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">revenue received from commercial sales of any of our product candidates that may receive regulatory approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the extent to which we need <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to&#160;in-license&#160;or</div> acquire other products and technologies. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual Obligations and Commercial Commitments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;1, 2016, the Company entered into an operating lease for office space in Hayward, California that originally expired in April 2018. The Company has entered into lease amendments that extend the lease commitment through June 2025. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-Balance&#160;Sheet</div> Arrangements </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company had no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">material&#160;off-balance&#160;sheet</div> arrangements as of September&#160;30, 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies and Significant Accounting Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The preparation of consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make judgments, assumptions and estimates that affect the amounts reported. Note 2 of the Notes to Consolidated Financial Statements included in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> describes the significant accounting policies used in the preparation of the consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting policies. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A critical accounting policy is defined as one that is both material to the presentation of the Company&#8217;s consolidated financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on the Company&#8217;s financial condition or results of operations. Specifically, these policies have the following attributes: (1)&#160;the Company is required to make assumptions about matters that are highly uncertain at the time of the estimate; and (2)&#160;different estimates the Company could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on the Company&#8217;s financial condition or results of operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimates and assumptions about future events and their effects cannot be determined with certainty. The Company bases its estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as the Company&#8217;s operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. In addition, management is periodically faced with uncertainties, the outcomes of which are not within its control and will not be known for prolonged periods of time. These uncertainties are discussed in the section above entitled &#8220;Risk Factors.&#8221; Based on a critical assessment of its accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that the Company&#8217;s consolidated financial statements are fairly stated in accordance with accounting principles generally accepted in the United States of America and provide a meaningful presentation of the Company&#8217;s financial condition and results of operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management believes that the following are critical accounting policies: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expense </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based Compensation Expense </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company records share-based compensation in accordance with ASC 718,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Stock Compensation</div></div>. ASC 718 requires the fair value of all share-based employee compensation awarded to employees <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;non-employees</div> to be&#160;recorded as an expense over the shorter of the service period or the vesting period. The Company values employee <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;non-employee&#160;share-based</div> compensation at fair value using the Black-Scholes Option Pricing Model. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting Standards recently adopted </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">New Accounting Standards and Interpretations not yet mandatory or early adopted </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ASU</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;2016-13</div></div></div>&#8212;In June 2016, the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU&#160;No.&#160;2016-13:&#160;&#8220;</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses</div></div>&#160;(Topic 326)&#8221;. This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November&#160;15, 2019. As such, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU&#160;2019-10:&#160;&#8220;</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates&#8221;</div></div>&#160;amended the effective date for the Company to be for reporting periods beginning after December&#160;15, 2022. The Company will adopt this ASU effective July&#160;1, 2023. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx230065_10" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a smaller reporting company, we are not required to provide the information pursuant to this Item. </div></div> <div id="tx230065_11" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4. Controls and Procedures </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have established disclosure controls and procedures (as defined in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rules&#160;13a-15(e)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(e)</div> under the Securities Exchange Act of 1934, as amended). As of the end of the period covered by this Report we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;13a-15</div> of the Securities and Exchange Act of 1934, as amended. Based upon that evaluation, our principal executive officer and principal financial and accounting officer concluded that our disclosure controls and procedures are effective. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no changes in our internal controls over financial reporting during the quarter ended September&#160;30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx230065_12" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">OTHER INFORMATION </div></div></div> <div id="tx230065_13" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1. Legal Proceedings </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are currently not a party to any material legal proceedings. </div></div> <div id="tx230065_14" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1A. Risk Factors </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">There have been no material changes to the risk factors disclosed in Item 1A of the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended June&#160;30, 2021. </div> <div id="tx230065_15" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div id="tx230065_16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3. Defaults Upon Senior Securities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div id="tx230065_17" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4. Mine Safety Disclosures </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div id="tx230065_18" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;5. Other Information </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx230065_19" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;6. Exhibits. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 90%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;">Number</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Description of Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;31.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d230065dex311.htm">Statement of CEO Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;31.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d230065dex312.htm">Statement of CFO Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;32.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d230065dex321.htm">Statement of CEO Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002** </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;32.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d230065dex322.htm">Statement of CFO Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002** </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.INS</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Instance Document*</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Schema Document*</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Calculation Linkbase Document*</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Definition Linkbase Document*</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Label Linkbase Document*</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Presentation Linkbase Document*</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File &#8211; the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed herewith. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furnished, not filed. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx230065_20" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 47%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 6%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 45%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Benitec Biopharma Inc.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Dated: November 15, 2021</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Megan Boston</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Megan Boston<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Executive Director (principal financial and accounting officer)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Jerel Banks</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Jerel Banks</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Chairman and Chief Executive Officer</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(principal executive officer)</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d230065dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 31.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statement Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Principal Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regarding Facts and Circumstances Relating to Exchange Act Filings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">I, Jerel Banks,<B> </B>certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma
Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November 15, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jerel Banks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Chairman and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d230065dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 31.2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statement Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Principal Financial Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regarding Facts and Circumstances Relating to Exchange Act Filings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">I, Megan Boston,<B> </B>certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma
Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this<B> </B>report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November 15, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Megan Boston</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Executive Director (principal
financial and accounting officer)</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d230065dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 32.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statement Pursuant to Section&nbsp;906 the Sarbanes-Oxley Act of 2002 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>By </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Principal Executive
Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regarding Facts and Circumstances Relating to Exchange Act Filings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated: November 15, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">I,
Jerel Banks, Chief Executive Officer of Benitec Biopharma Inc., hereby certify, to my knowledge, that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. the accompanying Quarterly
Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma Inc. for the three month period ended September&nbsp;30, 2021 (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a) or 15(d), as
applicable, of the Securities and Exchange Act of 1934, as amended; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of Benitec Biopharma Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has
executed this Statement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jerel Banks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Chairman and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>d230065dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 32.2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statement Pursuant to Section&nbsp;906 the Sarbanes-Oxley Act of 2002 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>By </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Principal Financial
Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regarding Facts and Circumstances Relating to Exchange Act Filings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated: November 15, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">I,
Megan Boston, Executive Director (principal accounting officer) of Benitec Biopharma Inc., hereby certify, to my knowledge, that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. the
accompanying Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma Inc. for the three month period ended September 30, 2021 (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a) or
15(d), as applicable, of the Securities and Exchange Act of 1934, as amended; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of Benitec Biopharma Inc. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Megan Boston</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Director (principal financial and accounting officer)</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>bntc-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 15-November-2021 [09:42:44] {AM}-->
<schema targetNamespace="http://www.benitecbiopharmainc.com/20210930" elementFormDefault="qualified" xmlns:bntc="http://www.benitecbiopharmainc.com/20210930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
<link:definition>1005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Business" id="Business">
<link:definition>1007 - Disclosure - Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<link:definition>1008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" id="GoingConcern">
<link:definition>1009 - Disclosure - Going concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Revenue" id="Revenue">
<link:definition>1010 - Disclosure - Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
<link:definition>1011 - Disclosure - Cash and Cash equivalents</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets" id="PrepaidAndOtherAssets">
<link:definition>1012 - Disclosure - Prepaid and other assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1013 - Disclosure - Property and equipment, net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" id="TradeAndOtherPayables">
<link:definition>1014 - Disclosure - Trade and other payables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Leases" id="Leases">
<link:definition>1015 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1016 - Disclosure - Stockholders' equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1017 - Disclosure - Income taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1018 - Disclosure - Commitments and contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1019 - Disclosure - Related party transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1020 - Disclosure - Subsequent events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" id="BusinessTables">
<link:definition>1022 - Disclosure - Business (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
<link:definition>1023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" id="RevenueTables">
<link:definition>1024 - Disclosure - Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
<link:definition>1025 - Disclosure - Cash and Cash equivalents (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables" id="PrepaidAndOtherAssetsTables">
<link:definition>1026 - Disclosure - Prepaid and other assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1027 - Disclosure - Property and equipment, net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" id="TradeAndOtherPayablesTables">
<link:definition>1028 - Disclosure - Trade and other payables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" id="LeasesTables">
<link:definition>1029 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>1030 - Disclosure - Stockholders' equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" id="BusinessSummaryOfEntitiesInControlDetail">
<link:definition>1031 - Disclosure - Business - Summary of entities in control (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<link:definition>1032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1033 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" id="GoingConcernAdditionalInformationDetail">
<link:definition>1034 - Disclosure - Going concern - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" id="RevenueSummaryOfRevenueFromCustomersDetail">
<link:definition>1035 - Disclosure - Revenue - Summary of revenue from customers (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" id="CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail">
<link:definition>1036 - Disclosure - Cash and Cash equivalents - Summary of cash and cash equivalent (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" id="PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail">
<link:definition>1037 - Disclosure - Prepaid and other assets - Summary of other current assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" id="PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<link:definition>1038 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" id="PropertyAndEquipmentNetAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Property and equipment, net - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" id="TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<link:definition>1040 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" id="LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<link:definition>1041 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1042 - Disclosure - Leases - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" id="LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<link:definition>1043 - Disclosure - Leases - Summary of supplemental balance sheet information related to leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" id="StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<link:definition>1044 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" id="StockholdersEquityScheduleOfEquityAwardsDetail">
<link:definition>1045 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" id="StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<link:definition>1046 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" id="StockholdersEquityAdditionalInformationDetail">
<link:definition>1047 - Disclosure - Stockholders' equity - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
<link:definition>1048 - Disclosure - Related party transactions - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
<import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="RoyaltiesAndLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_RoyaltiesAndLicenseFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreasedecreaseInAccountsAndOtherPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IncreasedecreaseInAccountsAndOtherPayables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IncreaseDecreaseInLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmortizationOfRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_AmortizationOfRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScheduleOfEntitiesInControlAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlAbstract" substitutionGroup="xbrli:item" />
<element name="GoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_GoingConcernAbstract" substitutionGroup="xbrli:item" />
<element name="GoingConcernDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_GoingConcernDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="TradeAndOtherPayablesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_TradeAndOtherPayablesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="RisksAndUncertainitiesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_RisksAndUncertainitiesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfEntitiesInControlLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlLineItems" substitutionGroup="xbrli:item" />
<element name="BenitecLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecLlcMember" substitutionGroup="xbrli:item" />
<element name="BenitecBiopharmaProprietaryLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecBiopharmaProprietaryLimitedMember" substitutionGroup="xbrli:item" />
<element name="TacereTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_TacereTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="BenitecBiopharmaProprietaryLimitedBblMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecBiopharmaProprietaryLimitedBblMember" substitutionGroup="xbrli:item" />
<element name="BenitecAustraliaProprietaryLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecAustraliaProprietaryLimitedMember" substitutionGroup="xbrli:item" />
<element name="BenitecLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecLimitedMember" substitutionGroup="xbrli:item" />
<element name="BenitecIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecIncMember" substitutionGroup="xbrli:item" />
<element name="RnaiTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_RnaiTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="LabEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_LabEquipmentMember" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="FinancialAssetsAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_FinancialAssetsAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MarketValueOfListedShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_MarketValueOfListedShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedLicenceFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AccruedLicenceFeesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedOpmdProjectCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AccruedOpmdProjectCostsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseMonthOfMaturityRevised" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_OperatingLeaseMonthOfMaturityRevised" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RemeasurementOfLeaseLiabilitiesDuringThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" substitutionGroup="xbrli:item" />
<element name="PreFundedWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PreFundedWarrantsMember" substitutionGroup="xbrli:item" />
<element name="FrancisAbourizkLightowlersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_FrancisAbourizkLightowlersMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>bntc-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 15-November-2021 [09:42:44] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DepositAssets" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_BNTC_RoyaltiesAndLicenseFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_BNTC_RoyaltiesAndLicenseFees" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" use="optional" order="15" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_BNTC_AmortizationOfRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_AmortizationOfRightOfUseAssets" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_BNTC_IncreasedecreaseInAccountsAndOtherPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_IncreasedecreaseInAccountsAndOtherPayables" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_BNTC_IncreaseDecreaseInLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_IncreaseDecreaseInLeaseLiabilities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaap_DueFromBanks" use="optional" order="1" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssets" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssets" xlink:to="loc_us-gaap_SecurityDeposit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_BNTC_MarketValueOfListedShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssets" xlink:to="loc_BNTC_MarketValueOfListedShares" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_BNTC_AccruedLicenceFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_BNTC_AccruedLicenceFeesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_AccruedOpmdProjectCostsCurrent" xlink:label="loc_BNTC_AccruedOpmdProjectCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_BNTC_AccruedOpmdProjectCostsCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedBonusesCurrent" use="optional" order="6" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>bntc-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 15-November-2021 [09:42:44] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BusinessSummaryOfEntitiesInControlDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#RevenueSummaryOfRevenueFromCustomersDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquityScheduleOfEquityAwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#CoverPage" roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#Business" roleURI="http://www.benitecbiopharmainc.com/role/Business" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BusinessTables" roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#GoingConcern" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#GoingConcernAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#Revenue" roleURI="http://www.benitecbiopharmainc.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#RevenueTables" roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#CashAndCashEquivalents" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#CashAndCashEquivalentsTables" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PrepaidAndOtherAssets" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PrepaidAndOtherAssetsTables" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PropertyAndEquipmentNet" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#SubsequentEvents" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#TradeAndOtherPayables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#TradeAndOtherPayablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#Leases" roleURI="http://www.benitecbiopharmainc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#LeasesTables" roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#RelatedPartyTransactions" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#CommitmentsAndContingencies" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#IncomeTaxes" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquityTables" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquityScheduleOfWarrantsOrRightsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747526" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_747079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingIncomeLoss_747079" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_747086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_747086" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_RevenuesAbstract_747066" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_747069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_Revenues_747069" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareAbstract_747098" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NetIncomeLoss_747099" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_747070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingExpensesAbstract_747070" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees_747072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_bntc_RoyaltiesAndLicenseFees_747072" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_747073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_747073" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_747074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_747074" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_747076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_OperatingExpenses_747076" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_StatementTable_747523" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_srt_ProductOrServiceAxis_747524" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525_default" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747150" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StatementTable_747147" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_747148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_747148" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_747152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_747152" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_747158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_CommonStockMember_747158" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_747164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_747164" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_747168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_RetainedEarningsMember_747168" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813481_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813481_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747172" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747171" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_NetIncomeLoss_747183" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail">
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_749255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_dei_EntityIncorporationStateCountryCode_749255" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable_747241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember_747251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLlcMember_747251" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember_747250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_TacereTherapeuticsIncMember_747250" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember_747247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLimitedMember_747247" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember_747248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIncMember_747248" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember_747249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_RnaiTherapeuticsIncMember_747249" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_ComputerEquipmentMember_747911" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember_747905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_bntc_LabEquipmentMember_747905" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_srt_RangeAxis_747916" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_747918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MaximumMember_747918" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MinimumMember_747919" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue_747932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_FinancialAssetsAtFairValue_747932" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_srt_ProductOrServiceAxis_747412" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_LicenseMember_747416" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember_1170848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847" xlink:to="loc_us-gaap_TransferredOverTimeMember_1170848" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_747484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_747484" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_747485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_EquipmentMember_747485" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_ComputerEquipmentMember_747487" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_747488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_747488" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748060" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_747654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseExpense_747654" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_StatementTable_748057" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_748064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_748064" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_748065" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1170863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_748065" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1170863" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_OperatingLeaseMonthOfMaturityRevised" xlink:label="loc_bntc_OperatingLeaseMonthOfMaturityRevised_1170862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_bntc_OperatingLeaseMonthOfMaturityRevised_1170862" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748515" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747597" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_747598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeasePayments_747598" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_StatementTable_748512" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xlink:label="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod_1170856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod_1170856" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xlink:label="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod_1170859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod_1170859" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_747993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_AwardTypeAxis_747993" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747995" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747965" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_768328" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_768325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_StatementTable_768325" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_770071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_IPOMember_770071" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_770073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_OverAllotmentOptionMember_770073" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_770074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_bntc_PreFundedWarrantsMember_770074" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_813644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_813644" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_770079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_770079" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_770083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_770083" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1170865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1170865" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_747694" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_FrancisAbourizkLightowlersMember" xlink:label="loc_bntc_FrancisAbourizkLightowlersMember_1170883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_747692" xlink:to="loc_bntc_FrancisAbourizkLightowlersMember_1170883" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1170879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_LegalFees_1170879" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1170884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1170884" use="optional" order="7" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>bntc-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 15-November-2021 [09:42:44] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport" xml:lang="en-US">Document Quarterly Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Principal place of business/country of incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Trade and other payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Amount due to related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Accrued employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Lease liabilities, current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion at September 31, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Lease liabilities, less current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Less: non-current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 12)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at end</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value&#8212;10,000,000 shares authorized; 8,171,690 shares issued and outstanding at September&#160;30, 2021 and June&#160;30, 2021, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Initial measurement at July&#160;1, 2021</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use asset at September&#160;30, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Less:&#160;non-current&#160;portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositAssets" xml:lang="en-US">Deposit Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepositAssets" xml:lang="en-US">Deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositAssets" xlink:to="lab_us-gaap_DepositAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Total property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock Par Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (loss):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign currency transaction loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US">Interest expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized gain on investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized loss on investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other loss, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenue:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenues from customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenues from customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Total revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Total comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xml:lang="en-US">Royalties And License Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xml:lang="en-US">Royalties and license fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RoyaltiesAndLicenseFees" xlink:to="lab_bntc_RoyaltiesAndLicenseFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xml:lang="en-US">Royalties and license fees</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other comprehensive income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized foreign currency translation gain</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Foreign currency translation loss (Gain)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Total other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Weighted-average shares outstanding:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance at end (In shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance at the beginning (In shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xml:lang="en-US">Forfeiture of share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xml:lang="en-US">Increase Decrease in Accounts and Other Payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:to="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xml:lang="en-US">Increase (decrease) in accounts and other payables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Accrued employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_bntc_IncreaseDecreaseInLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Increase Decrease In Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_bntc_IncreaseDecreaseInLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Increase decrease In lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_bntc_AmortizationOfRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xml:lang="en-US">Amortization of Right of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xml:lang="en-US">Amortization of right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AmortizationOfRightOfUseAssets" xlink:to="lab_bntc_AmortizationOfRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xml:lang="en-US">Amortization of right-of-use assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in provided by operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Re-measurement of operating lease right-of-use assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Effects of exchange rate changes on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlAbstract" xml:lang="en-US">Schedule Of Entities In Control [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract" xlink:to="lab_bntc_ScheduleOfEntitiesInControlAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of presentation and summary of significant accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_GoingConcernAbstract" xml:lang="en-US">Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GoingConcernAbstract" xlink:to="lab_bntc_GoingConcernAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_GoingConcernAbstract" xml:lang="en-US">Going concern</label>
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_GoingConcernDisclosureTextBlock" xlink:label="loc_bntc_GoingConcernDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xml:lang="en-US">Going Concern Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xml:lang="en-US">Going concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GoingConcernDisclosureTextBlock" xlink:to="lab_bntc_GoingConcernDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xml:lang="en-US">Going concern disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsAbstract" xml:lang="en-US">Other Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsAbstract" xlink:to="lab_us-gaap_OtherAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xml:lang="en-US">Other Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xml:lang="en-US">Prepaid and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related party transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Translation and Other Comprehensive Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:label="loc_bntc_TradeAndOtherPayablesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xml:lang="en-US">Trade and other payables [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:to="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xml:lang="en-US">Trade and other payables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Basic and Diluted Net Income (Loss) Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentrations of Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xml:lang="en-US">Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xml:lang="en-US">Trade and Other Receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RisksAndUncertainitiesPolicyTextBlock" xlink:label="loc_bntc_RisksAndUncertainitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" xml:lang="en-US">Risks And Uncertainities [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" xml:lang="en-US">Risks and Uncertainties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RisksAndUncertainitiesPolicyTextBlock" xlink:to="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" xml:lang="en-US">Risks and uncertainities.</label>
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xml:lang="en-US">Schedule Of Entities In Control [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xml:lang="en-US">Summary of entities in control</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:to="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xml:lang="en-US">Schedule of entities in control.</label>
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Schedule of property plant and equipment useful lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xml:lang="en-US">Summary of revenue from customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Summary of cash and cash equivalent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xml:lang="en-US">Summary of other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of property and equipment net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Summary of trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Summary of supplemental balance sheet information related to leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Schedule of supplemental balance sheet information related to leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Summary of maturities of the operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Schedule of equity awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of warrants or rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of share-basedcompensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTable" xml:lang="en-US">Schedule Of Entities In Control [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable" xlink:to="lab_bntc_ScheduleOfEntitiesInControlTable" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlLineItems" xml:lang="en-US">Schedule Of Entities In Control [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems" xlink:to="lab_bntc_ScheduleOfEntitiesInControlLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecLlcMember" xml:lang="en-US">Benitec LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecLlcMember" xml:lang="en-US">Benitec LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecLlcMember" xlink:to="lab_bntc_BenitecLlcMember" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedMember" xml:lang="en-US">Benitec Biopharma Proprietary Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedMember" xml:lang="en-US">Benitec Biopharma Proprietary Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:to="lab_bntc_BenitecBiopharmaProprietaryLimitedMember" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_TacereTherapeuticsIncMember" xml:lang="en-US">Tacere Therapeutics Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_TacereTherapeuticsIncMember" xml:lang="en-US">Tacere Therapeutics, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TacereTherapeuticsIncMember" xlink:to="lab_bntc_TacereTherapeuticsIncMember" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xml:lang="en-US">Benitec Biopharma Proprietary Limited BBL [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xml:lang="en-US">Benitec Biopharma Proprietary Limited ("BBL") [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:to="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xml:lang="en-US">Benitec Australia Proprietary Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xml:lang="en-US">Benitec Australia Proprietary Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:to="lab_bntc_BenitecAustraliaProprietaryLimitedMember" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecLimitedMember" xml:lang="en-US">Benitec Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecLimitedMember" xml:lang="en-US">Benitec Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecLimitedMember" xlink:to="lab_bntc_BenitecLimitedMember" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecIncMember" xml:lang="en-US">Benitec Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecIncMember" xml:lang="en-US">Benitec, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecIncMember" xlink:to="lab_bntc_BenitecIncMember" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_RnaiTherapeuticsIncMember" xml:lang="en-US">RNAi Therapeutics Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_RnaiTherapeuticsIncMember" xml:lang="en-US">RNAi Therapeutics, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RnaiTherapeuticsIncMember" xlink:to="lab_bntc_RnaiTherapeuticsIncMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer hardware [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software and Software Development Costs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_LabEquipmentMember" xml:lang="en-US">Lab equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_LabEquipmentMember" xlink:to="lab_bntc_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary of significant accounting policies [Table].</label>
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary of significant accounting policies [Line Items].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial liabilities at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_FinancialAssetsAtFairValue" xml:lang="en-US">Financial Assets At Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_FinancialAssetsAtFairValue" xml:lang="en-US">Financial assets at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_FinancialAssetsAtFairValue" xlink:to="lab_bntc_FinancialAssetsAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_FinancialAssetsAtFairValue" xml:lang="en-US">Financial assets at fair value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">Licensing revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xml:lang="en-US">Revenue from External Customer [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransferredOverTimeMember" xml:lang="en-US">Transferred over Time [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromBanks" xml:lang="en-US">Due from Banks</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DueFromBanks" xml:lang="en-US">Cash at Bank</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromBanks" xlink:to="lab_us-gaap_DueFromBanks" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_bntc_MarketValueOfListedShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_MarketValueOfListedShares" xml:lang="en-US">Market value Of listed shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_MarketValueOfListedShares" xml:lang="en-US">Market value of listed shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_MarketValueOfListedShares" xlink:to="lab_bntc_MarketValueOfListedShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_MarketValueOfListedShares" xml:lang="en-US">Market value of listed shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssets" xml:lang="en-US">Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssets" xml:lang="en-US">Total other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Lab equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Total property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Trade payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_bntc_AccruedLicenceFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xml:lang="en-US">Accrued Licence Fees Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xml:lang="en-US">Accrued license fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AccruedLicenceFeesCurrent" xlink:to="lab_bntc_AccruedLicenceFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xml:lang="en-US">Accrued licence fees current.</label>
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_AccruedOpmdProjectCostsCurrent" xlink:label="loc_bntc_AccruedOpmdProjectCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AccruedOpmdProjectCostsCurrent" xml:lang="en-US">Accrued OPMD Project Costs Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AccruedOpmdProjectCostsCurrent" xlink:to="lab_bntc_AccruedOpmdProjectCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AccruedOpmdProjectCostsCurrent" xml:lang="en-US">Accrued OPMD project costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xml:lang="en-US">Accrued Bonuses, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total operating lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Initial measurement at July&#160;1, 2021</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating lease liabilities at September&#160;31, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Operating lease discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Operating lease has a remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_OperatingLeaseMonthOfMaturityRevised" xlink:label="loc_bntc_OperatingLeaseMonthOfMaturityRevised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_OperatingLeaseMonthOfMaturityRevised" xml:lang="en-US">Operating Lease Month Of Maturity Revised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_OperatingLeaseMonthOfMaturityRevised" xml:lang="en-US">Opearting lease month of maturity revised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_OperatingLeaseMonthOfMaturityRevised" xlink:to="lab_bntc_OperatingLeaseMonthOfMaturityRevised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_OperatingLeaseMonthOfMaturityRevised" xml:lang="en-US">Operating lease month of maturity revised.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Amortization of right of use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Principal payments on operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xlink:label="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xml:lang="en-US">Operating Lease Right Of Use Asset Remasurement During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xml:lang="en-US">Re-measurement during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xlink:to="lab_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xml:lang="en-US">Operating lease right of use asset remasurement during the period.</label>
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xlink:label="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xml:lang="en-US">Remeasurement Of Lease Liabilities During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xml:lang="en-US">Re-measurement during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xlink:to="lab_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xml:lang="en-US">Remeasurement of lease liabilities during the period.</label>
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Weighted average Exercise Price Of Class Of Warrants Or Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Exercise price of class of warrants or rights outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Exercise price of class of warrants or rights outstanding and excercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Weighted-average exercise price of class of warrants or rights outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Outstanding, ending of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Outstanding, beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock Options,Outstanding, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock Options, Outstanding, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Stock Options, Exercisable, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Exercise price, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise Price, Exercise price, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise Price, Exercisable, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted-average Remaining Contractual Term, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted-average Remaining Contractual Term, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee stock option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Number of Warranrs exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Number of Warranrs exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognised share based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock issue price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of stock net consideration received on the transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_PreFundedWarrantsMember" xml:lang="en-US">Pre Funded Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_PreFundedWarrantsMember" xml:lang="en-US">Pre-funded warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PreFundedWarrantsMember" xlink:to="lab_bntc_PreFundedWarrantsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_FrancisAbourizkLightowlersMember" xlink:label="loc_bntc_FrancisAbourizkLightowlersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_FrancisAbourizkLightowlersMember" xml:lang="en-US">Francis Abourizk Lightowlers [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_FrancisAbourizkLightowlersMember" xlink:to="lab_bntc_FrancisAbourizkLightowlersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_FrancisAbourizkLightowlersMember" xml:lang="en-US">Francis abourizk lightowlers.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>bntc-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 15-November-2021 [09:42:44] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#CoverPage" roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#Business" roleURI="http://www.benitecbiopharmainc.com/role/Business" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#GoingConcern" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#Revenue" roleURI="http://www.benitecbiopharmainc.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#CashAndCashEquivalents" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PrepaidAndOtherAssets" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PropertyAndEquipmentNet" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#TradeAndOtherPayables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#Leases" roleURI="http://www.benitecbiopharmainc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#IncomeTaxes" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#CommitmentsAndContingencies" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#RelatedPartyTransactions" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#SubsequentEvents" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BusinessTables" roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#RevenueTables" roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#CashAndCashEquivalentsTables" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PrepaidAndOtherAssetsTables" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#TradeAndOtherPayablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#LeasesTables" roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquityTables" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BusinessSummaryOfEntitiesInControlDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#GoingConcernAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#RevenueSummaryOfRevenueFromCustomersDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquityScheduleOfWarrantsOrRightsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquityScheduleOfEquityAwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20210930.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_747112" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_747113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentType_747113" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_747125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_AmendmentFlag_747125" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_767989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentQuarterlyReport_767989" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_747252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentTransitionReport_747252" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_747133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityFileNumber_747133" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_747131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityRegistrantName_747131" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_748326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityTaxIdentificationNumber_748326" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_747126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentPeriodEndDate_747126" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_747127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentFiscalYearFocus_747127" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_747128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentFiscalPeriodFocus_747128" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_747132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCentralIndexKey_747132" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_747136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_CurrentFiscalYearEndDate_747136" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_747140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCurrentReportingStatus_747140" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_747120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityInteractiveDataCurrent_747120" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_747142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityFilerCategory_747142" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_747143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntitySmallBusiness_747143" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_747144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityEmergingGrowthCompany_747144" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_747141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityShellCompany_747141" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_748327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityIncorporationStateCountryCode_748327" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_748405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressAddressLine1_748405" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_747160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressStateOrProvince_747160" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_747162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressPostalZipCode_747162" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_748406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_CityAreaCode_748406" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_748407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_LocalPhoneNumber_748407" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_747163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_Security12bTitle_747163" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_747165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_TradingSymbol_747165" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_747166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_SecurityExchangeName_747166" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_747167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_747167" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1171705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressCityOrTown_1171705" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_746977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" xlink:to="loc_us-gaap_AssetsAbstract_746977" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_746978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_AssetsCurrentAbstract_746978" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_746979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_746979" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_746980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_746980" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1170841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1170841" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_746983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_AssetsCurrent_746983" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_746985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_746985" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets_746986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_DepositAssets_746986" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_813025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_813025" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_746987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_746987" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_746988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_Assets_746988" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_746991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_746991" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_746992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_746992" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746993" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_746994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_746994" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_746995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesCurrent_746995" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_746999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_746999" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_747001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_Liabilities_747001" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_747005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_CommitmentsAndContingencies_747005" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_747013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_StockholdersEquityAbstract_747013" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_747014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_CommonStockValue_747014" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_747015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_747015" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_747016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_747016" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747017" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_StockholdersEquity_747018" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_747019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_747019" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_747035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_747035" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_747045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_747045" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_747047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesIssued_747047" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_747049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_747049" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_747061" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_747061" xlink:to="loc_us-gaap_StatementTable_747523" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_srt_ProductOrServiceAxis_747524" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_us-gaap_StatementLineItems_747526" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_RevenuesAbstract_747066" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_747069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_Revenues_747069" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_747070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingExpensesAbstract_747070" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees_747072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_bntc_RoyaltiesAndLicenseFees_747072" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_747073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_747073" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_747074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_747074" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_747076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_OperatingExpenses_747076" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_747079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingIncomeLoss_747079" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_747086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_747086" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NetIncomeLoss_747099" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareAbstract_747098" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747109" xlink:to="loc_us-gaap_StatementTable_747147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_747148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_747148" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_747152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_747152" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_747158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_CommonStockMember_747158" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_747164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_747164" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_747168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_RetainedEarningsMember_747168" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementLineItems_747150" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747171" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747172" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_NetIncomeLoss_747183" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747184" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747185" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_747054" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_NetIncomeLoss_747025" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_747028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_747028" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_bntc_AmortizationOfRightOfUseAssets_747029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_bntc_AmortizationOfRightOfUseAssets_747029" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747031" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_747033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_ShareBasedCompensation_747033" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_747036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_747036" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_747037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_747037" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables_747039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables_747039" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_747040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_747040" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_bntc_IncreaseDecreaseInLeaseLiabilities_747041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_bntc_IncreaseDecreaseInLeaseLiabilities_747041" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747042" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_747043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_747043" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_747046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_747046" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_747056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_747056" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_747053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_747053" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747055" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747057" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_747058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_747058" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Business">
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747235" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_747236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747235" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_747236" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747291" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747291" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747294" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/GoingConcern">
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract_747261" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_GoingConcernDisclosureTextBlock" xlink:label="loc_bntc_GoingConcernDisclosureTextBlock_747262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747261" xlink:to="loc_bntc_GoingConcernDisclosureTextBlock_747262" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Revenue">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747296" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_747298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747296" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_747298" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747347" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_747353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747347" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_747353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747424" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_747428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747424" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_747428" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747472" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_747473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747472" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_747473" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747548" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_747549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747548" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_747549" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747580" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_747581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747580" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_747581" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747939" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_747940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747939" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_747940" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747712" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_747713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747712" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_747713" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747700" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_747701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747700" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_747701" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_747674" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_747675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_747674" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_747675" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_747496" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_747497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_747496" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_747497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747292" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_813075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_813075" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_747299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_747299" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_813076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_UseOfEstimates_813076" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RisksAndUncertainitiesPolicyTextBlock" xlink:label="loc_bntc_RisksAndUncertainitiesPolicyTextBlock_1170843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_RisksAndUncertainitiesPolicyTextBlock_1170843" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_747300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_747300" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_747302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_747302" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_747303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_747303" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_747304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_747304" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_747305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_747305" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_747306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_747306" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_747307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_747307" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_747308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_747308" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:label="loc_bntc_TradeAndOtherPayablesPolicyTextBlock_747309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_TradeAndOtherPayablesPolicyTextBlock_747309" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_747312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_747312" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_747314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_747314" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_747315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_747315" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_747318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_747318" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_747319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_747319" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_747320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_747320" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_747323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_747323" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessTables">
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747237" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock_747238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747237" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock_747238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747293" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_747892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747293" xlink:to="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_747892" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747316" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_747330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747316" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_747330" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747348" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_747356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747348" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_747356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747437" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_747440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747437" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_747440" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747477" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_747479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747477" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_747479" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747553" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_747555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747553" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_747555" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747587" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_747591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747587" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_747591" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_747588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747587" xlink:to="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_747588" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747942" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_747943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_747943" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_747945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_747945" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_747947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_747947" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail">
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747239" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable_747241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747239" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTable_747241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember_747247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLimitedMember_747247" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember_747248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIncMember_747248" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember_747251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLlcMember_747251" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember_747249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_RnaiTherapeuticsIncMember_747249" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember_747250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_TacereTherapeuticsIncMember_747250" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_749255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_dei_EntityIncorporationStateCountryCode_749255" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747899" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747899" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember_747905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_bntc_LabEquipmentMember_747905" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_ComputerEquipmentMember_747911" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_srt_RangeAxis_747916" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MinimumMember_747919" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_747918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MaximumMember_747918" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747924" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747924" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue_747932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_FinancialAssetsAtFairValue_747932" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract_747274" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747274" xlink:to="loc_us-gaap_NetIncomeLoss_747276" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747274" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747280" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_747399" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_747399" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_srt_ProductOrServiceAxis_747412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_LicenseMember_747416" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember_1170848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847" xlink:to="loc_us-gaap_TransferredOverTimeMember_1170848" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/exampleGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks_747364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_DueFromBanks_747364" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747366" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747453" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_747454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_747454" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_747455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_SecurityDeposit_747455" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_bntc_MarketValueOfListedShares_747458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_bntc_MarketValueOfListedShares_747458" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_747459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_OtherAssets_747459" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_813108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_813108" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_813109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_OtherAssetsCurrent_813109" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747480" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747480" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_747484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_747484" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_747485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_EquipmentMember_747485" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_ComputerEquipmentMember_747487" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_747488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_747488" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747493" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_747494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747493" xlink:to="loc_us-gaap_Depreciation_747494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747565" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_747566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_747566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_bntc_AccruedLicenceFeesCurrent_747567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_bntc_AccruedLicenceFeesCurrent_747567" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_747569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_747569" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_AccruedOpmdProjectCostsCurrent" xlink:label="loc_bntc_AccruedOpmdProjectCostsCurrent_1181976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_bntc_AccruedOpmdProjectCostsCurrent_1181976" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_1181980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccruedBonusesCurrent_1181980" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_747570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_747570" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_747571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_747571" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747631" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1170860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1170860" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_747634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_747634" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_747635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_747635" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1170861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1170861" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_747636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_747636" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_747637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_747637" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_OperatingLeaseLiability_747638" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747645" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747645" xlink:to="loc_us-gaap_StatementTable_748057" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_748064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_748064" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_748065" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1170863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_748065" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1170863" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_StatementLineItems_748060" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_747654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseExpense_747654" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_OperatingLeaseMonthOfMaturityRevised" xlink:label="loc_bntc_OperatingLeaseMonthOfMaturityRevised_1170862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_bntc_OperatingLeaseMonthOfMaturityRevised_1170862" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_747593" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_747593" xlink:to="loc_us-gaap_StatementTable_748512" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_StatementLineItems_748515" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xlink:label="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod_1170856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod_1170856" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747596" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747597" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xlink:label="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod_1170859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod_1170859" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_747598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeasePayments_747598" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747599" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747978" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748447" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747985" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747990" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747990" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_747993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_AwardTypeAxis_747993" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747995" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747999" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748006" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747962" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747962" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747965" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_768322" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_768325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_768322" xlink:to="loc_us-gaap_StatementTable_768325" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_770071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_IPOMember_770071" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_770073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_OverAllotmentOptionMember_770073" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_770074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_bntc_PreFundedWarrantsMember_770074" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_768328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_StatementLineItems_768328" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_770079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_770079" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_770083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_770083" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_813644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_813644" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1170865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1170865" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_747689" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_747689" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20210930.xsd#bntc_FrancisAbourizkLightowlersMember" xlink:label="loc_bntc_FrancisAbourizkLightowlersMember_1170883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_747692" xlink:to="loc_bntc_FrancisAbourizkLightowlersMember_1170883" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_747694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_747694" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1170879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_LegalFees_1170879" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1170884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1170884" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g230065g1103070755124.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g230065g1103070755124.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "D F@# 2(  A$! Q$!_\0
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ME68%L#?S&0> 033-$L+2.UTZ\6!)9&DS+.TV/*.>FW/-5SPM>Q/)4O:YB?\
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MD+"=I/ !/^[Q^?-'M7=)K<3I*S:>QPE:.B_\A'_MD_\ *LZM'1?^0C_VR?\
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M,44:7_R%[+_KNG\Q17)B-T=F&V9W6H>$-$N-2NII=;:.225F9/+^Z2>E5O\
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MFPY.#V.<4G_")W7_ #\P_D:/^$3NO^?F'\C3]T-2:/5;!;R6X:XE8LP8;E.
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M]S\?^ ']D_W_ ,/^">H;E_O+^=&Y?[R_G7E^]_[[?G1YC_WV_.C^V_[GX_\
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MP9RM%=6/!F?^7W_QRD_X0X?\_O\ XY1_9F*_E_%!]?P_\WX,Y6BNJ_X0X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*0!_8UM_>E_,?X4?V-;?WY?^^A_A113 /[%MO[TOYC_"C^QK;^_+^8_PHHI
M']BVW]^7\Q_A1_8UM_?E_,?X444 ']C6W]Z7\Q_A1_8UM_>E_P"^A_A113 /
M[&MO[\OYC_"C^QK;^_+^8_PHHH /[&MO[TOYC_"C^QK;^_+_ -]#_"BB@ _L
M:V_OR_F/\*/[&MO[\OYC_"BB@ _L:V_O2_F/\*/[%MO[\O\ WT/\*** #^QK
H;^]+^8_PH_L:V_O2_F/\*** )+?2+=+F)@TF5<$<CU^E%%%1(:/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g230065g1103070755608.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g230065g1103070755608.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %+ DL# 2(  A$! Q$!_\0
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M7A=IS#-9C8<CLW(_#-=3KPQ<8QE':2NMUU.*>'EA9-Q>C3LQW_",Z1_SZ?\
MD1_\:/\ A&=(_P"?3_R(_P#C6M17=]1PO_/J/W+_ ".+ZU7_ )W][,G_ (1G
M2/\ GT_\B/\ XT?\(SI'_/I_Y$?_ !K6I&944LQ"J!DDG@4?4<+_ ,^H_<O\
M@^M5_P"=_>S*_P"$9TC_ )]/_(C_ .-'_",Z1_SZ?^1'_P :GT[6]*UCS/[,
MU.SO?*.)/LTZR;/KM)Q5^CZCA?\ GU'[E_D'UJO_ #O[V9/_  C.D?\ /I_Y
M$?\ QH_X1G2/^?3_ ,B/_C6M11]1PO\ SZC]R_R#ZU7_ )W][,G_ (1G2/\
MGT_\B/\ XT?\(SI'_/I_Y$?_ !K59E12S$*H&22> *;'+'-$LL3J\;C*LIR"
M/4&CZCA?^?4?N7^0?6J_\[^]F9_PC.D?\^G_ )$?_&C_ (1G2/\ GT_\B/\
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M2/\ GT_\B/\ XT?\(SI'_/I_Y$?_ !K6HH^HX7_GU'[E_D'UJO\ SO[V9/\
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M-=!110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>>>)%5-?N@JA1E3@#N5!/ZUZ'7GOB;_ )&&Z_X!_P"@"O XC_W6/^)?DSU<
MH_COT_5#O$G_ "'[K_@'_H(K*K5\2?\ (?NO^ ?^@BLJN+$_QI^K_,];#_P8
M>B_(U)()[JQLA:(TBHI#JG.U]QY/IQCFK4N93<26J1W%T#&KG:).-OS$ \?>
M[U@T52KI=/Z\A.BWU_J]S5@M3<01^7"A9+D^;MQA5XQD^G!J?9 0(Y=JP_V@
MP(Z#&/Y5AT4*LET_K3_('1;ZFZD3F6!;ZVBCE-RH11&%W+_$,#J.G-.1&2:
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M0126NH10LZ;IH)<%>N1&[%3_ +P%;EUX7M;_ .P-?75U<S6;;A*Y0-+[/M4
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MKC4[67R83 #-IXD"KG@H"_RM_M<_2IY? \N97M-7:WE>+R@_D!L# !XW#TH
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M )H_X1^W_P"?J]_[_FM:BCZCA_Y$'UFM_,9/_"/V_P#S]7O_ '_-'_"/V_\
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MU1OO"EY)I.I WS7>HW?EE92BQA&7@$#MQ0!<C\;:5-=300QWDOD F61+<E$
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M"\W2LQ,@="N<G@@;NG:J\NE:C)J%W#;6&HR+<2JTMW,'B= 9D)5?FPR[=W.
M<"@#U&BN"TWP[=Z?JZW$,5V%BU1DBW2LRK:E">A/W=Q[]Z[V@ HHHH ****
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MZCV!]JT(+VTNFD6WNH9FC.'$<@8J?0XZ52M/$6D7D-S-'?VXCMI3%*SRJ K
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MEJY<9!PKR3[W^\]/!S4Z$6NUON"BBBN8Z0HHHH **** "BBB@ HHHH ****
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M61?V,#ZA]I.I/:3&,(0KJ,C/O55Z2IPC[-;-/M^9E"JZDY.H]T:]%87V1/\
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M "T?9$_Z&&;_ +_+1];G_)_Y-'_,/J\?YOP?^1NT5A?9$_Z&&;_O\M'V1/\
MH89O^_RT?6Y_R?\ DT?\P^KQ_F_!_P"1NT5A?9$_Z&&;_O\ +1]D3_H89O\
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MO\S^\H?V+IG_ #XP?]\4?V+IG_/C!_WQ5^BCZK0_D7W(/;5?YG]Y0_L73/\
MGQ@_[XH_L73/^?&#_OBK]%'U6A_(ON0>VJ_S/[RA_8NF?\^,'_?%']BZ9_SX
MP?\ ?%7Z*/JM#^1?<@]M5_F?WE#^Q=,_Y\8/^^*/[%TS_GQ@_P"^*OT4?5:'
M\B^Y![:K_,_O*']BZ9_SXP?]\4?V+IG_ #XP?]\5?HH^JT/Y%]R#VU7^9_>4
M/[%TS_GQ@_[XH_L73/\ GQ@_[XJ_11]5H?R+[D'MJO\ ,_O*']BZ9_SXP?\
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M9FZNXU\HJ<B([F8J#CH,CFJ/B;P-KNNWTO$+QF=761[QPOEC'R>4%QGKR2:
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M6*)7MF?8LK+N!R=I_O#!P:GE\+W\G@F^TLV]G]HN+DSB!7(BVF0-MSCTXZ4
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MU7Q#I>HZQ/>WEA/#;I#^[2"1%!; R,R''6K^H^);]+FZM=/2S:6.XA@1I-Q
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MG9T*!FQM9MV21CJ,5"WBSQ'#I\3I:VMX]W=>1926]N<.H7)8J\HST./F&>M
M'H-%>>:UX@UV[T2_M6M[33YH=,\^\CN02QW;AA"KX7IU.[KBM37]>U'2K#3X
M]+2.:Y>W:5XF@\P[% RV3+&% SZGZ4 =?17G\/C76KBT?5%M;%=/A>W62([C
M*_FJA.U@<#!?T.?:IM'U34=5\3:+>7DEEY%U83S0Q0!@R*3'P^6.X^X [\4
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M7'K6A10!DGPOH)D@D.CV6^!=D3>2N4'H/2BU\,:%8OOM=(LH6)SF.%0:UJ*
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M/#NBV$DLEII=I \T?ER-'"%+)_=/M2Z?HEIIE]?7=NN)+LIN^4 *J*%51@=
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M/^>UM_WTW^%'_"(:A_SVMO\ OIO\*[6BC^S:'G]X?VE7\CBO^$0U#_GM;?\
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M17F/]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-'^LE+^1_@']CS_F1Z=17F/\
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M17F/]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-'^LE+^1_@']CS_F1Z=17F/\
M:NH_\_\ =?\ ?YO\:/[5U'_G_NO^_P W^-'^LE+^1_@']CS_ )D>G4R66.&,
MR2R+&@ZLYP!^->:?VKJ/_/\ W7_?YO\ &NKT72K/4-.M[Z\B,]RQ)9Y)&.[#
M$#(S@\ 5TX7.'C)NG1AK:^KT_!/^NIA7R]8>//4EIY(FNKUM9<Z?8)(8"^VX
MN@<*%&,A3W)Z?_6.:VHHD@A2*,;410JC/0#I1%%'!&(XHUC0=%1< ?A3Z].C
61E%NI4=Y/\%V1Q5*B:48*R7]79__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g230065g1103070758718.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g230065g1103070758718.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Z ED# 2(  A$! Q$!_\0
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MDI: "EHI: "EHI: "EI*=0 4X4E.H *44@IPH 44M%**  4X4E.H *=12@4
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M@;R:>!-ZCU!R#G\#7CV*[V]U+PGK%CH?VKQ%)9W&G1@-&EG*S$YS@,!@?K0
MEAINF?\ "U#8Q60-D)"/(N(N.G]UAT^M;FKZ,PT36I=7\-:?9Q0\V4NGP@2-
MSP6VD\?7 K"'C'3+KXA6^LRE[?3X5\OS70EF 'WB%!-/M=<\+Z!<:OJ%AK,^
MIW%^K*MJMI)$@)[L6X.* .!KT/P797E_!:B#PKI,^GABMS>76))&/<J"<K]
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MI* $HHHH *[G[.9/!<4<']H06HLVEDFAG MY9O,(V.FWYG(V@9;/3C%</2T
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M<@=>,UR-+0 5("F.5;/^]_\ 6IE** ) 8_[K?]]?_6I<Q_W6_P"^O_K4P4M
M$@,?]UO^^O\ ZU.S'_=;_OK_ .M48IU $@,?]UO^^O\ ZU*#'_=;_OK_ .M3
M*<* '@Q_W6_[Z_\ K4X&/^ZW_?7_ -:HQ3A0!)F/^ZW_ 'U_]:E&S^ZW_?7_
M -:F4Z@!_P G]UO^^O\ ZU.^3^ZW_?7_ -:F"E% $F4_NM_WU_\ 6I?D_NM_
MWU_]:F4Z@!^4_NM_WU_]:E^3^ZW_ 'U_]:F4Z@!WR?W6_P"^O_K4[Y/[K?\
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M_K4E)0 OR?W6_P"^O_K4F4_NM_WU_P#6I** #Y/[K?\ ?7_UJ3Y/[K?]]?\
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MG"@!:=2"E% #J=313J '"G4T4X4 **<*04X4 **6D%.% "BEI!3J %I:2G4
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MSV=DURUQ;NT>SSH$+>9#O&5W9 'Y$X) - &6*<*:*<* %IPIM.% #J=3:=0
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M)3&/88JZD8I:/\43"*;UC^!G>(;F6?3IO,<D!#@=J\LB<^6O"]/[HKT[6O\
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MKH,@,A]%_P"^133(?1?^^10::: )K1R=1M>%_P!<G\(]17M=O_JE^E>)6?\
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ME%%%?-'T(4444 9FM_\ (.G_ -PUYC&Y\M>%Z?W17IVM_P#(.N/^N9KRZ/\
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M0^B_]\BDIIKVCQA3(?1?^^13?,/HO_?(H--- $UFY.HVG"_ZY/X1ZBO:[?\
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M>;)_?;\Z::0U[9XHOFR?WV_.F^9)_?;\Z0TV@">SD<ZG: NW^N3O[BO;;?\
MU8^E>(67_(3M/^NR?S%>WV_^K'TKP\W^*)[>5?#(EHHHKQSU0I&^Z:6D;[II
M@>7_ !")74+4J2"4;.#]*XWS9/[[?G78_$3_ (_K3_=;^E<77U&!_P!WB?-8
M[_>)?UT'>;)_?;\Z8S%CEB3]:*2NLY!*2EI* "EI*ZD:=I_]F_9C:*;@Z:;W
M[5YC[P^[.W;G;MP,=,]\]J .9I:Z;2--L);33X9[199=0,X\\NX:':/EV@$
M\\G(.>G%+JFG6$5C?PP6BQS6 @/V@.Y:7>/FW G:.3D8 QCO0!S%.%-J['I6
MHRHLD=A=.C#*LL+$$?E0!6%+W'UJV-'U3_H&WG_?AO\ "G#1]3R/^)=>=?\
MG@W^% 'M.G_\>L?^Z*MU2M2\5NBF*0$#!RAJ;SV!QY4G_?L_X5\BZ4V]CZSV
ML+;D]%0>>W_/*3_OV?\ "CSG_P">4O\ W[/^%+V,^P>UAW)CTKS[Q_UL_P#?
M/\J[OSF_YY2_]^V_PKBO'%G=W0M#!:7$@#'.V)CCCZ5UX&G.->+:.;&U(NA)
M)G#4X5:_LG4O^@?=_P#?EO\ "G#2=2_Z!]W_ -^6_P *^D/G"K3JL_V3J7_0
M/N_^_+?X4X:5J7_0/N_^_+?X4 5J[CP)_P >D_\ UTKDO[*U+_H'W7_?EO\
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M[5T82E-5HMKJ88JI%T9)/H<125<_LO4/^?"Z_P"_+?X4G]EZC_SX77_?EO\
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MN@CTJWT_5+X,YN(K2(#,T(7]XX  *Y/(+>O8U-_PC%@9O*75Y2YN3:C_ $3
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M#C!4D44DT@CBC>1ST5%R3^%=;9P6EI-:P[-,GD%GMFE%S;$1N9&.?WF4D.W
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M\OU]*TK(@:,6&!B[C,A/9<?RS6O'J6GS7]_$UI9*DLBKO1G8R MU^9B/?@4
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MWL[J\;%M;33DL% BC+<G/''?@_E4MWH^IV$7FWFFWEO&3C?- R#/IDBK+_\
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M[>*U"ZE<PO,K(JK$D9"O[!6;<?3 H XRFUZ%HK6&I:?/>SQ:9%<0RO&"MO;
M*F8RN5D*H<_. S'/7&<5%:R6$4E\9=*L3>"^D\ZVFN+6 )'QM5?,0C'WAF,@
M_I0!PD44D\JQ0QO)(W144DG\!3*]+TN71HH$=WT]!'$CP3&:V5]QQE=JH).
M2"78YQG'IYH>M "444E !2TE+0 M+3:6@!:=3:6@!U%)2T +3A3:44 .%+31
M3J )8I9(9%DBD:.13E60X(_&DI@IPH <*44VG"@!U2/+)*%$DC/L7:NXYP/0
M>U1"EH F6618WC61@CXW*#PV/45/;Q76HW,%I$6EE8B.)&?ID]!G@<FJE:&B
MW,=IK%I<3/LCCD#,V"<#\* )+?3=2\V\2"-U>U1C<8<+M7H>_/T'6J%=4=<T
M\VQ99&6XN8'%R=IQO"%5 ^O!ICWVGF*XN$U"'SKB*%%A:*0["I7.X[<8^7MF
M@#F@:LR1W-BP5BT1ECSA6^\I]<?RKJ]1UQ+K3/+A\0K#=%RT@CDN3&RX^ZI9
M-RC_ &3Q[TVRU^SAAVP7,$-QY<8,L_VA00 <KF+#=2.#P: .5>*:U\J0Y3>N
M^-E;MZ\4^ZO[R^96N[J>X91A3-(7(_.M'79_-MK,MY8D8R28B!"[6;C&[G'!
MZUBT .I:;10!*LLBHR*[!'^\H/!^M".R.&1BK Y!!P14=+0!-Y\N)!YKXD^_
M\Q^;OSZU8DTV\BCM9'A(6Z&82&!W<X]>/QJE740:S8"PACG<L]M K0@*?];R
M"#[8- &%?P7=K>R07N[[0F X9]Q''KDU7KI6U"PO)W\R_6$">.;>\;G> H!
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M"&Q*^Y5DR5_>*.@[=.:O7.L_;S,S7=C<P06MP2\)NF=0RA55C/G@L5X!QD4
M<59ZA>Z=*9;&[N+61AM+P2%"1Z9%022/+(TDKL\CDLS,<EB>I)IM)0 4E%%
M!2444 %%%% "TM)10 M+24M "TM)2T +2TE% #J<*;2B@!U**2B@!XI::*=0
M ZE%-%+0 ZG4VE% #@:6FTZ@!V:6FTHH =2YIM+0 ZEIHI: '9HI** '9I<T
MVEH 6BDI: %S1FDHH 7-%)10 N:,TE% "YHI** "C-)10 9HI** "DHI* "D
MS0:2@ I**0T &:;2TE "9I**0T )2&EIM !3:4TE "&D-%-- !2&EIM !3:6
<D- "4E+24 %-I:2@ I**0T %%%)0 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g230065g1103070759171.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g230065g1103070759171.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #O ED# 2(  A$! Q$!_\0
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M ,I#3C24 ,IIIYI#0 PTTT^FT ---IU(: &&FT\TTT ----/IIH ::2E-)0
ME)3J;0 E)2TE "4444 )1110 4M)2T +2TE+0 4ZDI: %I:2E% "BG"D%.H
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M--/IM #:;3J:: &FFT\TTT ----.-(: &44II* $IM.I* &TE.I* $I*6B@
MKO[.")_"]FK&^M]/6V\ZXGCGQ;22>;@I(H7YG(P/O9QCC%<!2T >FR#4_,N5
MNQ/_ &D)KK^R@_WPNSCRO]GIMQQG[O-9)AFD\7Z7->1.TZ10+=/*N<3E3M$A
M/&XX7KZ<]ZXFIA<S?9/LH?$!?S"@ Y;&,GUXS^9]: ._']M'3!G[8?$HM_\
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M\B@!*<*4.?1?^^13@Y]%_P"^10 @IU&\^B_]\BG!SZ+_ -\B@!!2T[>?1?\
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MA]5_[Z%&P^J_]]"@!E%.V'U7_OH4;#ZK_P!]"@!AHIQ0^J_]]"C8?5?^^A0
MRDI^P^J_]]"DV'U7_OH4 ,I*?L/JO_?0I-A]5_[Z% #*2G[#ZK_WT*38?5?^
M^A0!'3)/N&I=A]5_[Z%,D0[#RO\ WT* /5]()6Q@(.#L%:7FR?WS^=9FD_\
M'A!_N"M"OCI_$SZY)<J'^;)_?/YT>;)_?/YTRBI'9#C(^#\Y_.O/OB!_JK7_
M 'S7?'I7 ^/QF.U Q]\]377@?]XB<V-7^SR.*I#4GEGU7_OH4TQGU7_OH5]0
M?,D=-J3RSZK_ -]"F^6?5?\ OH4 02_ZLU[?I7_'C#_N"O$ID/EGE?\ OH5[
M=I7_ !XP_P"X*\?-_AC\SU\IWG\B]1117AGLA2'I2TAZ4P/./B1]RS_WS_*N
M KT#XCKE+/&/OGJ<=JX+RV]5_P"^A7TN7?[NCYS,/]X9'25)Y;>J_P#?0IC
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MY@L[B6WA_P!9*D3,J?4@8'XT 0BG*2.1C\1FFBG"@"02-Z+_ -\BG"0^B_\
M?(J(4X4 ==X3\(-XIAD9=0BM71MH5X V[@=\CUKJ/^%/7?\ T&;?_P !A_\
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MU]+EW^[H^=S#^.Q?,;T7_OD4QB6Y./P&*6D-=QPB4E+24 %+24M "TX4VEH
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M2_\ @0O_ ,17+7%M<6DIBN8)891R4D0J?R-1UC]4H?RFOUNO_,==_P )FO\
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MR(F?;GIG XK.I1A4MSJ]C2G6G3^!V.O/Q%&?^0;*/^WH?_&Z3_A8P_Z!DO\
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M)'9K=P%4]&)QP.#S[5"VF7ZV OFL;D69X%P8F\L\X^]C'6@"I24M)0 E%%%
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M8Q@&;;E#MQD R+G\F^E8G]JQ;40^:52S-N!VW'OUZ5 ="U( '[."3CY5E0L
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M=QSZ=*I6NJ0KI^HO(W[W>6M]S?-E^#Q]/YU2?1+N)4>4VRQN0 RW43;N<?*
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MJ?\ PB^H&T$H$?F&38$,T85AM!!5MV&SG@#-5(]"U"9%:%(92Q V1W$;.,G
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M0!K?VQ%<&$7UC;R,FU3<+O\ -V ]  X4G''(K/O[HWM_/=,,&5RV/K5<TAH
M2D-!I* $---*:;0 5=L-6N--4K $_P!='-E@3\R9P.O0[CFJ)IIH V6\37KW
M(G=(';SY)F4J<-YBA67@_=P,<8/O2-XAWSV\C:58[;9-D$:M,@C^8MD%9 V<
MD\DFL8TE &[=>*9[K4X]2:PLEO5;<TR^9E^,88%R.G?&>.M0KK4-R]N-0T^W
MD,>Q6ND\SSMBXXQO"$X&.1^O-8])0!/?W;7VH7%VXPTTC2$#MDYJM2TE "44
)4E !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g230065g1103070759608.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g230065g1103070759608.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $S ED# 2(  A$! Q$!_\0
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MDI: "EHI: "EHI: "EI*<* "G"D%.H *44"G"@ %+13A0 4HH%+0 4ZBE H
M *6EI0* #%+12XH *7%+BEH 2EI:6@!,4M%+0 F*7%+BC% "8I<4N*,4 )BC
M%.HQ0 VEQ2XHQ0 E)BG8HQ0 W%&*=28H ;BC%.Q10 S%%.Q24 -Q24^DH 92
M8I])0 S%)3Z3% #,4E.I"* &8I*?24 1TAI]-- #:;3S24 ,---/I#0 RD-.
M-)0 VFTXTE #:2G4E #:2G4E "4E+24 )24M% "4444 %+110 M%%+0 4M%+
M0 4M%+0 4X4@IPH !2T4HH 45-;0275S%;Q*6DD<(H'<FHA71>"KS2M-\2V]
M_K%QY-O;9D3]VS[G'W1\H/?^5 '>:UH>CW'A_5-$LK"VCU31;>*5IXXU$DQQ
ME\D#)_\ KBN%_P"$7W^#D\06]YYI^T>1+;^5CRSV.[//4=N]=-HOQ/4^(VFU
M/2-'M+*Y+)<7-O:-Y^P]-Q!);MGBHO"OB'PWI=[K6F:C=;M#NG\R"00N1D-D
M?*%R.#Z=J *$_@":/7=,T>._1[J[@$\P:/:+=<9.>3GH?3I3]1\&Z/:>'+C6
M;/Q.+R.*4PA5L63=)_=R6X^N,5K^&M3'B+XL3ZJN]K=5D,;#@+&%(!(X./;W
MJ7Q1&VN>$[B[TO5].FT^RGWSV]IICV@+G^([F.X_E0!YD!4D0S*F1GYA6IJD
M.@1Z;8-I=[<3WSKF[CD0A8V] =H_F:S(R%D5CT!!- 'M%S8>7KVDZ?;>#M,N
M-+N($-S=&PP4R.3Y@X&.OK7 GPQ#K'C+4+#29XXM/MV9VG<Y6-!U^O/%;U]\
M0+5?$VF2VFH2W&CK;)!>0%'\L]F^1AR1Z@51T'Q+HGACQ=?RV5S(^D72%(YX
M82##DY'R,,G!]NGK0!EZIX6M8-$.KZ1K,>J6<<GE3,(&B*,>G!SD>]:@\ V$
M2::;WQ+!:MJ,:M!&UN2Q8]N&Z>YQ2^)?%4=]HTMDGC"ZUEI7!$8TY+=%4'^(
M[0Q/TKH=8/AV&'PM=ZUJ4UG);VRR(JP-(LH&.,KR#TYH XVU\$7L_B.\TF6>
M*!;,%Y[EN55/7W^E+J7A2UBT)M9T?68]4LXY/+E(@:)D/T).16K:>.-/G\4Z
MO<WZ31:;J49@WJF6C7LQ%5+W6=!TKPG<:%H=_+J4MW*'EG:W:)44=L-SF@!F
MI^#]/T?2+:^OO$$<374(D@@^S,S.>XX/ ]ZO>)?#WAK3_#6FW=KJ7EW,T)9/
MW$A^U'\3A*RO%VKZ?J\>CK93>:UK:"*7Y&7:W''(&?PJUJNK:%JWA+3(6U%[
M?4]/C*"U-NS"0Y_O]!0 MMX*M5AL5U77H;"]OEW6UL8&D+ ]-S X7-5=.\&W
M5WKUYIMS<1VJ60+7$[#<JJ.X'&:ZF/Q_:76F6*KXHN-#G@C$<UO_ &<+@2X[
MJVTX_P \5DZ3XLTY=<U=M4N[J2QU&(Q&Z>(;QZ$J@_D* +>IVEG9_"YDT_4X
M]0MVO05F1"GX%3R#7GV*[#4=5\.0>"6T/2=2FNYA<B7=);M&''<C(X'U.:Y"
M@#IM+\)P76@G6-2U>/3[5I/*C)@:7+?[6/NCWJ[H,-U'X2\2"VO+4V\8VR9@
M+F0>JMN&/R-.\'Z_I6B0*]UXAN;8%C]HTY[0S1SCMM('RFHK'Q%I,>A^([?=
M]E>_;-K!Y;'(],@$#\30!LV$$EMX$TV[TWPU8:I>2S%9/.LO-.WUR.1]353Q
M#INEP>-M)@M[2&%I@C75JN"B,>V/Z54_X2U+'P=IEEIFI31:C;SEY8XPZ@KZ
M$XP1[9--U76- N?$VFZU93JA8H][&('7RW'4].?PS0!K>+-*TVYO8KO3;*"!
M;2\%K=PQ(%7DC#8 QS6)XOTN,^.7T^QMXXE<HB1Q(% S["K%OXHTZ+QIJ5S+
M*TFC7[XD=4;( P5;;C/!'IFK)\2: _CZ?79+PM:Q1YMR87_>2 8 QC(_&@#1
MU_2])O-"U*RT^QMXKW1]F^2.-0THQ\V2.3S7%>&;BSAUB".ZTN.^,TBHOG.=
MD>3R2H^]^)KI=%^(<;:M-_:VEZ39V-TK+//:VK"4@]-Q!)/Y5@Z/_8,6O-<W
M>L_9+6"820,+623S0#TP.5_$4 2^,XX=.\:72VMK;I%$X*PB,"/Z%1VKH_"N
MJIJL&H7^J>'/#L.G6419GAL &9NP!)(_2N?\:7FB:KJTFI:5JWVMIV^>'[,\
M?EC'JV,_E4FI:YIL/@NST+2;DS22/YMZVQUP?[O(&: .6G=9IY)$0(KL6"@8
M"@GI6UH/AH:O:W=]=W\=AI]H/WMPZ%\'T"CK6'BNI\.ZWI$>@:AH6LSR6D-T
M0Z721&0*P[%1S0!4MO#":GK\>G:1JEO>P.GF?:@I0(O?<IY!'I5J[\(69TF\
MO]&UV+4Q9-BXC$#1%?<9)S3M%UG0O#7B,26=Q<WFG20F&>?R=A.[J54\X'O4
M[ZSX<T+0]4M-$U&;4KK4?ER;9HEA7/?=U/TH BA\%V(TG3=1U#Q##917V BO
M 6;<>@ !Y'OQBKWAW0-1T'X@'3X;JV$RP,R3R0&1&4@?PAE.?QK0NH]#;P7X
M8;6M0ELEC^='6 R*V,9! Y'UJE!XUTJ;X@MJ\TKP:;';F"*1HV);@ ' !/-
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MT ,I*<:2@!*2EI* &T4M)0 E)2TE "44M)0 M%%+0 4M%+0 4M%+0 4M%**
M%%.I!2T  IPH%.% !3J04HH 4"E HIU %O3M3OM(O%N].NI+:X7HZ?R(/!'L
M:T-6\6>(=>@$&J:K+/"#GRPBQJ3[A0,_C6,*6@  IU%**  "G 44M  !5Z^U
M;4-4CMX[ZY\Y+9/+A'EJNQ?3@#/3O5.EH ,4 4M+0  48I:6@!,#TI<4M+0
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M]YO^^?\ Z]+B/^\W_?/_ ->FBE% #\)_>;_OG_Z]. C_ +S?]\__ %ZC%.H
MD C_ +S?]\__ %Z4"/\ O-_WS_\ 7IE.H ?B/^\W_?/_ ->E 3^\W_?/_P!>
MFBEH ?A/[S?]\_\ UZ< G]YO^^?_ *],%.H =A/[S?\ ?/\ ]>G83^\W_?/_
M ->F4M #\)_>;_OG_P"O2X3^\W_?/_UZ;2T .PG]YO\ OG_Z]+A/[S?]\_\
MUZ;2T .PG]YO^^?_ *].PG]YO^^?_KTVB@!V$_O-_P!\_P#UZ7"?WF_[Y_\
MKTVEH =A/[S?]\__ %Z7"?WF_P"^?_KTVB@!V$_O-_WS_P#7HPG]YO\ OG_Z
M])10 ["?WF_[Y_\ KT83^\W_ 'S_ /7IM+0 N$_O-_WS_P#7HPG]YO\ OG_Z
M])10 N$_O-_WS_\ 7HPG]YO^^?\ Z])10 N$_O-_WS_]>DPG]YO^^?\ Z])1
M0 N$_O-_WS_]>C"?WF_[Y_\ KTE)0 N$_O-_WS_]>DPG]YO^^?\ Z]%)0 83
M^\W_ 'S_ /7HPG]YO^^?_KT4E !A/[S?]\__ %Z3"?WF_P"^?_KT4E "83^\
MW_?/_P!>DPG]YO\ OG_Z]%)0 83^\W_?/_UZ3"?WF_[Y_P#KT4E !A/[S?\
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M;_V!^5(=;X_U8_(5CTAZ4<[#ZK2['"_%&\EO(;9Y#P),*HZ 8->9UZ)\1O\
MCTMO^NO]#7G=?1Y=_ 1XF/25=I"4E+25W'$)28I:* "NBTV>RM= )?4+?[2+
MR*Y%MLDWD)N!&=FW)W CG_"N>% H [?^T])A2^LUU..1-0EGD\\0R!8 RX4,
M"N2<GG:#CWJ".>UAU+3]1^U(UC9+%9M*%8&0E6W,BD9(7/?!Z<<UR-+0!UPO
M-,_L7^P_[4AXCW?:_*E\K=Y@;;C;NZ#KMZ\>]6Y]<TJYO(;X7@3[$TH6%HWW
MS@J I7 P,D<Y(Q[UPXI10 HIX(!Y /UIHI: ) R_\\U_,_XT[<O_ #S7]?\
M&HQ3J ) P_YYK^9_QI0P_P">:_F?\:93A0 \,/\ GFOZ_P"-.##_ )YK^O\
MC48IPH DW#_GFOZ_XTH8?\\U_7_&F4X4 /##_GFOZ_XT[</^>:_K_C3!3A0
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MZ_XT4E !N'_/-?U_QI"P_P">:_K_ (T4TT !8?\ /-?U_P :;N'_ #S7]?\
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M.G4 /\Q_[[?G2^8_]]OSIE+0 _S'_OM^=+YC_P!]OSIE+0 [S'_OM^=+O?\
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M?5?^^A3MA]5_[Z% "4M+L/JO_?0I=A]5_P"^A0 E+2[#ZK_WT*78?5?^^A0
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M< G]YO\ OG_Z]  *<* $_O-_WS_]>G83^\W_ 'S_ /7H !3A1A/[S?\ ?/\
M]>G )_>;_OG_ .O0 @IPH 3^\W_?/_UZ< G]YO\ OG_Z] !2TH"?WF_[Y_\
MKTH"?WF_[Y_^O0 "G"C"?WF_[Y_^O7<>$/#VAZO9;M0$RR;B%=6P#[$5C7KQ
MHQYI&M*E*J[1.(%+7K__  K[PQV>?_OL_P"-+_PK_P +_P!^?_OL_P"-<O\
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M12_)C[S?]\__ %Z,)_>;_OG_ .O7UA\J-HIV$_O-_P!\_P#UZ/D_O-_WS_\
M7H 913L)_>;_ +Y_^O1A/[S?]\__ %Z &TE.PG]YO^^?_KT83^\W_?/_ ->@
M!E)3\)_>;_OG_P"O283^\W_?/_UZ &TTU)A/[S?]\_\ UZ;A/[S?]\__ %Z
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M "#8O^NP_D:ZL'_'CZG/B_X$O0X"FFG&FFOJCY<0TTTIIIH 8_W37L'A;_D
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MT+33Z9-%$@RSNC "A5:;^TOO#V<^S* IPH#C^XOYG_&G!A_SS7]?\:T("E%
M<?\ /-?S/^-.##_GFOZ_XT %>@^#?^00/]\UY_N']Q?U_P :] \&G.D#C'SF
MO-S3^!\ST<K_ (_R.GHHHKYT]\**** .3\:_\@O_ +:+_.N+'2NU\:?\@OIG
M]XO\ZXL,,?<7]?\ &OH\K_@?,\#,_P"-\@HIVX?W%_7_ !HW#^XOZ_XUZ)YP
ME+2[A_<7]?\ &C</[B_K_C0!VG@__D&M_P!=#745S'@\YTYN,?O#73U\IB_X
M\O4^IPO\"'H%%%%<QN%<OXP_Y!G_  ,5U%<SXNQ_9C9&<,*Z,+_&CZF.)_@R
M]#B>U%.W#'W%_7_&C</[B_K_ (U]8?*C:*=N']Q?U_QI-P_N+^O^- #3TKO_
M  H2ND0$'!]:X(L,?<7]?\:[SPL<Z/#QBO+S7^$O4]/*_P"*_0Z/SY?[YH\^
M7^^U1T5X%SW.5=B3SY?^>C4>?+_?-1T47#E78X[QKS:PD_\ /6N.KL?&AQ:0
M\9_>UR&X?W%_7_&OH\M_@?,^?S+^/\AE)3]P_N+^O^-)N']Q?U_QKT#@&4T]
M*DW#^XOZ_P"--+#'W%_7_&@#T#P;_P @.+_>/\ZZ6N:\&\Z)'QCYC_.NEKY+
M$_QI>I]5A_X,?0****P-@KB_'?\ R#HO^NH_D:[2N+\=G&GP\9_>C^1KJP7\
M>/J<^+_@2]#@33:>7'_/-?U_QI-Z_P#/-?U_QKZH^7(S334A<?\ /-?U_P :
M;O'_ #S7]?\ &@")_NFO8/"__( L?^N2_P J\A=AM/[M?U_QKU[PO_R ++_K
MDO\ *O)S;^''U/5RK^)+T-NBBBO!/;"D/2EI#TH \[^(_P#J+3_?/\J\^KT3
MXBX%K;,5!Q)CGZ&O/MZ_\\U_,_XU]-EW^[H^<S#^.R.DJ3>O_/-?S/\ C3&(
M)R !]*[CB&TE+24 +2TVEH =2T@I: %%**;3A0 X4M(*6@!PIU-%.H ],^&E
MW+:6<\D38/FD$=B,"O2/[=DQ]VO+_A[_ ,@ZX_ZZ_P!!7<]J^7QK:KR/H\-1
MA.A%R70U_P"W)/[M']N2?W:R**Y>=FWU:EV-?^W9/[M<CX]U*>]T"Y5VQ&JY
M"CUK7KF_&/\ R +O_<K:A)NK'U1%2A3C3DTNAYDGW13Q4:?=%/KZP^9'"G4T
M4HH ?7H/@S_D$?\  S7GM>A>"_\ D$?\#->;FG\#YGHY7_'^1U%%%%?.GOA1
M110!R?C;_D%_]M%_G7%#I7:>-O\ D%?]M%_G7%#I7T>5_P #YG@9G_&^0ZEI
MM+7HGG"TM)10!V_@[_D&M_UT-=17+>#O^0:W_70UU-?*8O\ CR]3ZG"_P(>@
M4445S&X5S/B[_D&-_O"NFKF?%W_(+;_>%=&%_C1]3'$?P9>AQ%%':BOK#Y4*
M*2B@ /2N_P#"O_('AKS\]*] \*_\@:&O+S7^$O4]/*OXK]#?HHHKY\]T****
M8'&^-?\ CTA_ZZ_TKCJ[#QM_Q[0?]=:X^OI,M_@?,^>S+^.)244E=YP!33TI
M::>E 'HG@S_D!Q_[Q_G72US7@W_D!Q?[Q_G72U\EB?XTO4^JP_\ !CZ!1116
M!L%<5X\_Y!T/_78?R-=K7%>/3_Q+H?\ KL/Y&NK!?QX^ISXO^!+T.!---+33
M7U1\N)3:4TTT -;[IKV'PM_R +'_ *Y+_*O'7^Z:]B\+?\B_8_\ 7)?Y5Y.;
M?PX^IZN5?Q)>AMT445X)[84AZ4M(>E 'GWQ&_P"/.V_ZZ_T->=UZ'\1O^/.V
M_P"NO]#7GE?39=_NZ/G<Q_CL2DI:;7<<(4E+24 %+24M "TM)2T +71:9HUC
M<V=J+@W'VJ]\WR6C=0D>P<;@5);)]",#UKG:UK/7I[.R6W6WMW>/?Y,[AM\.
M\8;;@@?F#@\B@#,%.IHJ:"YGMGWV\TD3D8W1L5./PH 8*<*M?VQJ?_01N_\
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MH ZSP@ZIIC%B!^\-=$;N(=64?C7F8U;4@,#4+L#VF;_&E_M?4_\ H(W?_?\
M;_&O*JY9[2;GS;GJ4LR]G!0Y=CTO[9%_?7\Z/M<7]]?SKS3^U]3_ .@C=_\
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M2]_\"'_QJ/[)7\Q7]J_W3UG[9#_?7_OJN/\ ';J^F0E6!_?#H?8URG]N:O\
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M^8?]J_W3K_B(RO96Q5@1YO8^QKSVM!M=UAQA]5OF'H;AS_6F?VSJG_02O/\
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M &A;^'H;DPQ1W[?:9(EFV&#Y0I(_BW=>>F*DD\,1I>K;_:Y8\1&67[1"L+(
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M"F4X4 :WAHE?$VF,.HN4/ZBNLC,40N]0B9-^KVLQ*#JH6-C)],N!^%>?THH
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MHH *6BB@ HHHH **** $HHHH *2BB@ I*** $HHHH 2FFBB@ I*** &TE%%
M"&DHHH ;2&BB@!#3:** $---%% "4AHHH ;2444 )2444 )2444 )2&BB@ I
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g230065g1103070800124.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g230065g1103070800124.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %/ ED# 2(  A$! Q$!_\0
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M*6@ I:*6@ I:*6@ HHI: %I:*6@!:**<*  4HH%+0 4ZBE H ,4M%.H *7%
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M:UET:]^SR^1&JF1, ;FP.><_D:YCP+K.E^';Z\U6^E'VJ&W86<)C9O,D(QU
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M6Y;-MJ,5OYFS&<$HRYZ'TJ+Q)XD758K*T3Q/<ZTRSAV8V*6T:CM@;0Q/XXH
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M_6HRG]UO^^O_ *U $=)4GR?W6_[Z_P#K4?)_=;_OK_ZU $5)4GR?W6_[Z_\
MK4GR?W6_[Z_^M0!'25)\G]UO^^O_ *U)\G]UO^^O_K4 1TE2?)_=;_OK_P"M
M2?)_=;_OK_ZU $5)4GR?W6_[Z_\ K4GR?W6_[Z_^M0!$:2I?D_NM_P!]?_6I
MIV?W6_[Z_P#K4 1&FU+\G]UO^^O_ *U-_=_W6_[Z_P#K4 1&D-2GR_[K?]]?
M_6IN8_[K?]]?_6H B-)4F8_[K?\ ?7_UJ3,?]UO^^O\ ZU $5--2DQ_W6_[Z
M_P#K4A,?]UO^^O\ ZU $-(:E)C_NM_WU_P#6IN8_[K?]]?\ UJ (S3:E)C_N
MM_WU_P#6II,?]UO^^O\ ZU $=)4F8_[K?]]?_6I,Q_W6_P"^O_K4 1TE29C_
M +K?]]?_ %J8V,_*"![G- #:*** %HHK2BT.^GL6NXOLSQ(GF,JW<1=5SC)3
M=NZD=N] &?2U>U#1K_2T1KN)45V* I*CX88RK;2=K#(X.#4Q\.ZJ(H9!:AO.
M9$55E1G!<93<H.5R.1D"@#+IPJU?:;=::\:7*(/,7>C1RK(K#)'#*2#R".M5
MA0 HI:04M #A3J:*=0 HIPI*<*  4ZD%.% "TX4E.% "THI!3J %I:*44 +2
MT4M !3J2G4 %+12T %+12T %%+10 4M%+0 E+110 444M "44M% "44M% "4
M444 )12T4 -HI:2@!*2G4E #:2G4E #:2G4E #:;3Z;0 VFT^FT -I#3J;0
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MTUJMEI]C;7277V97+S1JRJ2S9P-P!X ';O66*04HH DW+_SS7\S_ (TH9?\
MGFOYG_&F4HH E#+_ ,\U_7_&E##_ )YK^O\ C3!2B@"3<O\ SS7]?\:7</\
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M\C).6R/IZWH?$^G6]TUY''=/-=-#]IC9%"QJBX;8=Q+$]L@8]Z ,#4-,;3Q
MXN8+F&=2T<T&[:<'!'S $$?3N*IBM'5+RTEMK.SLC.\-LK_O)T",S,V3\H)
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M?^^11O/HO_?(H 924_>?1?\ OD4;SZ+_ -\B@!E)3]Y]%_[Y%&\^B_\ ?(H
MCI*DWGT7_OD4F\^B_P#?(H CI*DWGT7_ +Y%)O/HO_?(H CJUI4,-SJUO!.I
M:-VPP!QD?6J^\^B_]\BKFC,3KMF./O\ 8#TK*LVJ<FNS-**3J13[H],A\ >%
M[B)9$EN%R.06Y%2?\*Y\,8YFN/\ ONI(B0O!J3<WJ?SKYKZY6_F?WGO/ 0OI
M^2*W_"N/#'_/6X_[[H_X5QX7_P">MQ_WW5G<WJ?SHW-ZG\Z/KE;^9_>+ZA#^
MDBH_PZ\*QH7:6X"@9/[RO+O$=K:66MSV]DC);IC:';)/'>O6923&<DUY5XG8
MC7[CIVZ@'M7?E]>I4JVDV]#EQN&A2I76]S$---2[SZ+_ -\BFESZ+_WR*]L\
M@B---2ESZ+_WR*;O/HO_ 'R* (9/NU[?IO\ QYQ?[@KQ*1SMZ+_WR*]LTS_C
MRA_W!7CYOM#YGL93O/Y%VBBBO#/8"D/2EI#TH \\^(V?(M1_MG^5>?&O0OB*
M2(;0C'WSU&>U>?F1O1?^^17TV7?[NCYS,/X[&4E2>8WHO_?(IC$DY./P&*[C
MB&TE+24 +2TE;W_"/$Z)9WRF]9[KA,6G[A3YA3!EW<'C.-O<4 8=**U]6T:"
MQMS-:WK7*QW#6TV^'R]K@9^7YCN4\\\'CI5Z/PFLSBWAOR;J)HA<HT.$C#C.
M5;<2V.,C ]LT <X*45?U+3X+2*UN+2Y>XMKE6*M)%Y; J<$%0S>QSGO5&@ %
M/%-%.% "TZD%+0 ZG4VG4 .%.%-%.% #A3A313A0 M.%(*44 +3A2"EH =2T
M@IPH *=24M "TM)2T +2TE+0 4M%% "]J[CP?_R"1_OFN'KN/"'_ ""1_O&O
M-S3^#\STLK_C?(Z6BBBOG3W@HHHH YWQ;_R!+CZ#^=<,.E=SXM_Y EQ]!_.N
M&'2OH,J_A/U/"S3^*O0****]0\P2BEI* "DI:* $I*6B@!M%+24 )24M)0 E
M)2TE "5;T;_D/6?^_P#TJI5S1O\ D.V?^_\ TK*O_"EZ,UH?Q8^J/58_NT^F
M1_=I]?(GUC"BBBD(9+]PUY5XH_Y&"X_X#_*O59?N&O*_%'_(P7'_  '^5>GE
M?\;Y'G9G_!^9BFFFG&FFOH3P!M-IU-- $<GW:]NTS_CRA_W!7B,GW:]NTW_C
MRA_W!7CYOM#YGKY3O/Y%VBBBO#/9"D/2EI#TI@>>?$;_ %-I_OG^5>?&O0?B
M-_J;3_?/\J\^KZ7+O]W1\YF'\=B4E+25W'$)24M)0 M;-CK%MIEI)]CLYA>R
MQB-YI;@,F P;A @P<J.K&L:EH W=0UNRO4:*/3YH89)WN95^TAB9&&!@[.%'
M/&"3GK5N/Q8D,JW$.GD7,C1&Z9I\K*$&,*-HV9[\GVQ7,4M &EJ.H0W<5K;V
MML]O;6ZL$627S&)8Y)+8'L.G:J(IHIU $@D;T7_OD4X2-Z+_ -\BHA3A0!()
M#Z+_ -\BG"0^B_\ ?(J,4X4 2"1O1?\ OD4[S#Z+_P!\BHQ3A0!)YA]%_P"^
M12ASZ+_WR*C%.% $@<^B_P#?(IP<^B_]\BHQ3J ) Y]%_P"^13@Y]%_[Y%1B
MG4 /#GT7_OD4[>?1?^^148IU #]Y]%_[Y%.WGT7_ +Y%1TZ@!^\^B_\ ?(IP
M<^B_]\BHZ=0 [>?1?^^12[SZ+_WR*93J '[SZ+_WR*-Y]%_[Y%-HH ?O/HO_
M 'R*7>?1?^^13*6@!V\^B_\ ?(KM_")SI0_WC7#=J[CPA_R"5_WC7FYI_!7J
M>EE?\;Y'2T445\Z>\%%%% '.^+?^0+<?A_.N(#''1?\ OD5V_BSG1;CZ#^=<
M,.E?095_"?J>%FG\5>@[<?1?^^11O/HO_?(I**]0\P7>?1?^^11O/HO_ 'R*
M;10 N\^B_P#?(HWGT7_OD4VB@!=Y]%_[Y%&\^B_]\BDI* %WGT7_ +Y%)O/H
MO_?(I*2@!V\^B_\ ?(I-Y]%_[Y%)24 +O/HO_?(I-Y]%_P"^124E "[SZ+_W
MR*M:.Q.NV8X^_P!@/2J9JWHW_(=L_P#?_I65?^%+T9K0_BQ]4>JQ_=%/ID?W
M13Z^1/K&%%%%(0R7[AKRSQ,Q'B"XQCMU /:O4Y?N&O*O$W_(P7/X?R%>GE?\
M;Y'G9G_!7J9)<^B_]\BFESZ+_P!\BD-(:^A/  R'T7_OD4TR'T7_ +Y%%--
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M_*O'S?:'S_0]C*=Y_(N4445X9[ 4AZ4M(>E 'GOQ&_X]K7_KH?Y5YY7HGQ%
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M_GZNO_ 9?_BZ7R]/_P"?JZ_\!E_^+J"VM+F\<I:V\T[@9*Q(6('KQ41!5BK
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MIKO=:?<R_92DHEU%"KMN<E697&,@CJ0#TS56]NK1?%,4LACG@VQK,N1(B_*
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M"8SG.<5!:)<2W<26A87!;]V5;:0?8]J .KO42'4(KL0P+!:6[2++%' @E?)
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M ->YUV!_#XM;::R6/R%C:VD^T;]PQDA0?*SGG/!_&N1-:$&BZA=%1% /F1I
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MLTR2&28QSQAKHD@^7\NXXXX&.F:JZAH1BU)H;20&!KLVL1E;YL\<G QCYA0
M^P\1BRCDC^SR?/*\GF0S^7(FX+]UMIP?EZX[T:KXF?4I;9TB>%X)1(LDDQD8
MD!1DG )/RYID'A>YFMEG>[MH5;?M\P28(7[QW*A7C'3.?:DM?#_V^%EL[A;F
M?SQ&KQ!MA&TL3@J&XQZ?0&@!^JZ[#-J5Z;6+-M);_9X@#M"C*G.".Y'3WK3A
MU[3;GP\MO/<?9IXX3%A1ESA HVGRFX.!D!T_&LN^\+W&G6D[W)/F)&)8R$=
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M*** "EI** %I:2B@!U%)2T .I:;2T +2TE% #Z6F4Z@!U**:*6@!XI::*44
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H$2;Y) #C(+[0"V"<*/;TK!I* %8Y8D]2<TVBB@!***2@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g230065g1103070800546.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g230065g1103070800546.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $[ ED# 2(  A$! Q$!_\0
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MDI: "EHI: "EHI: "EI*=0 4X4@IU !2BDIPH 44M%*!0  4M%.H *4"@"G
M4 &*6BEH *7%+BEH *,4N*6@ Q12TM "8I<4N*7'K0 E&*7%+@CJ* $HQ3L&
MB@!N*,4[%&* $HIV#1@F@!M)BGX.,TF* &XHQ3L>U&,]* &XI,4[%% #<4F*
M=BB@!F*,4ZDH ;BDQ3\$]!FFXH ;3<4_%)0 RDI])B@!F*2G4A% #*0BGFFT
M -IM/--- #2*::?330 VD-.-)0 RDIU)0 VDI:* &TE.I* &T4M)0 E)2T4
M)1110 4M%% "T44M !2T4M !2T4M !3A2"E% "BEHI10!W'@6ULK'3=5\1ZI
M8PW=K:HL4<4R!E:1B.Q]/ZU-XD\*V9^(=O8PSK9Z?J>R6WD2,%5#=@,CC/\
M.D3QI8Z'X.T[2-)MK#49F9IKY;ZU9D5^P . 3TYYZ4>(?%UAXA\,Z5,YAM==
ML9<""WA94$?;:>0!P.,]J *MMX%=]3UVWNKW[/;Z2C.\YBSO_N\9XR.>M2Z-
MX'M+W3]/N=3UQ=/;4I#'9Q"W,IDP<<D$!>?6MCQ;XXT34_#$L6ER-_:FHB(7
MP\IEVA1SR1@^G%;NDW%MI7A#PY!-=VUG<S!F@^TZ>UVV\MPR%6&SK^M 'EWB
M+2K?1-;N-.M[PW8@.UY#$8_F[C!)_.LL5U]]H^G:=XUO[7Q;J<I4@R&XMT.7
M=N1QM./IBN3?9YC>628\G:3U([4 =[\-[2&XM=<E;3+:_N(;??!'/ )06[ #
MK^56/$MK!)X$AU#5=$M-'UEKC9%%;P^3YB=R4Z^O7TK'\&^(;+0M/UI+B[DM
M[BYMMENR*V2_L5''UI]]XAT_7?!D,&J73'7K.3]Q*\;,TT?H7Q_,]A0!):>!
M[06M@=6UV.PN]0&ZVMQ;M(2#TW$'"YJ+2O T]]XAU#1KF\2UFLXRY?9N5L8]
MQ@8/6ND@^(-G<Z181?\ "376AW%M$(YH5L!<"7 P"#M./\\4WP3J$>J^,M:O
M'N+FXADM&_>RJJR,HP,X4 #\J .<U'PC;1>'GUC2M9BU*&&3RK@)$4V-TXSU
M'OQ5JW\#V4<5@FK:_%87M^H:WMO(,F0>FY@0%IU[KV@:7X/GT30KR>]FNYA)
M(\D!C\I1V.>I[<5<EU_PIK;Z3J.JZA<V=Y81K');K;,XEV]-K#@?C0!FZ9X$
MGO/$6H:-<WB6TMG&7,FS<K#\Q@8K0\*^'/#%_P"(;BS?5AJ,<<!8 021@L <
MD$'M^M-L?&EA/XFUO5;YFMH;NV:*!2A8^@!P#6-X)UFRT'75N+\LEL\31.Z*
M6*9&,X')H DL_#%MK&OS6>E:FLUC"ADENY(6C$8'7Y3R:75/"]K!HO\ :^D:
MLNI6:2>5*?(:)D;MP>HJ_P"'?$>D>%_$5VUM?3W.G7,93[6EN5:-B<YV-UQ_
MD4_Q%XJCO=)>TB\5WFKO(X8(;%($4 Y^8[02?I0!;T'PG::7JNB3W^M0V^H7
M#+-%9M$?F7_?S@'\*YKQASXPU7_KN?Y"NH;Q+X4U"]T?5[^]NH+ZQ14>V2W+
M;BO0[NF*Y#Q#>V^I>(K^]M7+V\TI9&*D9&/0\T /\,SV5KXCLIM09%MDD!9I
M!E1Z$^U=WJL5IK8M9]0U&TU 6+-)<7%F P=2?W<0('+'TKS!%1W578(A.&8C
M.!ZUUEMXETW3M7TNVL3)_8MB^^20)AII#U?'7CM0!D>(9=4N=4:XU2SFM"XQ
M#!)&4V1CH #5KP5;PW/B[3X;B&.:)WPR2*&4_4&K?BS7K'4K6SLK+4)]2\EW
MD>ZFC9#\QX7YN>*SO"NHVND^);*^O9#';Q/EV"EL#Z#F@#6MO"\6O>*-9MDN
MH[&.V+./W?R  ].","JFJ^%[6UT%-8TW5X]1MA+Y4A6(IM;VR>1[UH:/XDTJ
MSUS7KNXN"L%Y$ZP-Y;'<3TX R/QK/36+!/ $FD>:1>O="41[&QM]<XQ^M '8
M>(=$L-9/A^"[UJ*QFEM5CAB,1=G;\",#W-8OA73=0T[5=>LHKBWBDM[9UD,D
M!D##V^88^O-,U+Q)I%UK?AVYBN"T5C$JW#>4PV$=>W/X4^R\4Z/!XC\0WTET
MPM[V)D@;RG^8GIQC(_&@"UI=M:7?PM9+[4([&W%YN>9T+=^@4<DUG1^&I]"\
M7:,+2^AGBNF$EO<F+*GZIG^M)INL>'9/!/\ 8>JWTUM*]QYFZ.!GV#L3QR/I
MS4]]XMTF;Q)H?V660Z7I@"F=XV!;U.W&?TH NZ?HNFZOXUUR/7+E)9XM[!(X
M713@<N,-QCT).:I^%[=8K[7$T/589K=+0EI9K-OF'.0 6!!]^:CT_P 3Z3;^
M.=2U*:9_[/O!(@F6-B5##KMQG]*BT'5]!T*\UA4U)Y[:XMC'!*;=UWL<\8P2
M/J: *&F>&+>?16UC5]533;$R>7&YA,C.WLH[5'K?A=](U*R@%VEQ:WH5H;A%
MQE2<9Q6A8:SH>H>%(]"UN\FL&MY3+#.D!E5@>Q YS46O^)-/U#4=*@T_S/[.
MTT(BRR*07P<DXZXH T9?AY9IJ<FEKXBA;4?*,L5OY!RPQW.<+^M<))&T4KQM
M]Y&*G\*[\^*]%/Q&_MH71^P^1L\WRGSG;CIC/Z5PERZS74TB'*N[,IQV)H E
MTS39]6U*"QM@#+,VU<]![FNGD\#64HOK?3?$$-YJ-BA>>V\@H..N&)P:P?#V
MK_V%KMKJ)C+I"^74=2.^*ZI/$/A71;G5-5TN_N;R]O8V2.V-LR>46ZY8\'\*
M +GA V.F>!M3U&#5Q9WF\++<?8S(T![)@_>SZ^]>:2L9)7<OO+,26QC/OBNE
MT_6K&#P1JVF3S%;VZG62./8Q##C/.,#\37,T =6/!!FDT+[-?>;%JJYW^5CR
MB!DC&>?TJ0^ 7C\0ZEIL]_Y<%C;F=KCRL[AC(XSQGZUH>&_&6E:;X1DL[^9Q
MJ-MYGV(;&.=P]0,#\34FI^.=+N_!K0PR-_;MS"D%P-C?='4[B,'\^] %33_#
MOAB;P#)J5WJ)AG$X5KKR)&\L_P!S:#@Y]:NZ!;-#\/1>Z9H%EJU^;PQCS[/S
MB4YY]1VK%T;5]#?P9>:%JU])8N\XFBE6!I0V!TP*2/Q-!9_#W^R;'4KBWU+[
M7Y@\G?&QCY_B''IQF@"]XUT"S;Q)I-GI]I%:7M[&OVBVA/RQL3Z=!Q_*M+Q/
MIND:AX=U2'2["W@NM$F5'>*-0TJX )) YY_E7)^#M6L-(UV;6-7NI)+B.)FA
M\Q6D:64CC)Y_,^M;FA?$:)]2N(M;TW2K/3[R-EGFM+1A(2>F[!)/4]J '_#O
M3Q=Z!K4L&E6%_?QE?LZ7D2NN?3+8Q^8J#X@Z9%::)I-Q<Z1;Z?JTH;[0ME'B
M#V&1\N?H35?PYJ_AZTT77M)U#5&MH;Y@L,RVSR94'K@#^>*AUK7M%M_!EOX9
MT:[GU%4E\U[J6(QA>O"AN>] '=-INS4]#L;7PEIMSIEQ:JUW<M9C<AYS^\Z
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M'-UH>IZW+J>CZJUX;IR\D1MGC\KICEOO5RIH ::0TZD- #*2G&D- #:*6DH
M;12TE "4E+24 )12TE "TM)3MC;=VT[?7'% "4M*49<;E(STR** "EHI: "E
M%%** %%.I!2T %.%(*<* %I0*!2T *!6_8>-/$VEV:V=EK$T5NO"H41]OT+
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M)2TE "4444 %=]IMS"?#D;WR7D-BMLL BD0?9Y7\W.]3G);KG"YP#SBN"I:
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MFU$\YIM>Z?V#X6_Z!T9_&C^P?"W_ $#HJX_[4I]C;ZE,\*--->[_ -@^%O\
MH'14?V#X6_Z!L5']J4^P?4IG@YIIKU_Q/IV@6FBW1LM-B$XB8A_[O%>0=177
MAL3&NFTMC*M0E2MS=1IIIIQIM=)@-IM/--- &EX:_P"1FLO]X_R->QQ_<KQS
MPW_R,ME_O'^1KV./[E>!FW\5>A[V5_PGZCZ***\H](*1ONFEI&^Z:8'EOQ#_
M .0C:_[A_I7&5V?Q#_Y"-K_N'^E<97U&!_W>)\UCO]XD)24II*ZSD$I*6B@
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MUA>%_P#D#0?2MVOD<1_%EZL^LH_PH^B"BBBL30*Q/$G_ "";C_=K;K$\2_\
M()N/]VM:/\1>I%7X'Z'GZ%=H^7]:7*_W3^=,3[HIU?7GR0N5_N_K1E?[OZTE
M% "Y7^[^M:.@E?[;@PN.O>LRM'0/^0Y!^-88G^#+T-\-_&CZGI,?W:=38_NT
MZODSZEA1112 :_W#7G?BC UH9&?W8[^]>B/]PUYUXI_Y#0_ZYC^=>CEG\='!
MF7\!F1E/[I_.DRG]T_G24E?1GSPN4_NG\Z3*?W3^=)24 !*X/RG\Z[[P;_R!
M8\?WC_.O/STKT#P;_P @2/\ WC_.O,S7^"O4]+*_XS]#I:***^>/>"BBB@#'
M\1?\@:\_ZXM_*O* 4VCY/UKUCQ%SH]V/^F+?RKR7^$5[V4_!(\7-?CB*2G]S
M]:;E/[A_.@TTUZQY(I*?W#^=-)3^X?SH--- &GX<*_\ "266%Q\Q[^QKV&/[
ME>.^&_\ D9++_>/\C7L4?W*\#-OXJ]#WLK_A/U'T445Y1Z04C?=-+2-]TTP/
M+OB"0-1MLC/R'O7'93^X?SKL/B'_ ,A&V_W#7&5]1@?]WB?-8[_>)#LI_</Y
MTQL$\#'XTM(:ZSD&T444 %=);:1:7NC6QM4CDNF -P_VCYHLR[<^7CI@KSGO
M7-BM.+6I[>Q:VMX;>$LH5YHTQ(P!S@G/J!^5 %[6M/L(K*2>RBDB\B\>U<.^
M[?@9#>QX/%8-:.I:U<ZH@29(8U\QI6$2;=[GJQ]^*SQ0 X GH#3@K>A_*FAF
M'0G\Z<&;^\?SH 7:W]T_E7LWAC_D V/_ %Q7^5>-;F_O'\Z]E\,?\@&Q_P"N
M*_RKR<V_AQ]3U<J_B2]#:HHHKP3VPHHHH YSQA_R +S_ '*\N13M'!_*O4?&
M'_( O/\ <KR]&;:/F/YU]!E7\)^IX>:_Q5Z#MK>A_*G!3Z'\J0,W]X_G3@S?
MWC^=>H>6*%;T/Y4X*?0_E2;F_O'\Z4,W]X_G0!N^$P1KL>0?NFO3$^[7F?A,
MDZY'DD_*:],3[M?.YI_'^1]!EG\#YCJ***\T] *9)]PT^F2?<-,#S/Q&"?$,
MV!_ O]:SMI]#^5:7B,D>(9<$CY%_K6=N;^\?SKZO"_P(^A\OBOXTO4-I]#^5
M+M/H?RHW-_>/YT;F]3^==!SB[3Z'\J-I]#^5&YO4_G1N;'4_G0!Z!X8_Y T'
MT/\ .MVL/PQ_R!H/H?YUN5\CB/XLO5GUE'^%'T04445B:!6)XE_Y!-Q_NUMU
MB>)3C2;@_P"S6M'^(B*O\-^AY\@.T<'\J=M/H?RI$+;1\Q_.G;CZG\Z^O/DA
M-I]#^5&T^A_*ERW]X_G2;F]3^= !M/H?RK0T$$:Y!D'O6?N;U/YUHZ"2=;@R
M3WK#$_P9>AOAOXT?4]'C^[3J;']VG5\F?4L****0#7^X:\[\4 G6A@?\L_ZU
MZ(_W#7G?B@D:T,$C]V/YUZ.6?QT<&9?P&8VT^A_*DVGT/Y4[<W]X_G2;F_O'
M\Z^C/GANT^A_*DVGT-+N;^\?SHW-_>/YT ,*G'0_E7?^#AC18\_WC_.N!+-@
M_,?SKO\ P?\ \@6/ZFO,S7^"O4]+*_XS]#I****^>/>"BBB@#(\0_P#((N_^
MN3?RKR?:=O0_E7K'B'_D$7?_ %R;^5>3[FQ]X_G7NY3\$CQ<U^.(TJWH?RI"
MK>A_*G%F_O'\Z:6;^\?SKUSR1I4^A_*F[3Z'\J>6;^\?SIFYO[Q_.@#1\-@C
MQ)99!^\?Y&O8H_N5X]X;8GQ)99)^\>_L:]AC^Y7@9M_%7H>]E?\ "?J/HHHK
MRCT@I&^Z:6D;[II@>6_$($ZE;8!/R&N.*M_=/Y5V/Q!)&IV^"1\AKCMS?WC^
M=?48'_=XGS.-_P!XD)M;^Z?RII!'44[<W]X_G322>IS76<HTT4M)0 "I%C=H
MVD",44@,P' SZFHQ7::;/I*^'6@%\ JK%+<1-"<O)YBD\]Q@ #\30!R4MO-
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M]#I****^>/>"BBB@#(\0_P#((N_^N3?RKR?M7K'B#_D$W7_7)OY5Y3A<??\
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MY[G@?K5>XTS&KR65LQXY7S>">,XZ<TN5=A\S[B?VUJ?_ #_W'_?9I?[:U/\
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M'UHH VKOQ%=7=O/"T<2K,%#%01C'I]>]9]K<);R[I+>.X4C!23./S!!JM2T
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ME"/L]M?M>0"4DL22O#'/^P/?D\UC.Q9RQ[G-)24 %)110 4M)10 ZBDI: '
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MH\QDFC21MFW. S[PH/'3:>*H?V5IEUJ=[:QVRP+8OO<B5B9(ESNSD]>G3UH
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M\ '&4E>DR:%966D:E<QV36\\<$D)812)'*"A)92\C;AE>& 7K^7FM !1124
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MBDHH 6C-)10 N:*2DH 6C-)10 9HS24E "TE%)0 4F:#24 %)12&@ S244E
M!FFT4AH 2D)I:;0 ^2625@TLC.0 H+'. .@J*E-)0 AI#0::: "D-+3: "FT
MM-H ***2@ IRS21HZ)(ZK(-KA3@,,YP?7D"F4E !244AH ***2@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g230065g1103070800905.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g230065g1103070800905.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Q ED# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* 3DXY/K2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^^J-TG_ #S'_?5 &7_8 _Z"NJ_^!1H_L ?]!75?_ HUJ;I/^>8_[ZHW2?\
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M_P \Q_WU0!E_V /^@KJO_@4:/[ '_05U7_P*-:FZ3_GF/^^J-TG_ #S'_?5
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M_P"^OYTNT>@_*C:/0?E0 GF1_P!]?SH\R/\ OK^=+M'H/RHVCT'Y4 )YD?\
M?7\Z/,C_ +Z_G2[1Z#\J-H]!^5 ">9'_ 'U_.CS(_P"^OYTNT>@_*C:/0?E0
M GF1_P!]?SH\R/\ OK^=+M'H/RHVCT'Y4 )YD?\ ?7\Z/,C_ +Z_G2[1Z#\J
M-H]!^5 ">9'_ 'U_.CS(_P"^OYTNT>@_*C:/0?E0 GF1_P!]?SH\R/\ OK^=
M+M'H/RHVCT'Y4 )YD?\ ?7\Z/,C_ +Z_G2[1Z#\J-H]!^5 ">9'_ 'U_.CS(
M_P"^OYTNT>@_*C:/0?E0 GF1_P!]?SH\R/\ OK^=+M'H/RHVCT'Y4 )YD?\
M?7\Z/,C_ +Z_G2[1Z#\J-H]!^5 ">9'_ 'U_.CS(_P"^OYTNT>@_*C:/0?E0
M GF1_P!]?SH\R/\ OK^=+M'H/RHVCT'Y4 )YD?\ ?7\Z/,C_ +Z_G2[1Z#\J
M-H]!^5 ">9'_ 'U_.CS(_P"^OYTNT>@_*C:/0?E0 GF1_P!]?SH\R/\ OK^=
M+M'H/RHVCT'Y4 )YD?\ ?7\Z/,C_ +Z_G2[1Z#\J-H]!^5 ">9'_ 'U_.CS(
M_P"^OYTNT>@_*C:/0?E0 GF1_P!]?SH\R/\ OK^=+M'H/RHVCT'Y4 )YD?\
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MH[)/^>O_ ([6=>';XCTTX)_<S=/^ 5I>9_TS?\J $V2?\]?_ !VC9)_SU_\
M':7S/^F;_E1YG_3-_P J $V2?\]?_':-DG_/7_QVE\S_ *9O^5'F?],W_*@!
M-DG_ #U_\=HV2?\ /7_QVE\S_IF_Y4>9_P!,W_*@!-DG_/7_ ,=HV2?\]?\
MQVE\S_IF_P"5'F?],W_*@!-DG_/7_P =HV2?\]?_ !VE\S_IF_Y4>9_TS?\
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M-DG_ #U_\=I?,_Z9O^5'F?\ 3-_RH 39)_SU_P#':-DG_/7_ ,=I?,_Z9O\
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M/OC)_G5.W\06=SJ#6:APP+*&.W#%>O .1^(% &E^]_V/UH_>_P"Q^M1RWEM
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M')JXS4FUV&I7=BS17->&(K='NH[>\>7"H67RS$5)S]Y&R0QQDGOQQ71>6?\
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MJ'RI84D6( ,,X*\BH;[3UO\ ;NGFB* [3$Y7!/?W_&K$$7DP)%O9]JXW-U-
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M50F]GCC#!1[]_P JDT_38M.$@ADE97()$CEN?7)IM_I,6HR*\LLR[!A0DA4
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BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g230065g1103070801374.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g230065g1103070801374.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $- ED# 2(  A$! Q$!_\0
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M32*ZS6='MDT/P^UEI5U!=WJX>6612L['&-HW'')[@=:K2^ _%$,$\\FCSB.
M$R'<O 'ISS^&: .:(I*U]'\-ZQX@>1=+L9+CROOD$*!^)(%-UKPYJWAYXDU6
MS:V:4$H"ZMD#KT)H R#2&G&FF@!M%*:2@!*;3J2@!M)3J2@!*2EHH *6DI:
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MKCRY+=A_$PSG'>O,]N>-[[?[H8XI=GH[J/16(H ])\-V\=S;^+=(L;G[5<3
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MV=(\/^PW?_/K/_W[-)]AN_\ GUG_ ._9KW#^U8!_RP3_ +YI?[6A_P">*?\
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M=_\ =-5'<'L>2+T_$T&A>GXF@U]BMCY![C32&EI#3$----.--H ::::<:0T
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M3_D+/_N5C;V]:V_"K$ZL^3_!7+C?]WD=6"_WB)WR_=%+2+]T4M?*GTP4444
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MN7&_[O(ZL%_'B>A+]T4M(OW12U\J?3!1110 4444 %5+_P#X]W_W35NJE_\
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M;>QO%@$PNK$0F61W!23>.<+CY<$CN<^U '/4M)5F"QN[I"]O;2RJ#@E%)YH
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MA_SY3_\ ?!IO]E:A_P ^4_\ WP: *1I*NG2=0_Y\I_\ O@TW^R=1_P"?*?\
M[X- %(TTU?71M3D.$L+ACZ",T[_A']8_Z!EU_P!^C2ND.S9F&FFM/_A']8_Z
M!EU_WZ-(?#^L?] R[_[]&CF7<.5]C,IIK4/A[6?^@9=_]^C3#X>UG_H%W?\
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M(9+J*&WO]X\Z2*9Y(P@4HH8D9;D8/?'X4R^\/6%I82WBZKYJ)M4)&(W;<=V
M=KD ?+Z]^E '.4VNNT_3M-FT.V$D-LUW<0S,NXR"5F4MMVD'8!QWHN-+TYM%
M\N&&U^VBSBG&&D$@)QN9BQV;>>@YH X\TVNFTS3K3R[BSN8[*>Z,;M'LG+N3
MMR-C*?+&",D,<T^^L-.AM;N'[$ UBL#F99&#R[OO YR!G/&!QCO0!RIIIK6U
M^"W@U15MH!#$\,3^6&) +(">3[FKCZ1#-XGU6PMXXU2(2^4K9(&#QCD?F<T
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MP015C^V;[SVE\U"64(5,2%,#H-F-OZ5GTE %UM4NVECD\Q5:/=LV1JH7/7
MQ2G5[THR&8$-@\HN01T(..#]*HTE &G_ &[?^9OWPAL$$BVC^8'^]\OS?CFJ
MT>H7,,TDL4@1I""VU% X.1QC Y]*JTE %R+5+R%@T<V")#)]T'YB,'MZ=JCN
M+V:YSY@B&3N^2%$Y_P" @56I* +UQJDLMXUS$/*D>/8^.=W&">G>JLEQ+)#%
M$[Y2($(,=,G)J*DH M6VI7=GY?V><Q^6YD0@#AB,9_*G1ZM>Q.C+,"4# !D5
MAACD@@C!Y]:I4E &H_B'4G8LTL1<C:'^SQ[@,8X;;D<>E0S:U?S2>8\J>9M*
M%Q"@9@>N2!D_4U0II- &K'K]T)8GG$4WE\J?*17SC )?;N./<UE.Q=V8GDG)
MI*::  T]+F6."6!'Q'+C>N!SCI_.HZ:: +T&LW]M:_9H9@L8R%S&I90>H#$9
M /L:A?4KMY)9&F):602N=HY89P>GN:JFDH N#5[Y)%D6X(82M,#M'WV&">G<
M#&.E)=:M>7<+12M$(V(++% D8)&<'Y0/4U2K6B86>@PW<<<33O=,-TD2N %4
M8&&!'\1_2@"O#KFH6]FMK%*BQJ&53Y*%U#9SAB-PSD]#22:[J$EE]D:9/*\L
M19$*!R@Z*7 W$<#O78/<P++>M.NF6\,#VW+Z?&<JRL64;4)R<>WU%87A]M.;
M5-3DFMT:S\AMJR*&\M6D5=PST(#=: ,>WU>]M+5K:"55C;//E*6&1@X8C<N1
MZ$4Z37-0EMXH))E:.,J0#$GS;?N[CC+ >C9K=U+2X]*\-7%E-!%]MCN(I'EV
MC<H??A<]<853^-0KH&FPW>I&]FN(K.UNEA23LP(<\D*?[J\@'KTH PM0U2[U
M25)+MHV=%"J4A2/@=!\H&:EN/$&I7,C2R2Q"1E96=+>-&8-UR54$_4UI:MI%
MCI=@EP]K<EKDL(-EVCH@ 4@E@GS9SG VX%:NLZ'H5KLGNKH6\UQ!YD:H&"J0
M, ;5B8-DCGYEZ_F <PWB+4WN1<M+"9=I5F^S1_O >N\;</T'WLU$^M7[S0R^
M;&C0S>?&(X415?"C.% '\*_E4OB&&.'5G,2*B2QQS;%& I= Q 'IS650!J#Q
M'JBA1'-%%M8-^ZMXTW8!'S;5&X<G@Y'--'B'45D=U:V&]0K(+.'8V"2"4V[2
M1D\XSS6710 Z:5IYGE?;N=BQVJ%&?8#@?05'2TE !2444 %+244 +2TE+0 M
M+244 .I:2EH 6E%-I: 'BEIHIU #A3JC%.% #Q2TVG"@!U.I@I10 \4ZF4Z@
M!P-.IE** '@TM-I10 ^EIE.H =5I;^=+6.W4[1')YB.N0RDCG!JG3J )DN9T
M5E2:15;[P#$ _6FQR/$X>-V1QT93@BHZ6@"?[5<8 \^3 4J!O/ /4?2IO[3O
M_*2+[=<^7']Q/-;"_09XJG10!H-K>JONWZG>-N&&S.QR/3K3(=3OK=R\%[<Q
M,0%+)*RD@=!P>E4Z* +5U>S7?E^:0?+7:.3SZDY[FH,TVB@!V:*;10 ZC--H
MH 6BDI* %HI*2@!:*2DH 6DI** "DHI* "DHIIH ,TE%)0 A-)124 !IM%(:
M $I#0:2@!#4XO9!I[66%,32"0$CE3C''U_H*KTAH DDNKB0.'GE8/C<&<G=C
MIGZ5&DLD8<)(RAUVL%.-PSG!]1D#\J::2@"66[N90XDN)7WD%]SD[B.!GUQF
MK"Z]K"",)JU\HC&$ N'&T>@YXJ@:;0!=;6=483AM2O"+C_7 SM^\XQ\W//''
M-":UJD<3Q+J5X(I/]9&)W"OQCD9YXXJC10!/?7DM_>2W4VT/(<X7H/0#V%5J
36FT %)2TE "444E !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d230065d10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bntc="http://www.benitecbiopharmainc.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bntc-20210930.xsd" xlink:type="simple"/>
    <context id="PAsOn09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2019To06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn11_15_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="P08_01_2021To08_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecBiopharmaProprietaryLimitedBblMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_BenitecBiopharmaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecBiopharmaProprietaryLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bntc:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bntc:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_LicenseMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P10_06_2020To10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-06</startDate>
            <endDate>2020-10-06</endDate>
        </period>
    </context>
    <context id="P10_06_2020To10_06_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-06</startDate>
            <endDate>2020-10-06</endDate>
        </period>
    </context>
    <context id="P10_06_2020To10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-06</startDate>
            <endDate>2020-10-06</endDate>
        </period>
    </context>
    <context id="PAsOn10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-06</instant>
        </period>
    </context>
    <context id="PAsOn10_06_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-06</instant>
        </period>
    </context>
    <context id="PAsOn10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-06</instant>
        </period>
    </context>
    <context id="P04_30_2021To04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="P04_30_2021To04_30_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P07_01_2021To09_30_2021">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber contextRef="P07_01_2021To09_30_2021" id="hidden29143025">84-4620206</dei:EntityTaxIdentificationNumber>
    <dei:DocumentFiscalYearFocus contextRef="P07_01_2021To09_30_2021">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="P07_01_2021To09_30_2021">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P07_01_2021To09_30_2021">0001808898</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P07_01_2021To09_30_2021">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="P07_01_2021To09_30_2021">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="P07_01_2021To09_30_2021">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="P07_01_2021To09_30_2021">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="P07_01_2021To09_30_2021">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P07_01_2021To09_30_2021">001-39267</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P07_01_2021To09_30_2021">BENITEC BIOPHARMA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2021To09_30_2021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="P07_01_2021To09_30_2021">3940 Trust Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P07_01_2021To09_30_2021">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P07_01_2021To09_30_2021">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P07_01_2021To09_30_2021">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P07_01_2021To09_30_2021">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P07_01_2021To09_30_2021">780-0819</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P07_01_2021To09_30_2021">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P07_01_2021To09_30_2021">BNTC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P07_01_2021To09_30_2021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="P07_01_2021To09_30_2021">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P07_01_2021To09_30_2021">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P07_01_2021To09_30_2021">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P07_01_2021To09_30_2021">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P07_01_2021To09_30_2021">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="P07_01_2021To09_30_2021">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn11_15_2021"
      decimals="INF"
      unitRef="Unit_shares">8171690</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">15727000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">19769000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">642000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">814000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">16372000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">20608000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">323000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">375000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositAssets
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:DepositAssets>
    <us-gaap:DepositAssets
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">9000</us-gaap:DepositAssets>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">169000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">185000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">947000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">202000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">17836000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">21379000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1106000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">880000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">301000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">276000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">194000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1601000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1369000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">760000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2361000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1369000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn09_30_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn06_30_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2021"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2021"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2021"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">151854000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">151583000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-135164000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-130119000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-1216000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-1455000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">15475000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">20010000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">17836000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">21379000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">55000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:Revenues
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">55000</us-gaap:Revenues>
    <bntc:RoyaltiesAndLicenseFees
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</bntc:RoyaltiesAndLicenseFees>
    <bntc:RoyaltiesAndLicenseFees
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">134000</bntc:RoyaltiesAndLicenseFees>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2780000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">774000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2042000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1837000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4822000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2745000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-4822000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2690000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-240000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-54000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">27000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-223000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-28000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-5045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2718000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">239000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">239000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-4806000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2540000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-5045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2718000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P07_01_2021To09_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.62</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.45</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P07_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_shares">8171690</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P07_01_2020To09_30_2020"
      decimals="0"
      unitRef="Unit_shares">1108374</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">1108374</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">128826000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-116636000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1953000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">10238000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">38000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">38000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-14000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P07_01_2020To09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2020To09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2718000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2718000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">1108374</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">128850000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-119340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1775000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">7736000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">151583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-130119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1455000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">20010000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">271000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">271000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2021To09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">239000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">239000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-5045000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">8171690</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">151854000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-135164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">15475000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-5045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2718000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">52000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">45000</us-gaap:DepreciationDepletionAndAmortization>
    <bntc:AmortizationOfRightOfUseAssets
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">50000</bntc:AmortizationOfRightOfUseAssets>
    <bntc:AmortizationOfRightOfUseAssets
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">47000</bntc:AmortizationOfRightOfUseAssets>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">271000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">38000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-27000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-179000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-374000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <bntc:IncreasedecreaseInAccountsAndOtherPayables
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">293000</bntc:IncreasedecreaseInAccountsAndOtherPayables>
    <bntc:IncreasedecreaseInAccountsAndOtherPayables
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-119000</bntc:IncreasedecreaseInAccountsAndOtherPayables>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-8000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-8000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <bntc:IncreaseDecreaseInLeaseLiabilities
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-52000</bntc:IncreaseDecreaseInLeaseLiabilities>
    <bntc:IncreaseDecreaseInLeaseLiabilities
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-46000</bntc:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-4278000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2360000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">173000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-173000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">236000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">182000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-4042000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2351000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">19769000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">9801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">15727000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">7450000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">794000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Business &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Benitec Biopharma Inc. (the &#x201c;Company&#x201d;) is a corporation formed under the laws of Delaware, United States of America, on November&#160;22, 2019 and listed on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) under the symbol &#x201c;BNTC&#x201d;. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#x201c;BBL&#x201d;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April&#160;15, 2020. On August&#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&#x2019;s business focuses on the development of novel genetic medicines. Our proprietary platform, called &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DNA-directed&lt;/div&gt; RNA interference, or ddRNAi, combines RNA interference, or RNAi, with&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the year ended June&#160;30, 2021, the Company completed an organization res&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;t&lt;/div&gt;ructuring as part of the commercial desire to provide a more efficient structure for the future as the Company continues to transition its operations to the US. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s fiscal year end is June 30. References to a particular &#x201c;fiscal year&#x201d; are to our fiscal year end June&#160;30 of that calendar year. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principal&#160;place&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;business/country&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Biopharma Proprietary Limited (&#x201c;BBL&#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Australia&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Australia Proprietary Limited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Australia&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Limited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;United Kingdom&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec LLC&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;RNAi Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tacere Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec IP Holdings, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <bntc:ScheduleOfEntitiesInControlTableTextBlock contextRef="P07_01_2021To09_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principal&#160;place&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;business/country&#160;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Biopharma Proprietary Limited (&#x201c;BBL&#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Australia&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Australia Proprietary Limited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Australia&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Limited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;United Kingdom&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec LLC&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;RNAi Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tacere Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec IP Holdings, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </bntc:ScheduleOfEntitiesInControlTableTextBlock>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2021To09_30_2021_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2021To09_30_2021_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2021To09_30_2021_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2021To09_30_2021_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2021To09_30_2021_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2021To09_30_2021_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2021To09_30_2021_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2021To09_30_2021_BenitecBiopharmaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s consolidated financial statements contained in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; have been prepared in accordance with generally accepted accounting principles in the U.S. (&#x201c;GAAP&#x201d;)&#160;for interim financial information and with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 8 of U.S. Securities and Exchange Commission &#x201c;SEC&#x201d;) Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the year ended June&#160;30, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Reference is frequently made herein to the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-governmental&lt;/div&gt; entities. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements include the Company&#x2019;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of the Company&#x2019;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#x2019;s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected. &lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#x2019;s products and processes and clinical efficacy and safety of the Company&#x2019;s products under development, compliance with&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;government regulations and the need to obtain additional financing to fund operations. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Moreover, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&#160;current&#160;COVID-19&#160;pandemic,&#160;which&lt;/div&gt; is impacting worldwide economic activity, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented or inhibited from conducting business activities for an indefinite period of time which may &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;delay&#160;the&#160;start-up&#160;and&#160;conduct&lt;/div&gt; of the Company&#x2019;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#x2019;s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company&#x2019;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Foreign Currency Translation and Other Comprehensive Income (Loss) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s functional currency and reporting currency is the United States dollar. BBL&#x2019;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#x2019; equity as &#x201c;Accumulated other comprehensive loss.&#x201d; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Other comprehensive income for all periods presented includes only foreign currency translation gains. &lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company measures its financial assets and liabilities in accordance with US&#160;GAAP using ASC 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements.&lt;/div&gt;&lt;/div&gt; For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin-left:auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:6%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:93%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"/&gt;
&lt;td colspan="2" style="height:6pt"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"/&gt;
&lt;td colspan="2" style="height:6pt"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2021, and June&#160;30, 2021, the Company had no financial assets or liabilities measured at fair value on a recurring basis. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentrations of Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Trade and Other Receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; experience. The Company&#x2019;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. &lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 28%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 71%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-4&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer hardware&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shorter of the lease term or estimated useful lives&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#x2019;s expected future discounted cash flows or market value, if readily determinable. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. &lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic and Diluted Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of September&#160;30, 2021, and June&#160;30, 2021, there were 809,159 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue in accordance with that core principle by applying the following steps: &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 1: Identify the contract(s) with a customer. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 2: Identify the performance obligations in the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 3: Determine the transaction price. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606 &#x2013; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 606&#x201d;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Management has also made the judgement that the grant of the license and transfer of associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing revenues &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#x2019;s subsequent sales of products occur. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Services revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; trials. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-clinical&lt;/div&gt; and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being that the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company records share-based compensation in accordance with ASC 718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Compensation&lt;/div&gt;&lt;/div&gt;. ASC 718 requires the fair value of all share-based compensation awarded to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based compensation at fair value using the Black-Scholes Option Pricing Model. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to Australia and United States income tax laws. The Company follows ASC 740 &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt;, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13:&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments &#x2013; Credit Losses&lt;/div&gt;&lt;/div&gt; (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#x2019;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#x201c;SRC&#x201d;) as of November&#160;15, 2019. As such, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10:&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates&lt;/div&gt;&lt;/div&gt; amended the effective date for the Company to be for reporting periods beginning after December&#160;15, 2022. The Company will adopt this ASU effective July&#160;1, 2023. &lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s consolidated financial statements contained in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; have been prepared in accordance with generally accepted accounting principles in the U.S. (&#x201c;GAAP&#x201d;)&#160;for interim financial information and with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 8 of U.S. Securities and Exchange Commission &#x201c;SEC&#x201d;) Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the year ended June&#160;30, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Reference is frequently made herein to the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-governmental&lt;/div&gt; entities. &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements include the Company&#x2019;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of the Company&#x2019;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#x2019;s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <bntc:RisksAndUncertainitiesPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#x2019;s products and processes and clinical efficacy and safety of the Company&#x2019;s products under development, compliance with&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;government regulations and the need to obtain additional financing to fund operations. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Moreover, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&#160;current&#160;COVID-19&#160;pandemic,&#160;which&lt;/div&gt; is impacting worldwide economic activity, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented or inhibited from conducting business activities for an indefinite period of time which may &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;delay&#160;the&#160;start-up&#160;and&#160;conduct&lt;/div&gt; of the Company&#x2019;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#x2019;s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company&#x2019;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. &lt;/div&gt;</bntc:RisksAndUncertainitiesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Foreign Currency Translation and Other Comprehensive Income (Loss) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s functional currency and reporting currency is the United States dollar. BBL&#x2019;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#x2019; equity as &#x201c;Accumulated other comprehensive loss.&#x201d; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Other comprehensive income for all periods presented includes only foreign currency translation gains. &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company measures its financial assets and liabilities in accordance with US&#160;GAAP using ASC 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements.&lt;/div&gt;&lt;/div&gt; For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin-left:auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:6%"/&gt;
&lt;td style="vertical-align:bottom;width:1%"/&gt;
&lt;td style="width:93%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"/&gt;
&lt;td colspan="2" style="height:6pt"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"/&gt;
&lt;td colspan="2" style="height:6pt"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2021, and June&#160;30, 2021, the Company had no financial assets or liabilities measured at fair value on a recurring basis. &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <bntc:FinancialAssetsAtFairValue
      contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="INF"
      unitRef="Unit_USD">0</bntc:FinancialAssetsAtFairValue>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <bntc:FinancialAssetsAtFairValue
      contextRef="PAsOn09_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="INF"
      unitRef="Unit_USD">0</bntc:FinancialAssetsAtFairValue>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentrations of Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Trade and Other Receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; experience. The Company&#x2019;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. &lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 28%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 71%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-4&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer hardware&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shorter of the lease term or estimated useful lives&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="P07_01_2021To09_30_2021">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 28%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td style="width: 71%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-4&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer hardware&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shorter of the lease term or estimated useful lives&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;/div&gt; </bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2021To09_30_2021_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2021To09_30_2021_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2021To09_30_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2021To09_30_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2021To09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2021To09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P07_01_2021To09_30_2021_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">shorter of the lease term or estimated useful lives</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#x2019;s expected future discounted cash flows or market value, if readily determinable. &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <bntc:TradeAndOtherPayablesPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. &lt;/div&gt;</bntc:TradeAndOtherPayablesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic and Diluted Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of September&#160;30, 2021, and June&#160;30, 2021, there were 809,159 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2020To06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">809159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2021To09_30_2021"
      decimals="INF"
      unitRef="Unit_shares">809159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue in accordance with that core principle by applying the following steps: &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 1: Identify the contract(s) with a customer. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 2: Identify the performance obligations in the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 3: Determine the transaction price. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606 &#x2013; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 606&#x201d;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Management has also made the judgement that the grant of the license and transfer of associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing revenues &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#x2019;s subsequent sales of products occur. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Services revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. &lt;/div&gt; </us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; trials. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-clinical&lt;/div&gt; and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being that the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. &lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company records share-based compensation in accordance with ASC 718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Compensation&lt;/div&gt;&lt;/div&gt;. ASC 718 requires the fair value of all share-based compensation awarded to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based compensation at fair value using the Black-Scholes Option Pricing Model. &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to Australia and United States income tax laws. The Company follows ASC 740 &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt;, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13:&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments &#x2013; Credit Losses&lt;/div&gt;&lt;/div&gt; (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#x2019;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#x201c;SRC&#x201d;) as of November&#160;15, 2019. As such, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10:&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates&lt;/div&gt;&lt;/div&gt; amended the effective date for the Company to be for reporting periods beginning after December&#160;15, 2022. The Company will adopt this ASU effective July&#160;1, 2023. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <bntc:GoingConcernDisclosureTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Going Concern &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the three months ended September&#160;30, 2021, and 2020, the Company incurred a net loss of $5.0&#160;million and&#160;$2.7&#160;million and used net cash of $4.3&#160;million and $2.4&#160;million in operations, respectively. The Company expects to continue to incur additional operating losses in the foreseeable future. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2021, the Company had $15.7&#160;million in cash and cash equivalents. The Company has performed a review of the cash flow forecasts and believes that the current funding will be sufficient for a period of at least twelve months from the date of this Report. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s ability to continue as a going concern is dependent upon its ability to generate revenue and obtain adequate financing. While the Company believes in its ability to generate revenue and raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;going concern due to unsuccessful product development or commercialization, or the inability to obtain adequate financing in the future. &lt;/div&gt; </bntc:GoingConcernDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">-5000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-5"
      unitRef="Unit_USD">-2700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">-4300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2020To09_30_2020"
      decimals="-5"
      unitRef="Unit_USD">-2400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">15700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Revenue &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenues from customers (US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Months&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Months&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Licensing revenue from services transferred overtime&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="P07_01_2021To09_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenues from customers (US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Months&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Months&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Licensing revenue from services transferred overtime&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2020To09_30_2020_LicenseMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">55000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Cash and Cash equivalents &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash at Bank&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,727&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,727&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P07_01_2021To09_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash at Bank&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,727&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,727&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,769&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:DueFromBanks
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">15727000</us-gaap:DueFromBanks>
    <us-gaap:DueFromBanks
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">19769000</us-gaap:DueFromBanks>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">15727000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">19769000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Prepaid and other assets &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:77%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;763&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;967&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Security deposit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Market value of listed shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total other assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;811&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;642&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;814&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:77%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;763&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;967&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Security deposit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Market value of listed shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total other assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;811&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(185&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;642&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;814&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">763000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">967000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:SecurityDeposit
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">15000</us-gaap:SecurityDeposit>
    <bntc:MarketValueOfListedShares
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">34000</bntc:MarketValueOfListedShares>
    <bntc:MarketValueOfListedShares
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">17000</bntc:MarketValueOfListedShares>
    <us-gaap:OtherAssets
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">811000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">999000</us-gaap:OtherAssets>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">169000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">185000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">642000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">814000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Property and equipment, net &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer hardware&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,392&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,393&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,069&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,018&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;323&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Depreciation expense was $0.1&#160;million for the three months ended September&#160;30, 2021, and $45&#160;thousand, respectively, for the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;same&lt;/div&gt; period in 2020. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P07_01_2021To09_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer hardware&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,392&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,393&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,069&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,018&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;323&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1328000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1329000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">26000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">26000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">24000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">24000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1392000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1393000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1069000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1018000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">323000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">375000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P07_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P07_01_2019To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">45000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Trade and other payables &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trade payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;323&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued license fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued&#160;&lt;div style="text-indent: 0px;;display:inline;"&gt;OPMD project costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;279&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;Accrued bonuses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;&#160;&lt;div style="display:inline;"&gt;112&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right;"&gt;&lt;div style="white-space: nowrap;;display:inline;"&gt;&#160;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; width: 76%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;174&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,106&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;880&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 76%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P07_01_2021To09_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trade payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;323&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued license fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued&#160;&lt;div style="text-indent: 0px;;display:inline;"&gt;OPMD project costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;279&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;Accrued bonuses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-align: right;"&gt;&#160;&lt;div style="display:inline;"&gt;112&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right;"&gt;&lt;div style="white-space: nowrap;;display:inline;"&gt;&#160;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; width: 76%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;174&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,106&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;880&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 76%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">323000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">274000</us-gaap:AccountsPayableTradeCurrent>
    <bntc:AccruedLicenceFeesCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">135000</bntc:AccruedLicenceFeesCurrent>
    <bntc:AccruedLicenceFeesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">140000</bntc:AccruedLicenceFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">99000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">13000</us-gaap:AccruedProfessionalFeesCurrent>
    <bntc:AccruedOpmdProjectCostsCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">351000</bntc:AccruedOpmdProjectCostsCurrent>
    <bntc:AccruedOpmdProjectCostsCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">279000</bntc:AccruedOpmdProjectCostsCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">112000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">86000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">174000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1106000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">880000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9. Leases &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has entered into an operating lease for office space under an agreement that expires in 2022. The lease requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company&#x2019;s lease does not contain any residual value guarantees or material restrictive covenants. During August 2021, the Company extended the lease thr&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;ugh June 2025. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The tables below show the changes during the three months ended September&#160;30, 2021: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 68%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt; lease&lt;br/&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 88%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at July&#160;1, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;202&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 88%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; during the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 88%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amortization of right of use asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 88%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 88%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset at September&#160;30, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;947&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 88%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt; lease&lt;br/&gt; liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at July&#160;1, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; during the period&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Principal payments on operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities at September&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;954&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion at September&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2021, the Company&#x2019;s operating lease has a&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;remaining lease term of 3.71 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: &#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;235&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;287&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;297&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating lease payment&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;954&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recorded lease liabilities and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease assets for the lease based on the present value of lease payments over the expected lease term, discounted using the Company&#x2019;s incremental borrowing rate. Rent expense was $0.1&#160;million for the three months ended September&#160;30, 2021 and 2020, respectively, of which $7&#160;thousand was recorded in the general and administrative expense and $45&#160;thousand was record in research and development expenses. &lt;/div&gt; </us-gaap:LesseeOperatingLeasesTextBlock>
    <bntc:OperatingLeaseMonthOfMaturityRevised contextRef="P08_01_2021To08_31_2021">2025-06</bntc:OperatingLeaseMonthOfMaturityRevised>
    <bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock contextRef="P07_01_2021To09_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 68%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt; lease&lt;br/&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 88%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at July&#160;1, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;202&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 88%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; during the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 88%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amortization of right of use asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 88%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 88%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset at September&#160;30, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;947&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 88%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:88%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt; lease&lt;br/&gt; liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at July&#160;1, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; during the period&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Principal payments on operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities at September&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;954&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion at September&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">202000</us-gaap:OperatingLeaseRightOfUseAsset>
    <bntc:OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">794000</bntc:OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">49000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">947000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:OperatingLeaseLiability>
    <bntc:RemeasurementOfLeaseLiabilitiesDuringThePeriod
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">794000</bntc:RemeasurementOfLeaseLiabilitiesDuringThePeriod>
    <us-gaap:OperatingLeasePayments
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">51000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">954000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">760000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">194000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="PAsOn09_30_2021">P3Y8M15D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="PAsOn09_30_2021"
      decimals="4"
      unitRef="Unit_pure">0.0467</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P07_01_2021To09_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;235&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;287&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;297&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating lease payment&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of operating lease liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;954&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">235000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">287000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">297000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">228000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1047000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">93000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">954000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2020To09_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2020To09_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">45000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">45000</us-gaap:OperatingLeaseExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. Stockholders&#x2019; equity &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;6, 2020, the Company announced the closing of an underwritten public offering of 2,666,644 shares of its common stock at a price to the public of $3.10 per share. The Company also announced that the underwriter fully exercised its over-allotment option to purchase 483,870 additional shares of its common stock at the offering price of $3.10 per share. The gross and net proceeds were $11.5&#160;million and $9.9&#160;million, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;30, 2021, the Company announced the closing of an underwritten public offering of&#160;3,036,366&#160;shares of its common stock at a price to the public of $4.25&#160;per share. The Company also announced that the underwriter exercised the over-allotment option to purchase&#160;317,274&#160;additional shares of its common stock at the offering price of $4.25&#160;per share. The gross and net proceeds were $14.3&#160;million and $12.7&#160;million, respectively. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;6, 2020, the Company announced the closing of an underwritten public offering of 559,162 shares of common stock underlying &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants initially purchased for $3.09 per share and immediately exercisable at $0.01 per share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;Pre-Funded&lt;/div&gt; Warrants&#x201d;). All 559,162 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants issued had been exercised as of June&#160;30, 2021. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The activity related to warrants during for the three months ended&#160;September 30, 2021,&#160;is summarized as follows: &lt;/div&gt; &lt;br/&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Common&#160;Stock&lt;br/&gt; from Warrants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Exercise&#160;Price&lt;br/&gt; (per share)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; padding-top: 0pt; line-height: normal;"&gt;Outstanding at July&#160;1, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,095&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; padding-top: 0pt; line-height: normal;"&gt;Outstanding and exercisable at September&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,095&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee Share Option Plan &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Upon the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation,&lt;/div&gt; the Company assumed BBL&#x2019;s obligations with respect to the settlement of options that were issued by BBL prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation&lt;/div&gt; pursuant to the Benitec Officers&#x2019; and Employees&#x2019; Share Option Plan (the &#x201c;Share Option Plan&#x201d;). This includes the Company&#x2019;s assumption of the Share Option Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;exercise their options or the options are cancelled. After the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation,&lt;/div&gt; no new options have been or will be issued under the Share Option Plan. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity and Incentive Compensation Plan &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;9, 2020, the Company&#x2019;s stockholders approved the Company&#x2019;s 2020 Equity and Incentive Compensation Plan (the &#x201c;2020 Plan&#x201d;). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are outstanding under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company&#x2019;s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; on each anniversary of the applicable grant date for three years. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-employee&lt;/div&gt; director options vest in increments of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; on the day prior to each of the Company&#x2019;s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 12 months to exercise their options or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 90 days to exercise their options or the options are cancelled. Any future equity grants will be made under the 2020 Plan. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity Awards &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to equity awards, which are comprised of stock options during the three months&#160;ended September&#160;30, 2021,&#160;is summarized as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 92%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:59%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Stock&lt;br/&gt; Options&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Term&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Aggregate&lt;br/&gt; Intrinsic&#160;Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at June&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;702,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.07&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at September&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;702,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.82 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at September&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;54,158&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.84 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-Based Compensation Expense &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The classification of share-based compensation expense is summarized as follows:&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:83%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total share-based compensation expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of&#160;September 30, 2021, there was $1&#160;million of unrecognized share-based compensation expense related to stock options issued under the Share Option Plan and the 2020 Plan. &lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P10_06_2020To10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">2666644</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">3.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P10_06_2020To10_06_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">483870</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn10_06_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">3.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P10_06_2020To10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">11500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P10_06_2020To10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">9900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P04_30_2021To04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3036366</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">4.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P04_30_2021To04_30_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">317274</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn04_30_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">4.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P04_30_2021To04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">14300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P04_30_2021To04_30_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">12700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P10_06_2020To10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">559162</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">3.09</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn06_30_2021_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">559162</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="P07_01_2021To09_30_2021">&lt;br/&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Common&#160;Stock&lt;br/&gt; from Warrants&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Exercise&#160;Price&lt;br/&gt; (per share)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; padding-top: 0pt; line-height: normal;"&gt;Outstanding at July&#160;1, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,095&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; padding-top: 0pt; line-height: normal;"&gt;Outstanding and exercisable at September&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,095&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">107095</us-gaap:ClassOfWarrantOrRightOutstanding>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
      contextRef="PAsOn06_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.50</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_30_2021"
      decimals="INF"
      unitRef="Unit_shares">107095</us-gaap:ClassOfWarrantOrRightOutstanding>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
      contextRef="PAsOn09_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.50</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="P07_01_2021To09_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 92%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:59%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Stock&lt;br/&gt; Options&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Term&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;Aggregate&lt;br/&gt; Intrinsic&#160;Value&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at June&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;702,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.07&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at September&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;702,064&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.82 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at September&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;54,158&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.84 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">702064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2020To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P8Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">702064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P7Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">54158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">47.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P07_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P1Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P07_01_2021To09_30_2021">
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width:83%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total share-based compensation expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To09_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">81000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2020To09_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">9000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To09_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">190000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2020To09_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">29000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">271000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2020To09_30_2020"
      decimals="-3"
      unitRef="Unit_USD">38000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn09_30_2021"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Income taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For the three months ended September&#160;30, 2021, and 2020, the Company did not recognize a provision or benefit for income taxes as it has incurred net losses. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is more likely than not that the benefit will not be realized. &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Commitments and contingencies &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13. Related party transactions &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the three months ended September&#160;30, 2021, the Company had entered into a related party transaction with Francis Abourizk Lightowlers for legal fees totaling $1&#160;thousand. Peter Francis, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-executive&lt;/div&gt; director of the Company is a partner at Francis Abourizk Lightowlers. As of September&#160;30, 2021 and June&#160;30, 2021 there were amounts due to this related party of $1 thousand and $2 thousand, respectively, included in trade and other payables on the accompanying consolidated balance sheet. &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LegalFees
      contextRef="P07_01_2021To09_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:LegalFees>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="P07_01_2021To09_30_2021">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14. Subsequent events &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has evaluated subsequent events through the filing of this Quarterly Report on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Form&#160;10-Q,&lt;/div&gt; and determined that there have been no events that have occurred that would require adjustments or disclosures in the consolidated financial statements.&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895489941640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BENITEC BIOPHARMA INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-4620206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001808898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3940 Trust Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">780-0819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895495590696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,727<span></span>
</td>
<td class="nump">$ 19,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other assets</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">16,372<span></span>
</td>
<td class="nump">20,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">947<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">17,836<span></span>
</td>
<td class="nump">21,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Trade and other payables</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee benefits</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, less current portion</a></td>
<td class="nump">760<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,361<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value&#8212;10,000,000 shares authorized; 8,171,690 shares issued and outstanding at September&#160;30, 2021 and June&#160;30, 2021, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">151,854<span></span>
</td>
<td class="nump">151,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(135,164)<span></span>
</td>
<td class="num">(130,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,216)<span></span>
</td>
<td class="num">(1,455)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">15,475<span></span>
</td>
<td class="nump">20,010<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 17,836<span></span>
</td>
<td class="nump">$ 21,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895495320872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Par Value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">8,171,690<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares Outstanding</a></td>
<td class="nump">8,171,690<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895489572488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_RoyaltiesAndLicenseFees', window );">Royalties and license fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,780<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,042<span></span>
</td>
<td class="nump">1,837<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,822<span></span>
</td>
<td class="nump">2,745<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,822)<span></span>
</td>
<td class="num">(2,690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction loss</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investment</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other loss, net</a></td>
<td class="num">(223)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,045)<span></span>
</td>
<td class="num">(2,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized foreign currency translation gain</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (4,806)<span></span>
</td>
<td class="num">$ (2,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (2.45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">8,171,690<span></span>
</td>
<td class="nump">1,108,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_RoyaltiesAndLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties and license fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_RoyaltiesAndLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895489500648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Jun. 30, 2020</a></td>
<td class="nump">$ 10,238<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 128,826<span></span>
</td>
<td class="num">$ (116,636)<span></span>
</td>
<td class="num">$ (1,953)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeiture of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation loss (Gain)</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Sep. 30, 2020</a></td>
<td class="nump">7,736<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">128,850<span></span>
</td>
<td class="num">(119,340)<span></span>
</td>
<td class="num">(1,775)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Jun. 30, 2021</a></td>
<td class="nump">20,010<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">151,583<span></span>
</td>
<td class="num">(130,119)<span></span>
</td>
<td class="num">(1,455)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation loss (Gain)</a></td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Sep. 30, 2021</a></td>
<td class="nump">$ 15,475<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 151,854<span></span>
</td>
<td class="num">$ (135,164)<span></span>
</td>
<td class="num">$ (1,216)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,171,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895490037960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,045)<span></span>
</td>
<td class="num">$ (2,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_AmortizationOfRightOfUseAssets', window );">Amortization of right-of-use assets</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investment</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_IncreasedecreaseInAccountsAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">293<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued employee benefits</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,278)<span></span>
</td>
<td class="num">(2,360)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(4,042)<span></span>
</td>
<td class="num">(2,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">19,769<span></span>
</td>
<td class="nump">9,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">15,727<span></span>
</td>
<td class="nump">7,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Re-measurement of operating lease right-of-use assets and liabilities</a></td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AmortizationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AmortizationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease In lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncreasedecreaseInAccountsAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accounts and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncreasedecreaseInAccountsAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491396744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business</a></td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Business </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (the &#8220;Company&#8221;) is a corporation formed under the laws of Delaware, United States of America, on November&#160;22, 2019 and listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;BNTC&#8221;. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#8220;BBL&#8221;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April&#160;15, 2020. On August&#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&#8217;s business focuses on the development of novel genetic medicines. Our proprietary platform, called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DNA-directed</div> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with<div style="display:inline;">&#160;</div>gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended June&#160;30, 2021, the Company completed an organization res<div style="letter-spacing: 0px; top: 0px;;display:inline;">t</div>ructuring as part of the commercial desire to provide a more efficient structure for the future as the Company continues to transition its operations to the US. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s fiscal year end is June 30. References to a particular &#8220;fiscal year&#8221; are to our fiscal year end June&#160;30 of that calendar year. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principal&#160;place&#160;of</div></div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">business/country&#160;of</div></div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">incorporation</div></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Australia</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Australia Proprietary Limited</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Australia</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Limited</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">United Kingdom</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec LLC</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">RNAi Therapeutics, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tacere Therapeutics, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec IP Holdings, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td></tr></table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491478568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of presentation and summary of significant accounting policies</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Basis of Presentation and Summary of Significant Accounting Policies </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s consolidated financial statements contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with generally accepted accounting principles in the U.S. (&#8220;GAAP&#8221;)&#160;for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of U.S. Securities and Exchange Commission &#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended June&#160;30, 2021. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. </div>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with<div style="display:inline;">&#160;</div>government regulations and the need to obtain additional financing to fund operations. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;current&#160;COVID-19&#160;pandemic,&#160;which</div> is impacting worldwide economic activity, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented or inhibited from conducting business activities for an indefinite period of time which may <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">delay&#160;the&#160;start-up&#160;and&#160;conduct</div> of the Company&#8217;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#8217;s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company&#8217;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s functional currency and reporting currency is the United States dollar. BBL&#8217;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive loss.&#8221; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other comprehensive income for all periods presented includes only foreign currency translation gains. </div>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures its financial assets and liabilities in accordance with US&#160;GAAP using ASC 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements.</div></div> For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:6%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="2" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="2" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</td></tr></table></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2021, and June&#160;30, 2021, the Company had no financial assets or liabilities measured at fair value on a recurring basis. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade and Other Receivables </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </div>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective<div style="display:inline;">&#160;</div>accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 85%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 28%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 71%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Software</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">shorter of the lease term or estimated useful lives</div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/></div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade and other payables </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </div>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and Diluted Net Loss Per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of September&#160;30, 2021, and June&#160;30, 2021, there were 809,159 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue in accordance with that core principle by applying the following steps: </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606 &#8211; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (&#8220;ASC 606&#8221;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing revenues </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of products occur. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Services revenue </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expense </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being that the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. </div></div>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based Compensation Expense </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Compensation</div></div>. ASC 718 requires the fair value of all share-based compensation awarded to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation at fair value using the Black-Scholes Option Pricing Model. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to Australia and United States income tax laws. The Company follows ASC 740 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Income Taxes</div></div>, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13:</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments &#8211; Credit Losses</div></div> (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November&#160;15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates</div></div> amended the effective date for the Company to be for reporting periods beginning after December&#160;15, 2022. The Company will adopt this ASU effective July&#160;1, 2023. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895494327064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going concern<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_GoingConcernDisclosureTextBlock', window );">Going concern</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Going Concern </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the three months ended September&#160;30, 2021, and 2020, the Company incurred a net loss of $5.0&#160;million and&#160;$2.7&#160;million and used net cash of $4.3&#160;million and $2.4&#160;million in operations, respectively. The Company expects to continue to incur additional operating losses in the foreseeable future. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2021, the Company had $15.7&#160;million in cash and cash equivalents. The Company has performed a review of the cash flow forecasts and believes that the current funding will be sufficient for a period of at least twelve months from the date of this Report. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s ability to continue as a going concern is dependent upon its ability to generate revenue and obtain adequate financing. While the Company believes in its ability to generate revenue and raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>going concern due to unsuccessful product development or commercialization, or the inability to obtain adequate financing in the future. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going concern</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going concern disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491386744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Revenue </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"/>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:73%">&#160;</td>
<td style="vertical-align:bottom;width:11%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:11%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenues from customers (US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Months</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ended<br/> September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Months</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ended<br/> September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing revenue from services transferred overtime</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895572297752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash equivalents<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Cash and Cash equivalents </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:76%">&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash at Bank</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,727</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,727</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491399016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and other assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Prepaid and other assets</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Prepaid and other assets </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:77%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">763</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Security deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Market value of listed shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(169</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(185</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">642</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">814</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491482792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Property and equipment, net </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer hardware</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, gross</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated depreciation and amortization</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,069</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,018</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, net</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">323</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense was $0.1&#160;million for the three months ended September&#160;30, 2021, and $45&#160;thousand, respectively, for the <div style="letter-spacing: 0px; top: 0px;;display:inline;">same</div> period in 2020. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895572237208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Trade and other payables</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Trade and other payables </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade payable</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">323</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued license fees</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued&#160;<div style="text-indent: 0px;;display:inline;">OPMD project costs</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accrued bonuses</div></div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="text-align: right;">&#160;<div style="display:inline;">112</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right;"><div style="white-space: nowrap;;display:inline;">&#160;&#8212;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; width: 76%; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other payables</div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">86</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">174</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1,106</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">880</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895582965656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Leases </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into an operating lease for office space under an agreement that expires in 2022. The lease requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company&#8217;s lease does not contain any residual value guarantees or material restrictive covenants. During August 2021, the Company extended the lease thr<div style="letter-spacing: 0px; top: 0px;;display:inline;">o</div>ugh June 2025. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables below show the changes during the three months ended September&#160;30, 2021: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-</div></div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">use assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2021</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(49</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 88%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset at September&#160;30, 2021</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">947</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 88%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">954</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2021, the Company&#8217;s operating lease has a<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>remaining lease term of 3.71 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: &#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:85%">&#160;</td>
<td style="vertical-align:bottom;width:11%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2021</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">297</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease payment<div style="display:inline;">s</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">954</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded lease liabilities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease assets for the lease based on the present value of lease payments over the expected lease term, discounted using the Company&#8217;s incremental borrowing rate. Rent expense was $0.1&#160;million for the three months ended September&#160;30, 2021 and 2020, respectively, of which $7&#160;thousand was recorded in the general and administrative expense and $45&#160;thousand was record in research and development expenses. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895494574584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Stockholders&#8217; equity </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;6, 2020, the Company announced the closing of an underwritten public offering of 2,666,644 shares of its common stock at a price to the public of $3.10 per share. The Company also announced that the underwriter fully exercised its over-allotment option to purchase 483,870 additional shares of its common stock at the offering price of $3.10 per share. The gross and net proceeds were $11.5&#160;million and $9.9&#160;million, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;30, 2021, the Company announced the closing of an underwritten public offering of&#160;3,036,366&#160;shares of its common stock at a price to the public of $4.25&#160;per share. The Company also announced that the underwriter exercised the over-allotment option to purchase&#160;317,274&#160;additional shares of its common stock at the offering price of $4.25&#160;per share. The gross and net proceeds were $14.3&#160;million and $12.7&#160;million, respectively. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;6, 2020, the Company announced the closing of an underwritten public offering of 559,162 shares of common stock underlying <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants initially purchased for $3.09 per share and immediately exercisable at $0.01 per share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Pre-Funded</div> Warrants&#8221;). All 559,162 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funded</div> Warrants issued had been exercised as of June&#160;30, 2021. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activity related to warrants during for the three months ended&#160;September 30, 2021,&#160;is summarized as follows: </div> <br/>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Common&#160;Stock<br/> from Warrants</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted-<br/> average<br/> Exercise&#160;Price<br/> (per share)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding-top: 0pt; line-height: normal;">Outstanding at July&#160;1, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,095</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding-top: 0pt; line-height: normal;">Outstanding and exercisable at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,095</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Incentive Plan </div></div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Employee Share Option Plan </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> the Company assumed BBL&#8217;s obligations with respect to the settlement of options that were issued by BBL prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> pursuant to the Benitec Officers&#8217; and Employees&#8217; Share Option Plan (the &#8220;Share Option Plan&#8221;). This includes the Company&#8217;s assumption of the Share Option Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>exercise their options or the options are cancelled. After the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> no new options have been or will be issued under the Share Option Plan. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Equity and Incentive Compensation Plan </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;9, 2020, the Company&#8217;s stockholders approved the Company&#8217;s 2020 Equity and Incentive Compensation Plan (the &#8220;2020 Plan&#8221;). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are outstanding under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company&#8217;s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on each anniversary of the applicable grant date for three years. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> director options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on the day prior to each of the Company&#8217;s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 12 months to exercise their options or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan) and certain exercise conditions have been satisfied, generally, the option holder has 90 days to exercise their options or the options are cancelled. Any future equity grants will be made under the 2020 Plan. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Equity Awards </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to equity awards, which are comprised of stock options during the three months&#160;ended September&#160;30, 2021,&#160;is summarized as follows: </div></div></div> <div style="margin-top: 0px; margin-bottom: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 92%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:59%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Stock<br/> Options</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted-<br/> average<br/> Exercise<br/> Price</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted-<br/> average<br/> Remaining<br/> Contractual&#160;Term</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Aggregate<br/> Intrinsic&#160;Value</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">702,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.07&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">702,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.82 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">54,158</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.84 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Share-Based Compensation Expense </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The classification of share-based compensation expense is summarized as follows:</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"/>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:83%">&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of&#160;September 30, 2021, there was $1&#160;million of unrecognized share-based compensation expense related to stock options issued under the Share Option Plan and the 2020 Plan. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491387304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Income taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three months ended September&#160;30, 2021, and 2020, the Company did not recognize a provision or benefit for income taxes as it has incurred net losses. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is more likely than not that the benefit will not be realized. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895609700712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Commitments and contingencies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract commitments </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895494248760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Related party transactions </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended September&#160;30, 2021, the Company had entered into a related party transaction with Francis Abourizk Lightowlers for legal fees totaling $1&#160;thousand. Peter Francis, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> director of the Company is a partner at Francis Abourizk Lightowlers. As of September&#160;30, 2021 and June&#160;30, 2021 there were amounts due to this related party of $1 thousand and $2 thousand, respectively, included in trade and other payables on the accompanying consolidated balance sheet. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895494235128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Subsequent events </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through the filing of this Quarterly Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-Q,</div> and determined that there have been no events that have occurred that would require adjustments or disclosures in the consolidated financial statements.</div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895495523816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s consolidated financial statements contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with generally accepted accounting principles in the U.S. (&#8220;GAAP&#8221;)&#160;for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of U.S. Securities and Exchange Commission &#8220;SEC&#8221;) Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended June&#160;30, 2021. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_RisksAndUncertainitiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with<div style="display:inline;">&#160;</div>government regulations and the need to obtain additional financing to fund operations. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;current&#160;COVID-19&#160;pandemic,&#160;which</div> is impacting worldwide economic activity, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented or inhibited from conducting business activities for an indefinite period of time which may <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">delay&#160;the&#160;start-up&#160;and&#160;conduct</div> of the Company&#8217;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#8217;s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company&#8217;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s functional currency and reporting currency is the United States dollar. BBL&#8217;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive loss.&#8221; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other comprehensive income for all periods presented includes only foreign currency translation gains. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures its financial assets and liabilities in accordance with US&#160;GAAP using ASC 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements.</div></div> For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:95%;border:0;margin-left:auto">
<tr style="font-size: 0px;">
<td style="width:6%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;1:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="2" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;2:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="2" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Level&#160;3:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</td></tr></table></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2021, and June&#160;30, 2021, the Company had no financial assets or liabilities measured at fair value on a recurring basis. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy', window );">Trade and Other Receivables</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade and Other Receivables </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective<div style="display:inline;">&#160;</div>accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 85%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 28%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 71%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Software</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">shorter of the lease term or estimated useful lives</div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_TradeAndOtherPayablesPolicyTextBlock', window );">Trade and other payables</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade and other payables </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and Diluted Net Loss Per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of September&#160;30, 2021, and June&#160;30, 2021, there were 809,159 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue in accordance with that core principle by applying the following steps: </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606 &#8211; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (&#8220;ASC 606&#8221;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing revenues </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of products occur. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Services revenue </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expense </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-clinical</div> and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being that the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation Expense</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based Compensation Expense </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Compensation</div></div>. ASC 718 requires the fair value of all share-based compensation awarded to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation at fair value using the Black-Scholes Option Pricing Model. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to Australia and United States income tax laws. The Company follows ASC 740 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Income Taxes</div></div>, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13:</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments &#8211; Credit Losses</div></div> (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November&#160;15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates</div></div> amended the effective date for the Company to be for reporting periods beginning after December&#160;15, 2022. The Company will adopt this ASU effective July&#160;1, 2023. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_RisksAndUncertainitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_RisksAndUncertainitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_TradeAndOtherPayablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_TradeAndOtherPayablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -URI http://asc.fasb.org/topic&amp;trid=2196771<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895494571000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlTableTextBlock', window );">Summary of entities in control</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principal&#160;place&#160;of</div></div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">business/country&#160;of</div></div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">incorporation</div></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Australia</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Australia Proprietary Limited</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Australia</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Limited</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">United Kingdom</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec LLC</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">RNAi Therapeutics, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tacere Therapeutics, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec IP Holdings, Inc.</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of entities in control.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895494248760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Summary of property and equipment</a></td>
<td class="text">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 85%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 28%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 71%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Software</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">shorter of the lease term or estimated useful lives</div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491231464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of revenue from customers</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:73%">&#160;</td>
<td style="vertical-align:bottom;width:11%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:11%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenues from customers (US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Months</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ended<br/> September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Months</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ended<br/> September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing revenue from services transferred overtime</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895494174024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of cash and cash equivalent</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:76%">&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash at Bank</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,727</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,727</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895495545080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and other assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Summary of other current assets</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:77%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">763</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Security deposit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Market value of listed shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(169</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(185</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">642</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">814</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895494152696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment net</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer hardware</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, gross</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated depreciation and amortization</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,069</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,018</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, net</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">323</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895494120952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of trade and other payables</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade payable</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">323</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued license fees</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 76%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued&#160;<div style="text-indent: 0px;;display:inline;">OPMD project costs</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="display:inline;">Accrued bonuses</div></div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="text-align: right;">&#160;<div style="display:inline;">112</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; width: 5%; padding: 0pt 5pt 0pt 0pt; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; text-align: right;"><div style="white-space: nowrap;;display:inline;">&#160;&#8212;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; width: 76%; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other payables</div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">86</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">174</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">1,106</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">880</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 76%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 8%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491481672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of the operating lease liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:85%">&#160;</td>
<td style="vertical-align:bottom;width:11%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">September&#160;30,<br/> 2021</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2022</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">297</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease payment<div style="display:inline;">s</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(93</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">954</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Summary of supplemental balance sheet information related to leases</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-</div></div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">use assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2021</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(49</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 88%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 88%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset at September&#160;30, 2021</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">947</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 88%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:88%">&#160;</td>
<td style="vertical-align:bottom;width:8%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at July&#160;1, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">954</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491390728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants or rights</a></td>
<td class="text"><br/>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%">&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:7%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Common&#160;Stock<br/> from Warrants</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;">Weighted-<br/> average<br/> Exercise&#160;Price<br/> (per share)</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding-top: 0pt; line-height: normal;">Outstanding at July&#160;1, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,095</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding-top: 0pt; line-height: normal;">Outstanding and exercisable at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,095</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of equity awards</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 92%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:59%">&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:5%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Stock<br/> Options</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted-<br/> average<br/> Exercise<br/> Price</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Weighted-<br/> average<br/> Remaining<br/> Contractual&#160;Term</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Aggregate<br/> Intrinsic&#160;Value</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">702,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.07&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">702,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.82 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at September&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">54,158</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.84 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share-basedcompensation expense</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr>
<td style="width:83%">&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="vertical-align:bottom;width:6%">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-weight:bold;display:inline;width:100%;">(US$&#8217;000)</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895489442296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business - Summary of entities in control (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember', window );">Benitec Biopharma Proprietary Limited ("BBL") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember', window );">Benitec Australia Proprietary Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember', window );">Benitec Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember', window );">Benitec, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember', window );">Benitec LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember', window );">RNAi Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember', window );">Tacere Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedMember', window );">Benitec Biopharma Proprietary Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895495468264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember', window );">Lab equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember', window );">Lab equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">shorter of the lease term or estimated useful lives<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491272840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">809,159<span></span>
</td>
<td class="nump">809,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies [Line Items].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895574803672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going concern - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (5,045)<span></span>
</td>
<td class="num">$ (2,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in provided by operations</a></td>
<td class="num">(4,278)<span></span>
</td>
<td class="num">(2,360)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,727<span></span>
</td>
<td class="nump">$ 7,450<span></span>
</td>
<td class="nump">$ 19,769<span></span>
</td>
<td class="nump">$ 9,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going concern</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491544824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of revenue from customers (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue [Member] | Transferred over Time [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491516920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash equivalents - Summary of cash and cash equivalent (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromBanks', window );">Cash at Bank</a></td>
<td class="nump">$ 15,727<span></span>
</td>
<td class="nump">$ 19,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total</a></td>
<td class="nump">$ 15,727<span></span>
</td>
<td class="nump">$ 19,769<span></span>
</td>
<td class="nump">$ 7,450<span></span>
</td>
<td class="nump">$ 9,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A bank's noninterest bearing demand deposits in other banks (such as correspondents).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895580980088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid and other assets - Summary of other current assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 763<span></span>
</td>
<td class="nump">$ 967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_MarketValueOfListedShares', window );">Market value of listed shares</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Total other assets</a></td>
<td class="nump">811<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Less:&#160;non-current&#160;portion</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Current portion</a></td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">$ 814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_MarketValueOfListedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market value of listed shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_MarketValueOfListedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895495353656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net - Summary  of property and equipment net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 1,392<span></span>
</td>
<td class="nump">$ 1,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(1,069)<span></span>
</td>
<td class="num">(1,018)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,328<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895491412696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895580800344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other payables- Summary of trade and other payables (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payable</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_AccruedLicenceFeesCurrent', window );">Accrued license fees</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_AccruedOpmdProjectCostsCurrent', window );">Accrued OPMD Project Costs Current</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued Bonuses, Current</a></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other payables</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,106<span></span>
</td>
<td class="nump">$ 880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AccruedLicenceFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued licence fees current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AccruedLicenceFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AccruedOpmdProjectCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued OPMD project costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AccruedOpmdProjectCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895495467672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of maturities of the operating lease liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(93)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 954<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895574845896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease has a remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_OperatingLeaseMonthOfMaturityRevised', window );">Opearting lease month of maturity revised</a></td>
<td class="text">2025-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_OperatingLeaseMonthOfMaturityRevised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease month of maturity revised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_OperatingLeaseMonthOfMaturityRevised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895489583384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of supplemental balance sheet information related to leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Initial measurement at July&#160;1, 2021</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod', window );">Re-measurement during the period</a></td>
<td class="nump">794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use asset</a></td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset at September&#160;30, 2021</a></td>
<td class="nump">947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Initial measurement at July&#160;1, 2021</a></td>
<td class="nump">213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod', window );">Re-measurement during the period</a></td>
<td class="nump">794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Principal payments on operating lease liabilities</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities at September&#160;31, 2021</a></td>
<td class="nump">954<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Less: non-current portion</a></td>
<td class="num">(760)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion at September 31, 2021</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use asset remasurement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of lease liabilities during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895489508136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of warrants or rights (Detail)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period | shares</a></td>
<td class="nump">107,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, ending of period | shares</a></td>
<td class="nump">107,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding', window );">Exercise price of class of warrants or rights outstanding | $ / shares</a></td>
<td class="nump">$ 10.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding', window );">Exercise price of class of warrants or rights outstanding and excercisable | $ / shares</a></td>
<td class="nump">$ 10.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price of class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895490066520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of equity awards (Detail) - Employee stock option - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options,Outstanding, beginning of period</a></td>
<td class="nump">702,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding, end of period</a></td>
<td class="nump">702,064<span></span>
</td>
<td class="nump">702,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable, end of period</a></td>
<td class="nump">54,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price, beginning of period</a></td>
<td class="nump">$ 7.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercise price, end of period</a></td>
<td class="nump">7.16<span></span>
</td>
<td class="nump">$ 7.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercisable, end of period</a></td>
<td class="nump">$ 47.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Term, Outstanding</a></td>
<td class="text">7 years 9 months 25 days<span></span>
</td>
<td class="text">8 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Term, Exercisable</a></td>
<td class="text">1 year 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895581099272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Summary of share-based compensation expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895489227208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' equity - Additional information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Oct. 06, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognised share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">3,036,366<span></span>
</td>
<td class="nump">2,666,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share</a></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="nump">$ 14.3<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock net consideration received on the transaction</a></td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">317,274<span></span>
</td>
<td class="nump">483,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share</a></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember', window );">Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Number of Warranrs exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139895574852168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Amount due to related party</a></td>
<td class="nump">$ 1,106<span></span>
</td>
<td class="nump">$ 880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_FrancisAbourizkLightowlersMember', window );">Francis Abourizk Lightowlers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Amount due to related party</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_FrancisAbourizkLightowlersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_FrancisAbourizkLightowlersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>69
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M9SZ7^@-XOQ9"G6_T#^3GJ,/_ %!+ P04    " !(,6]3\(*[W28%  "U$P
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M',[L;<9HRJ0Q@/^W0NB7!S- \]%F_3]02P,$%     @ 2#%O4[8,YRDV!
MAA   !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RM6&UOVS80_BN$4& )
M,$>BWEW8!AHYWCJL75"WVV=&HB,BDNB25-S\^Y&R(ML4)3M;OUBB]#S'AW?'
M.]&S'65//,=8@!]E4?&YE0NQ?6_;/,UQB?@-W>)*OME05B(AA^S1YEN&4=:0
MRL)V'2>T2T0J:S%KGMVSQ8S6HB 5OF> UV6)V,LM+NAN;D'K]<$7\I@+]<!>
MS+;H$:^Q^+:]9W)D=U8R4N**$UH!AC=SZP-\OX*A(C2(OPG>\:-[H);R0.F3
M&GS,YI:C%.$"IT*90/+RC!-<%,J2U/&]-6IU<RKB\?VK]56S>+F8!\1Q0HM_
M2";RN15;(,,;5!?B"]W]CML%!<I>2@O>_(+='AMY%DAK+FC9DJ6"DE3[*_K1
M.N*( (<(;DMP+R5X+<'3"&XT0/!;@J\3G %"T!("C> -S1"VA":8]MY9C:>7
M2*#%C-$=8 HMK:F;)EP-6SJ85"JSUH+)MT3RQ"*A%:<%R9# &5@+>9%I(SB@
M&SFBZ5-.BPPS_@NX^UX3\0(FX-MZ":[>78-W@%3@:TYKCJJ,SVPAU2B;=MK.
M?+N?V1V8^2L5J##0DG%:0LM29B17X@SLY3C[0Y81E=&H />(9!.YA 1MB5G)
MW1E;:5J7==%X;HDW)"7"8&1UN9&_1(X9D N4-2)7F_<9@S\IUWQKRPAW87:[
M,+O--/[ -+>H0%6* 1) 3@(>\".I*E(]J@=_U-4-\)Q?@>NXCBF.>]-A8UI5
MJN<%=%POGMG/QV$SH$X12P/"C6,W/(7=]6$3",/0TW K$VX:>!WJQ%%>YRCO
MOSGJZJ-,NAPQS*\O<5JRGR8X7BQT8B_RS?K\3I\_JF^M)$Q4+<U *C-%I@E2
M"6V*F]^3H =M.0HY$1AT H-1@;+>;S 1-<.JAO CN5OTTM06TZX->CHFT-?R
MHH^! \X,.ZWA.:VR\U2RSC*&J_0%"(8J7C0.!87<>>#J-]F<KTW.#?MJ(LV[
MJW',B>2HDQR-2OXL/S:*7DW82XKZ3G0CJ(FZ.X<ZD15WLN)+MPVN,G59X^UX
M58E[.J)(W^-)?+:H],VHHA(XVJK[,%E4IIZOX58F7!0%9N],.^],W^(=K92<
M\U0R?5LI@<ZA]SL_I2M 8W=W>K+DYRS4')JTL+$0&BS!  :QI\70@)M SY%Q
MU()H!/K!0!3AT;<2_.G-P>2[I)WG6& ,(QA.G0&)ASX/QQO]6_I#:^HD@E$O
M...@4YF'+@O'V^S_J;RPWUI=KY<"XZ!3V8?F"\>[[UCUA?U>.@D</]"3^!SL
M5-JA[<+QOCM>@<T[..AOS<"/ GT'&V!ZDI@LP3C06[@!)W=P $-?#Y\)Z,)P
MP$N'A@_'._[EE=B\;_L=W;QO[:,3F3JA?T),U@H."KR13.<FDB;8_M"['PBZ
M;0YI#U3((U]SFV,DCUX*(-]O*!6O W7NZ_YZ6/P+4$L#!!0    ( $@Q;U,[
M0IJ_" 4  + 2   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULE5C;;MLX
M$/T5PNC#+E#'(B59=N 82-P6NT#;#>IV]YF1QA:WDNB2="[]^B4I15(DBMN\
M6!?/D&<.9^90W#QP\5WF  H]ED4EKV:Y4J?+Q4*F.9147O 35/J? Q<E5?I1
M'!?R)(!FUJDL%B0(EHN2LFJVW=AWMV*[X6=5L IN!9+GLJ3BZ08*_G UP[/G
M%U_8,5?FQ6*[.=$C[$%].]T*_;1H1\E8"95DO$("#E>S:WRY([%QL!9_,WB0
MO7MD0KGC_+MY^#.[F@4&$120*C,$U9=[V$%1F)$TCA_-H+-V3N/8OW\>_8,-
M7@=S1R7L>/$/RU1^-5O-4 8'>B[4%_[P!S0!68 I+Z3]10^U;;*<H?0L%2\;
M9XV@9%5]I8\-$3T'/8[;@30.9.@033B$C4-H ZV1V;#>446W&\$?D##6>C1S
M8[FQWCH:5IEEW"NA_V7:3VUWO)*\8!E5D*&]TA>]1DHB?D [*G/T0:^S1'/T
M;?\._?;F=_0&L0I]S?E9TBJ3FX72&,Q(B[29[Z:>CTS,%Z)/O%*Y1.^K#+*7
M_@N-O0V / =P0[P#[N%T@<+@+2(!P0X\NU]W#SQPPI;/T(X73O%I2#M8T@Z"
METC7FZ"*5<<Z89EB("\]\T3M/)&=)YJ8Y[.N\()+YPK4GDOK:<KX?CN/@RC>
M+.[[O#BL2()7K=4+6'$+*_:&?YW]JW.V3B'%=9VGO$I9 :AJ\)JWYCXU/)VE
M3CJ=3Z\E:=FB67I)>@>ZM:6,U@VCRA MN5#LIWWA8JX>+NYQ$I,!;6.3'K,O
M4"8MRL2+\KH'RM2=,)UGS@]S30^B4H)RKG(RQAH,L(Y-HL2-==5B77FQ?JNT
M5A3LIUXWNYH:,:ONH5YR%\K5",*\EV,US+%-X$:Y;E&NO2CW.14P-]T]0RDO
MM>3)FEUX-/?@ KH>@=#5,  ZM@DGZ@4'7?\-_ TCI]41Y* ,[*K;E"T8O6/%
M_Y8$[C5\["7GJZ 9V*&YRD&8&@5V3^\*<+=S[%F=FA:'"9G(,TPZF,0+\R\+
M;CK]&_?^I#A9#Y&-C<(DFH#6M7@<OHK!$WV:IB\<<[,.AS#'1G.,UQ,X.XG
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M2# 5I?)W9O,)ZWR.F2\VRH5?V%2VHZ,.Q*7S)J_!%$$N=?4OGNLZ[ !.!P<
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M(,4UJ[BYD=O/N(NG;_D2R;5;85OK]@8>))4V4NS Y('(B_K-'G=Y. ",@E<
MT0X0.;]K0\[+"V;8=*SD%I35)C:[<:$Z-#F7%_:C+(VBVYQP9KI0]'V5>0)6
MI(#W55Y2QDT'"C1CWY !J^8G.[)Y31:]0A;#M2Q,IN&R2#']%^^38XUWT=Z[
M>724<(EE%^*@ U$0A4?XXB;:V/'%;T3;@05GA7%!7SX'_8V:X-=LI8VB8OE]
MQ%ZOL==S]GK_)[M'R6Q[GNF2)3CQJ/\TJ@?TIC#LPA$KK0^WR_;[=Z,H''X,
M@N $**,&Q0I5DU;X6A782*VE7)LM4PAM"'MN:5VQU3,MA)TX&KGUM'4N15D9
M(LN82ATJ&M#3ND)JE$SR%')1*OF %JDAZM'3^BX-XU"^XO1&2:TM_6GDUK@U
M2Y)*5)P93*G?*/0D9W5'$Y()J4S^IS[X$':"P2F<N$TX@I,W;%&"*,(XBNTZ
M[+<N#MGQD0:?1M@R#>V@&U+W<6XO:!*"R9!^"A%$7?%H*_Z%[':<S7:O3^JR
MTB1T:);I$MTTXE2)>SK-!+Y4<OY!<PM4&S?"-"2R*DS=Y\UI,R5G]7!X5J]'
M[#53F[S0P'%-T* [['N@ZK%5"T:6;E2LI*'!X[8937I45H'NUU*:O6 --/\=
MT[]02P,$%     @ 2#%O4V1AJ]-S @  704  !D   !X;"]W;W)K<VAE971S
M+W-H965T,30N>&ULK51=;],P%'WOK[@*$P)I:K[:K=O:2NT& J1IU;K! ^+!
M26Z:,,<.MD.W?\^UDX9.HGWB)?;U/>?<C_AZNI7J21>(!IXK+O3,*XRI+WU?
MIP563 ]EC8(\N505,V2JC:]KA2QSI(K[41"<^14KA3>?NK.5FD]E8W@I<*5
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MB\N&9QVZ .#SG;5T,(+ .#V7OP!02P,$%     @ 2#%O4S(]GF(K @  T 0
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M]N\<KV*.\.UBX\EQ17P_@I^/^'G$S__G"H\B0N>=^TX6N!3<6A[=(XI\.I_
M'VSXU"!<VK:3YAD:Z7E9ZEX2EMQ7O_M2XVQ?-SPB5(H/K<%6;"D/M[UTA$X_
MPQUVUA%PAX0RAVGZZO8$_G8MR4&5M>CJV$L>"ML;&@IN7!W;]6*HTI_N0Z]?
M2U<KXT%CQ=)T\N94@!OZ9S#(=K%F-Y:X ^*TX2<'77#@_<I:VAOA@/$1RW\
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M @+^NE9()"T]@/M+8YKX@S9(?[OC]?\!4$L#!!0    ( $@Q;U.=HSPQA@(
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M3@/0=4NH%U:5O@P7RE)1^VE.712U,Z#SI5)VNW .FKX\_@=02P,$%     @
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M:318W,ZCF\'U<N3]@\,GB0=W9(.O9&W,9[]XO9E'B2>$"G/R"()?7_$6E?)
M3.-+@QFU*7W@L?V(_E>HG6M9"X>W1OTM-[2?1Y,(-K@5E:([<WB%33V!8&Z4
M"T\XU+Y7[)Q7CDS1!#.#0NKZ+;XU.AP%3)(G M(F( V\ZT2!Y4M!8C&SY@#6
M>S.:-T*I(9K)2>T_RCU9/I4<1XNWR"4YZ'\0:X7N?!83@_JC.&\ EC5 ^@1
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M2I=.V\SU\PG" /3\BG.UZY@%V@=Y]!=02P,$%     @ 2#%O4ZS;]@YX @
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M2+U4[0QL-T8NW1B92T-:W+*DWP8JZT#GA91FN[$!_(\H_0502P,$%     @
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M;&ZLMXZ&,+.+2R7T+-%^:K80D&.2(,P2Q%4* F$I04ETB9;EQB*^J6;6A1#
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M>'T9U1/)2G.>KYE4MX,9INK^1JX%ZGW"F-Q-]!71_B,(_P-02P,$%     @
M2#%O4]1'Y/V0 @  20<  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
MC57=;YLP$/]7+-2'5EH#X2,?%4%J4TW;U$E1TVX/TQZ<< E6#6;VD;3__<Y
M4;20="]@F_M]W&&?X[W2+R8#0/::R\+,G RQO'%=L\X@YV:@2BCHRT;IG"--
M]=8UI0:>UJ!<NK[GC=R<B\))XGIMH9-852A% 0O-3)7G7+_=@53[F3-TWA<>
MQ39#N^ F<<FWL 1\+A>:9F['DHH<"B-4P31L9L[M\&8^M?%UP \!>W,P9C:3
ME5(O=O(UG3F>-002UF@9.+UV, <I+1'9^--R.IVD!1Z.W]D_U[E3+BMN8*[D
M3Y%B-G,F#DMAPRN)CVK_!=I\(LNW5M+43[9O8SV'K2N#*F_!Y" 71?/FKVT=
M#@##\ 3 ;P'^_P*"%A#4B3;.ZK3N.?(DUFK/M(TF-CNH:U.C*1M1V+^X1$U?
M!>$P>0"J@6'7;-G\1J8V1(^5%BAHG6:8 :--HSF*8LNDC6=2\)603<CE/2 7
M\HHXGI?W[/+BBETP4;"G3%6&%ZF)722C5LY=MZ;N&E/^"5-+* <L\#XQW_.'
M/?#Y>?BWJC@%=ZD\78W\KD9^S1><K]&OVY5!3?ON]QG.H.,,:L[P!"=9\_L*
MTZ!&-<J>P%WB!U'L[GJDPDXJ_$@JZ)-J4-&AU&3<+Q5U4M%'4F&?5'0L-3TA
M->JD1A])17U2HV,I?](O->ZDQF>EGA1R>70&2OY&W0Q[M_?XR,30"T\D/.E<
M3,ZZ> !CF,C+"B&E\X6@P6"?^.1(_'H:]&M/.^WI6>T%:5&N;,=E!;8IG&D(
M?9:F1[MZ&H6=I>9,'\?XPW]MNP>-SEXRW[G>BL*0B0VAO,&8LM9-XVXFJ,JZ
M]ZT44B>MAQG==:!M 'W?*(7O$]M.N]LS^0M02P,$%     @ 2#%O4^P9-4\'
M P  = D  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULK59M;]HP$/XK
M5M1)K;22%T*@%2#QTKU(JU:UZ_9AV@=##F(UB3/;@?+O=W9"FB'P5JE?P';N
M>>ZYN^3.PRT73S(!4.0Y2W,Y<A*EBFO7E<L$,BH[O( <GZRXR*C"K5B[LA!
M8P/*4C?PO,C-*,N=\="<W8GQD)<J93G<"2+++*-B-X64;T>.[^P/[MDZ4?K
M'0\+NH8'4(_%G<"=V[#$+(-<,IX3 :N1,_&OY[ZG <;B.X.M;*V)#F7!^9/>
M?(Y'CJ<500I+I2DH_FU@!FFJF5#'[YK4:7QJ8'N]9_]@@L=@%E3"C*<_6*R2
MD3-P2 PK6J;JGF\_01U03_,M>2K-+]E6ME'DD&4I%<]J,"K(6%[]T^<Z$2T
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M;(S%4OX(X@=&EFX77TN#9P)WF>.Q#92=@,\W4IK[@5V@.0C.?P-02P,$%
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M6\$$TM0PH8['BM2ISS3 YGC#_LTFC\DLJ(*)2/^P2"=#I^>0"&):I/I6K']
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $@Q;U/ 6KX5+04  %,5   8
M          " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !(,6]3\(*[W28%  "U$P  &               @(%O#0  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 2#%O4\9Y?#IH @  C08
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M965T-RYX;6Q02P$"% ,4    " !(,6]3G)$,K^H3  "<.   &
M    @(&E*   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M2#%O4\8"5T7[ P  +0D  !@              ("!Q3P  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( $@Q;U.RHZ\>)@(  ,@$   9
M          " @?9   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#
M%     @ 2#%O4\OUB*HD @  VP0  !D              ("!4T,  'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !(,6]3#V<<T',"  !#
M!0  &0              @(&N10  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;%!+ 0(4 Q0    ( $@Q;U-DG$5*W (  $<&   9              " @5A(
M  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 2#%O4V1A
MJ]-S @  704  !D              ("!:TL  'AL+W=O<FMS:&5E=',O<VAE
M970Q-"YX;6Q02P$"% ,4    " !(,6]31,+&E]<#  #'"   &0
M    @($53@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M $@Q;U._N@1O&08  #00   9              " @2-2  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ 2#%O4TKITKBN @  S@4  !D
M             ("!<U@  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !(,6]3# P>1RL#   T!P  &0              @(%86P  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $@Q;U.Q;X;\6 (
M $D%   9              " @;I>  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ 2#%O4S(]GF(K @  T 0  !D              ("!
M26$  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !(,6]3
M++#UB5,5  #'0P  &0              @(&K8P  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( $@Q;U.=HSPQA@(  )L%   9
M      " @35Y  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ 2#%O4UFS%2:1 @  FP4  !D              ("!\GL  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !(,6]3:LE+^S$"  #@!
M&0              @(&Z?@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( $@Q;U.-KRB:+P(  -$$   9              " @2*!  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 2#%O4UPAJY"
M @  -P4  !D              ("!B(,  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !(,6]33RIIHYP"  "C!0  &0
M@($_A@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $@Q
M;U/L>I&G? (  %4%   9              " @1*)  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ 2#%O4PBH*3L= P  < <  !D
M         ("!Q8L  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " !(,6]3ZTU9IR<#  "S!P  &0              @($9CP  >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( $@Q;U-^WY$^3P,  ,$0
M   9              " @7>2  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ 2#%O4Q.6<NA) P  @ X  !D              ("!_94
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !(,6]3\.#
MQ-D"  #J!P  &0              @(%]F0  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( $@Q;U.OB!BOP@(  )P'   9
M  " @8V<  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M2#%O4ZS;]@YX @  E 8  !D              ("!AI\  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " !(,6]3@G/G1TD"  !.!@  &0
M            @($UH@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( $@Q;U.Z+7(KN (  *0'   9              " @;6D  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 2#%O4_8\3:HA P
M_PL  !D              ("!I*<  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " !(,6]389*M[4L"  !6!0  &0              @('\
MJ@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $@Q;U-;
MWKCBO0(  !T(   9              " @7ZM  !X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ 2#%O4]1'Y/V0 @  20<  !D
M     ("!<K   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $@Q;U,>3!>4X0(  ,X(   9              "
M@0+   !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 2#%O
M4TYHVB'7 P  [0P  !D              ("!&L,  'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " !(,6]3]?"/LYD"    !P  &0
M        @($HQP  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( $@Q;U,OZEJ"'@,  # 2   -              "  ?C)  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ 2#%O4Y>*NQS     $P(   L
M ( !0<T  %]R96QS+RYR96QS4$L! A0#%     @ 2#%O4VCPMJ(8!   Z!\
M  \              ( !*LX  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M $@Q;U.2+*"6N $  .<<   :              "  6_2  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $@Q;U.,3^J/N@$  .X<   3
M              "  5_4  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     X
- #@ /P\  $K6      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>80</ContextCount>
  <ElementCount>255</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Going concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/GoingConcern</Role>
      <ShortName>Going concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Cash and Cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Prepaid and other assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets</Role>
      <ShortName>Prepaid and other assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessTables</Role>
      <ShortName>Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Business</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Revenue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Cash and Cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Prepaid and other assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables</Role>
      <ShortName>Prepaid and other assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Trade and other payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables</Role>
      <ShortName>Trade and other payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Leases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Business - Summary of entities in control (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail</Role>
      <ShortName>Business - Summary of entities in control (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Going concern - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail</Role>
      <ShortName>Going concern - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Revenue - Summary of revenue from customers (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail</Role>
      <ShortName>Revenue - Summary of revenue from customers (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Cash and Cash equivalents - Summary of cash and cash equivalent (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail</Role>
      <ShortName>Cash and Cash equivalents - Summary of cash and cash equivalent (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Prepaid and other assets - Summary of other current assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid and other assets - Summary of other current assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and equipment, net - Summary  of property and equipment net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Property and equipment, net - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and equipment, net - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail</Role>
      <ShortName>Trade and other payables- Summary of trade and other payables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Summary of maturities of the operating lease liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Leases - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Leases - Summary of supplemental balance sheet information related to leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail</Role>
      <ShortName>Leases - Summary of supplemental balance sheet information related to leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail</Role>
      <ShortName>Stockholders' equity - Schedule of warrants or rights (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail</Role>
      <ShortName>Stockholders' equity - Schedule of equity awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail</Role>
      <ShortName>Stockholders' equity - Summary of share-based compensation expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Stockholders' equity - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' equity - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d230065d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Related party transactions - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related party transactions - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="d230065d10q.htm">d230065d10q.htm</File>
    <File>bntc-20210930.xsd</File>
    <File>bntc-20210930_cal.xml</File>
    <File>bntc-20210930_def.xml</File>
    <File>bntc-20210930_lab.xml</File>
    <File>bntc-20210930_pre.xml</File>
    <File>d230065dex311.htm</File>
    <File>d230065dex312.htm</File>
    <File>d230065dex321.htm</File>
    <File>d230065dex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g230065g1103070755124.jpg</File>
    <File>g230065g1103070755608.jpg</File>
    <File>g230065g1103070758718.jpg</File>
    <File>g230065g1103070759171.jpg</File>
    <File>g230065g1103070759608.jpg</File>
    <File>g230065g1103070800124.jpg</File>
    <File>g230065g1103070800546.jpg</File>
    <File>g230065g1103070800905.jpg</File>
    <File>g230065g1103070801374.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d230065d10q.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "contextCount": 80,
   "dts": {
    "calculationLink": {
     "local": [
      "bntc-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bntc-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d230065d10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bntc-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bntc-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bntc-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 300,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 6,
    "total": 6
   },
   "keyCustom": 18,
   "keyStandard": 237,
   "memberCustom": 11,
   "memberStandard": 20,
   "nsprefix": "bntc",
   "nsuri": "http://www.benitecbiopharmainc.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://www.benitecbiopharmainc.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Revenue",
     "role": "http://www.benitecbiopharmainc.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Cash and Cash equivalents",
     "role": "http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents",
     "shortName": "Cash and Cash equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Prepaid and other assets",
     "role": "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets",
     "shortName": "Prepaid and other assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Property and equipment, net",
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet",
     "shortName": "Property and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Trade and other payables",
     "role": "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables",
     "shortName": "Trade and other payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Leases",
     "role": "http://www.benitecbiopharmainc.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Stockholders' equity",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquity",
     "shortName": "Stockholders' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Income taxes",
     "role": "http://www.benitecbiopharmainc.com/role/IncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Commitments and contingencies",
     "role": "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Related party transactions",
     "role": "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions",
     "shortName": "Related party transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Subsequent events",
     "role": "http://www.benitecbiopharmainc.com/role/SubsequentEvents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:ScheduleOfEntitiesInControlTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Business (Tables)",
     "role": "http://www.benitecbiopharmainc.com/role/BusinessTables",
     "shortName": "Business (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:ScheduleOfEntitiesInControlTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Revenue (Tables)",
     "role": "http://www.benitecbiopharmainc.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Cash and Cash equivalents (Tables)",
     "role": "http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables",
     "shortName": "Cash and Cash equivalents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Prepaid and other assets (Tables)",
     "role": "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables",
     "shortName": "Prepaid and other assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Property and equipment, net (Tables)",
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables",
     "shortName": "Property and equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Trade and other payables (Tables)",
     "role": "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables",
     "shortName": "Trade and other payables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Leases (Tables)",
     "role": "http://www.benitecbiopharmainc.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Stockholders' equity (Tables)",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationStateCountryCode",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Business - Summary of entities in control (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail",
     "shortName": "Business - Summary of entities in control (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bntc:ScheduleOfEntitiesInControlTableTextBlock",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "dei:EntityIncorporationStateCountryCode",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Going concern - Additional information (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail",
     "shortName": "Going concern - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Revenue - Summary of revenue from customers (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail",
     "shortName": "Revenue - Summary of revenue from customers (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2020To09_30_2020_LicenseMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromBanks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Cash and Cash equivalents - Summary of cash and cash equivalent (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail",
     "shortName": "Cash and Cash equivalents - Summary of cash and cash equivalent (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromBanks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Prepaid and other assets - Summary of other current assets (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail",
     "shortName": "Prepaid and other assets - Summary of other current assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail",
     "shortName": "Property and equipment, net - Summary  of property and equipment net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Property and equipment, net - Additional information (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and equipment, net - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail",
     "shortName": "Trade and other payables- Summary of trade and other payables (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail",
     "shortName": "Leases - Summary of maturities of the operating lease liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Leases - Additional information (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Leases - Summary of supplemental balance sheet information related to leases (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail",
     "shortName": "Leases - Summary of supplemental balance sheet information related to leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "bntc:OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail",
     "shortName": "Stockholders' equity - Schedule of warrants or rights (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail",
     "shortName": "Stockholders' equity - Schedule of equity awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail",
     "shortName": "Stockholders' equity - Summary of share-based compensation expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Stockholders' equity - Additional information (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' equity - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Related party transactions - Additional information (Detail)",
     "role": "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related party transactions - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LegalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure - Business",
     "role": "http://www.benitecbiopharmainc.com/role/Business",
     "shortName": "Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:GoingConcernDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Going concern",
     "role": "http://www.benitecbiopharmainc.com/role/GoingConcern",
     "shortName": "Going concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d230065d10q.htm",
      "contextRef": "P07_01_2021To09_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bntc:GoingConcernDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 31,
   "tag": {
    "bntc_AccruedLicenceFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued licence fees current.",
        "label": "Accrued Licence Fees Current",
        "terseLabel": "Accrued license fees"
       }
      }
     },
     "localname": "AccruedLicenceFeesCurrent",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_AccruedOpmdProjectCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued OPMD project costs.",
        "label": "Accrued OPMD Project Costs Current"
       }
      }
     },
     "localname": "AccruedOpmdProjectCostsCurrent",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_AmortizationOfRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of right-of-use assets.",
        "label": "Amortization of Right of Use Assets",
        "verboseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "AmortizationOfRightOfUseAssets",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_BenitecAustraliaProprietaryLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Australia Proprietary Limited [Member]",
        "verboseLabel": "Benitec Australia Proprietary Limited [Member]"
       }
      }
     },
     "localname": "BenitecAustraliaProprietaryLimitedMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_BenitecBiopharmaProprietaryLimitedBblMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Biopharma Proprietary Limited BBL [Member]",
        "verboseLabel": "Benitec Biopharma Proprietary Limited (\"BBL\") [Member]"
       }
      }
     },
     "localname": "BenitecBiopharmaProprietaryLimitedBblMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_BenitecBiopharmaProprietaryLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Biopharma Proprietary Limited [Member]",
        "verboseLabel": "Benitec Biopharma Proprietary Limited [Member]"
       }
      }
     },
     "localname": "BenitecBiopharmaProprietaryLimitedMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_BenitecIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Inc [Member]",
        "verboseLabel": "Benitec, Inc. [Member]"
       }
      }
     },
     "localname": "BenitecIncMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_BenitecLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Limited [Member]",
        "verboseLabel": "Benitec Limited [Member]"
       }
      }
     },
     "localname": "BenitecLimitedMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_BenitecLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec LLC [Member]",
        "verboseLabel": "Benitec LLC [Member]"
       }
      }
     },
     "localname": "BenitecLlcMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_FinancialAssetsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets at fair value.",
        "label": "Financial Assets At Fair Value",
        "terseLabel": "Financial assets at fair value"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValue",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_FrancisAbourizkLightowlersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Francis abourizk lightowlers.",
        "label": "Francis Abourizk Lightowlers [Member]"
       }
      }
     },
     "localname": "FrancisAbourizkLightowlersMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_GoingConcernAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going concern",
        "label": "Going Concern [Abstract]"
       }
      }
     },
     "localname": "GoingConcernAbstract",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bntc_GoingConcernDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going concern disclosure.",
        "label": "Going Concern Disclosure [Text Block]",
        "terseLabel": "Going concern"
       }
      }
     },
     "localname": "GoingConcernDisclosureTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/GoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease In lease liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_IncreasedecreaseInAccountsAndOtherPayables": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accounts and other payables.",
        "label": "Increase Decrease in Accounts and Other Payables",
        "verboseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "IncreasedecreaseInAccountsAndOtherPayables",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab Equipment [Member].",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment [Member]"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_MarketValueOfListedShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market value of listed shares.",
        "label": "Market value Of listed shares",
        "terseLabel": "Market value of listed shares"
       }
      }
     },
     "localname": "MarketValueOfListedShares",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_OperatingLeaseMonthOfMaturityRevised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease month of maturity revised.",
        "label": "Operating Lease Month Of Maturity Revised",
        "verboseLabel": "Opearting lease month of maturity revised"
       }
      }
     },
     "localname": "OperatingLeaseMonthOfMaturityRevised",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right of use asset remasurement during the period.",
        "label": "Operating Lease Right Of Use Asset Remasurement During The Period",
        "verboseLabel": "Re-measurement during the period"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants [Member]",
        "terseLabel": "Pre-funded warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement of lease liabilities during the period.",
        "label": "Remeasurement Of Lease Liabilities During The Period",
        "verboseLabel": "Re-measurement during the period"
       }
      }
     },
     "localname": "RemeasurementOfLeaseLiabilitiesDuringThePeriod",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_RisksAndUncertainitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainities.",
        "label": "Risks And Uncertainities [Policy Text Block]",
        "verboseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertainitiesPolicyTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_RnaiTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RNAi Therapeutics Inc [Member]",
        "verboseLabel": "RNAi Therapeutics, Inc. [Member]"
       }
      }
     },
     "localname": "RnaiTherapeuticsIncMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_RoyaltiesAndLicenseFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties and license fees",
        "label": "Royalties And License Fees",
        "terseLabel": "Royalties and license fees"
       }
      }
     },
     "localname": "RoyaltiesAndLicenseFees",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bntc_ScheduleOfEntitiesInControlAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Entities In Control [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfEntitiesInControlAbstract",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bntc_ScheduleOfEntitiesInControlLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Entities In Control [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEntitiesInControlLineItems",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bntc_ScheduleOfEntitiesInControlTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Entities In Control [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntitiesInControlTable",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bntc_ScheduleOfEntitiesInControlTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of entities in control.",
        "label": "Schedule Of Entities In Control [Table Text Block]",
        "verboseLabel": "Summary of entities in control"
       }
      }
     },
     "localname": "ScheduleOfEntitiesInControlTableTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of property plant and equipment useful lives.",
        "label": "Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Summary of property and equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental balance sheet information related to leases.",
        "label": "Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]",
        "terseLabel": "Summary of supplemental balance sheet information related to leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies [Line Items].",
        "label": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bntc_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies [Table].",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "bntc_TacereTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tacere Therapeutics Inc [Member]",
        "verboseLabel": "Tacere Therapeutics, Inc. [Member]"
       }
      }
     },
     "localname": "TacereTherapeuticsIncMember",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "bntc_TradeAndOtherPayablesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and other payables.",
        "label": "Trade and other payables [Policy Text Block]",
        "verboseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherPayablesPolicyTextBlock",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price of class of warrants or rights outstanding.",
        "label": "Weighted average Exercise Price Of Class Of Warrants Or Rights Outstanding",
        "periodEndLabel": "Exercise price of class of warrants or rights outstanding and excercisable",
        "periodStartLabel": "Exercise price of class of warrants or rights outstanding"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding",
     "nsuri": "http://www.benitecbiopharmainc.com/20210930",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Principal place of business/country of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail",
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r190",
      "r193",
      "r226",
      "r227",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r395",
      "r397",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r190",
      "r193",
      "r226",
      "r227",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r395",
      "r397",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r146",
      "r219",
      "r221",
      "r359",
      "r394",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r146",
      "r219",
      "r221",
      "r359",
      "r394",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r190",
      "r193",
      "r224",
      "r226",
      "r227",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r395",
      "r397",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r190",
      "r193",
      "r224",
      "r226",
      "r227",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r395",
      "r397",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Trade and other payables",
        "totalLabel": "Total",
        "verboseLabel": "Amount due to related party"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r13",
      "r36"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r39"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r39"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r167"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r48",
      "r49",
      "r50",
      "r387",
      "r405",
      "r409"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r50",
      "r58",
      "r59",
      "r60",
      "r87",
      "r88",
      "r89",
      "r279",
      "r400",
      "r401",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r248",
      "r249",
      "r250",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r90",
      "r91",
      "r92",
      "r93",
      "r101",
      "r150",
      "r151",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r178",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r264",
      "r265",
      "r266",
      "r267",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r337",
      "r360",
      "r361",
      "r362",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r228",
      "r230",
      "r253",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r230",
      "r240",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from the computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r84",
      "r129",
      "r138",
      "r144",
      "r154",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r275",
      "r280",
      "r301",
      "r346",
      "r348",
      "r376",
      "r386"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r45",
      "r84",
      "r154",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r275",
      "r280",
      "r301",
      "r346",
      "r348"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r231",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r6",
      "r86",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "verboseLabel": "Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/Business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r31",
      "r76"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r316"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r82",
      "r84",
      "r102",
      "r103",
      "r104",
      "r106",
      "r108",
      "r112",
      "r113",
      "r114",
      "r154",
      "r179",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r191",
      "r192",
      "r195",
      "r199",
      "r301",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r208",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding, ending of period",
        "periodStartLabel": "Outstanding, beginning of period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r176",
      "r379",
      "r391"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r177",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock Par Value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, Shares Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22",
      "r348"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value\u201410,000,000 shares authorized; 8,171,690 shares issued and outstanding at September\u00a030, 2021 and June\u00a030, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r63",
      "r381",
      "r393"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r120",
      "r121",
      "r148",
      "r299",
      "r300",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r120",
      "r121",
      "r148",
      "r299",
      "r300",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r117",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "verboseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepositAssets": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.",
        "label": "Deposit Assets",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r74",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r74",
      "r128"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r231",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of equity awards"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueFromBanks": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A bank's noninterest bearing demand deposits in other banks (such as correspondents).",
        "label": "Due from Banks",
        "verboseLabel": "Cash at Bank"
       }
      }
     },
     "localname": "DueFromBanks",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "verboseLabel": "Effects of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognised share based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee stock option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r58",
      "r59",
      "r60",
      "r87",
      "r88",
      "r89",
      "r91",
      "r98",
      "r100",
      "r111",
      "r158",
      "r205",
      "r207",
      "r248",
      "r249",
      "r250",
      "r266",
      "r267",
      "r290",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r400",
      "r401",
      "r402",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities at fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r310",
      "r312",
      "r314",
      "r315"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency transaction loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "verboseLabel": "Foreign Currency Translation and Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative [Member]",
        "verboseLabel": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r163",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r169",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r258",
      "r259",
      "r262",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Trade and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "verboseLabel": "Accrued employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 11.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating lease discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of maturities of the operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease has a remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r84",
      "r139",
      "r154",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r276",
      "r280",
      "r281",
      "r301",
      "r346",
      "r347"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r84",
      "r154",
      "r301",
      "r348",
      "r377",
      "r389"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r84",
      "r154",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r276",
      "r280",
      "r281",
      "r301",
      "r346",
      "r347",
      "r348"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licensing revenue [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in provided by operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r51",
      "r54",
      "r60",
      "r62",
      "r75",
      "r84",
      "r90",
      "r94",
      "r95",
      "r96",
      "r97",
      "r99",
      "r100",
      "r105",
      "r129",
      "r137",
      "r140",
      "r143",
      "r145",
      "r154",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r292",
      "r301",
      "r380",
      "r392"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 9.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other loss, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (loss):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r129",
      "r137",
      "r140",
      "r143",
      "r145"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "periodStartLabel": "Initial measurement at July\u00a01, 2021",
        "terseLabel": "Operating lease liabilities at September\u00a031, 2021",
        "verboseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "periodEndLabel": "Current portion at September 31, 2021",
        "terseLabel": "Lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "negatedLabel": "Less: non-current portion",
        "terseLabel": "Lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r328",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Principal payments on operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "periodEndLabel": "Operating lease right-of-use asset at September\u00a030, 2021",
        "periodStartLabel": "Initial measurement at July\u00a01, 2021",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "negatedLabel": "Amortization of right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r39"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r18",
      "r375",
      "r385"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets [Abstract]"
       }
      }
     },
     "localname": "OtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r43",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Current portion"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "OtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "negatedLabel": "Less:\u00a0non-current\u00a0portion",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r48",
      "r311",
      "r313",
      "r317"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 15.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Unrealized foreign currency translation gain",
        "verboseLabel": "Foreign currency translation loss (Gain)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r52",
      "r55",
      "r273",
      "r274",
      "r278"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 14.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 13.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r161",
      "r162"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from Issuance Initial Public Offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r171",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r166"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r168",
      "r348",
      "r383",
      "r390"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r168",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of property and equipment net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r225",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r225",
      "r340",
      "r343",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r338",
      "r339",
      "r341",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related party transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r255",
      "r358",
      "r418"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r207",
      "r251",
      "r348",
      "r388",
      "r404",
      "r409"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r87",
      "r88",
      "r89",
      "r91",
      "r98",
      "r100",
      "r158",
      "r248",
      "r249",
      "r250",
      "r266",
      "r267",
      "r290",
      "r400",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r126",
      "r127",
      "r136",
      "r141",
      "r142",
      "r146",
      "r147",
      "r148",
      "r218",
      "r219",
      "r359"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "exampleGuidance": "Revenues from customers",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenues from customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r220",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "verboseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r61",
      "r84",
      "r126",
      "r127",
      "r136",
      "r141",
      "r142",
      "r146",
      "r147",
      "r148",
      "r154",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r301",
      "r382"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r333",
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Re-measurement of operating lease right-of-use assets and liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Sale of stock net consideration received on the transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of Stock, Number of Shares Issued in Transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock issue price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of trade and other payables"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of cash and cash equivalent"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of share-basedcompensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r230",
      "r239",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of revenue from customers"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Summary of other current assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r231",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r208",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrants or rights"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Stock Options, Exercisable, end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average Exercise Price, Exercisable, end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r235",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock Options, Outstanding, end of period",
        "periodStartLabel": "Stock Options,Outstanding, beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average Exercise Price, Exercise price, end of period",
        "periodStartLabel": "Exercise price, beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r229",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r231",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end (In shares)",
        "periodStartLabel": "Balance at the beginning (In shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of presentation and summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r82",
      "r84",
      "r102",
      "r103",
      "r104",
      "r106",
      "r108",
      "r112",
      "r113",
      "r114",
      "r154",
      "r179",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r191",
      "r192",
      "r195",
      "r199",
      "r205",
      "r301",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r42",
      "r58",
      "r59",
      "r60",
      "r87",
      "r88",
      "r89",
      "r91",
      "r98",
      "r100",
      "r111",
      "r158",
      "r205",
      "r207",
      "r248",
      "r249",
      "r250",
      "r266",
      "r267",
      "r290",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r400",
      "r401",
      "r402",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r111",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, Forfeited",
        "verboseLabel": "Forfeiture of share-based payments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r26",
      "r27",
      "r84",
      "r149",
      "r154",
      "r301",
      "r348"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Number of Warranrs exercised",
        "terseLabel": "Number of Warranrs exercised"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "auth_ref": [
      "r219",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by timing of transfer of good or service to customer.",
        "label": "Timing of Transfer of Good or Service [Axis]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "auth_ref": [
      "r219",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.",
        "label": "Timing of Transfer of Good or Service [Domain]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.",
        "label": "Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]",
        "verboseLabel": "Trade and Other Receivables"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransferredOverTimeMember": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred over time.",
        "label": "Transferred over Time [Member]"
       }
      }
     },
     "localname": "TransferredOverTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r90",
      "r91",
      "r92",
      "r93",
      "r101",
      "r150",
      "r151",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r178",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r264",
      "r265",
      "r266",
      "r267",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r337",
      "r360",
      "r361",
      "r362",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 12.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Unrealized loss on investment",
        "terseLabel": "Unrealized gain on investment"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r115",
      "r116",
      "r118",
      "r119",
      "r122",
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "310",
   "URI": "http://asc.fasb.org/topic&trid=2196771"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "c(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r419": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r421": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r422": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r423": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r424": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r425": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001193125-21-328795-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-328795-xbrl.zip
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MG,BS*Q@4 M9*!.4S@;KR[CO#GER,[N>$"*XC:ANV1/@ PGH/$2)IB#,!*)&
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M HJ<6_H.TECK.K*BGAYW^=)W47-?J^J&?26#JR@HMR4TP1=2T-B'_#2&\Q%
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M<KQ%[PV*"J9__+PG&_/B5P:@PG6@:L?V>WZ/KI))P7$:Z",*Q_EV#]ZB[!8
MV6*W>(8!\&L::KGUX6 )*#*2E3%&C]&,++Z]/.F7(P#QK_$>*EDJC*J^U<"T
MJWIL>K7CMZ2V.63C4,A#(@!)S?S;_P%02P,$%     @ 2#%O4YV'F]J!0@
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MLP]5'O_ZX3EBDW:[KWAX--<2^UV7E1#VQLLN@^G>2% 10<;V*X*0M"C1[K]
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MC-'7)KRXX/TQJV(!XM????M:0)C_YB_W^2%*>=4RMFK>)#'O_AW5'B?9FP,
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MS#6;UZQB!HA[%;5XMMN[,;U!WN6-DE:Y_.*]G#WR;G@Z!K$TG1<%+Z8F?@[
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MK>FZV1$:H6QO#E7#R\RO>IQ'B6QZVNSCP->?\;.-9/SC$.-@Q: &<-*I\30
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M(^32H;%+<#Q+W #&>D,RX4^GQT!+7BW*KJN1!I4_F35-.;LH!F#*X(WVG")
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M1D].8X7 [78BG(V^Q,K;BRP0M7KQ.))8L8=DN\!X3O#KTA^-^G.2^1+C74_
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MZTHV*I1DGJ,7A EX_;8A[5-1!3ALQY*!$BG08X1RQSKBO.U:JW+G-QZ3K];
M2<T0^U!SBCER)4.)X:JMB5:'(Y?Y;W$Q6>"]3JFSBM[T\YR^:!D]!J\* :PQ
M&B<D\"/6S<5 +%Y-Z.'([8Q>@^DL09_+.*+O20*9.,6&W:7%4_AG().GQ :M
M-WRJ.S(3V;*$[RX!77 !/ O2'ZK-8[49F^PGX/W D)YBS1.B<60IK%M[MFON
MHX-/P#?31A)@!].57S$K@@32EW2'T2R((P)\5$P0YB%PRW66_>Z\Q)3X_$]
MB^S*Y Q65D%KMDTN:V;O<NH5A2]?Z6.$J"*F8O+"]GSZP NLBJQBG5)CZ4/8
M1A6G-;] LRR/U7[.M9:<"L")E_8<E:$ C;.0!'1]"? /5+!U>S2^B?,"12Q0
M3AKA+NW 80(;2LR990BF#\EM*T0QVQ X>N#[H[W>B1"X\IELGD& ^'>;I:%V
M=Q2V_WXR.!CL=48]S; T]6*<<NZFZ)G6I/" O_JCSW9C3HTN:^LFD/;>7]O]
MU6'[X8);5"@?-B!_![I!2,NVD"D97"E,NC.A.($PV>SXO8/#$U^KW(JX(3G(
MVN+U*VS,G?R[?/3@\,2;(#-#KLKNK>9P_0HE<R<7+M\[.#SQM>J7@*&6(B%
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M>LM#Z'+%W3(1JC7"DJR>;12!*L!6Q]/.=\."5)$6'!F)LMKKEM5&9&@]:41
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M:YNX \YZ'JIS/P6NL9>AL:Q,?D2YC@Q[B5HB<.0O'W@>><J=2[F;6@*M8%S
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M=&+@I&"C0/.I8W\C;XCO!2EUZ,\0%O!-!#W,5L>B@:@KCG\JQ TLNOUJ^9G
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MX\,O\CKE4MVF/*:NS-N.^9C<K2S5<Z%Y\Z-"!(LPP5*P)V*X)8T':<83/3Q
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MWC!3W[]^"@OV>^G!?JM  #S7._[QT[?KAT^7UL?KF]O?NG=?N];UM\OF2MD
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M';6S- XI@I=&PGJR8^NGQ2)25X(PKG*QH/P6!@A*+5P&JR5]83IEX5N8_(\
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M="I=Y=ZLJ4Q Y#YB=J7%Z1,@%GI6$H:L"I,O[S'"3+9\#IM9(#S[=0;\A(6
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MNLPH0@1<,0(5")4)>4PL4:8J%W)3>*5V#L93*@>@[Z" XT#=',5,Q8'M/FD
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M2;,-DN8SM7S TA$)YI!&XY"@EV$7QD.%*LS '0PC@UG;6',T$!:U6$0V-\0
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M*XZ#6K;J39F )R/T6.&KUZ]1,LF17#*!4G</6X&8*/'U(KV)Z'G6D-;,X%9
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M8V(=@D[:5X<8$A$2Q,M4_OUR=B!0 A@:QV:RU ]58[E6GCOG[+OGN>. FW(
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MLP0_=&,CV.QP-U$>8E9E4LM0QFN[B2*20>?;<^/E=[\U*$B[]BAEBNL5%L3
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M?K,7K7K^X:7#:)V^T$2C_;#S/U!+ P04    " !(,6]3LWP== H$   "#
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M6/S&MEG8M=UL7A1130_Q*#2S_[]02P,$%     @ 2#%O4Q^4S<;8 P  5@L
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M%JZ]O>^6=67KBS$:S7WZ'U!+ P04    " !(,6]3J[^PW_\L   X.P  &0
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MUR^:,=1Q*H,# <AO;2% 5&VAERBI1$E3LSYJ_80Z2'.$RK/)ZHK ]PF\$SD
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M-T%)24TR/,[I*V-@SWO*4>VR<<U%)IO^1(N+ U/HGTETAZZ1L.J<_YGOIL&
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M[?^$=%V-;?NXK'L]/]2_SU' #Z0F%.^(UTKD7ZX6IFIJTAMLJ['[#)FLWZF
M]8F^ F**P8+.7TR*\W'<H/ETKQJFL!+-[2OM2,.D&>\^:?PN[#3$&TNC&ZQL
M=,=-<>$E4!.#LT2LERB;@$5ER,<\@&*FL<[EIBE;$B^QP4? _S4AH1@I+%J
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MR]S3LI/P-;CSY/[(&4"U3QNJ*)=,)I@\"UD,7=:/\G,>=2+OG7T:C<=..X8
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M7XLE-(UW0;21,AU2)YD..?+!NDH0?1T!N@GDF9DE?_NE3T\7%\DKIM8+61'
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M&:0-FG_U6ZK4.,N7YQE ^&"/%HSC<5#4U->-OS/C2B3N??S.Y*M /\>8HAB
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M'=.!*#82Y_$S )9M+#*.E$ZF1>L6#2=#1I,<(>"Q:=HIV$\_^/(,E" ]_HK
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M[7A"+C +ON^U'D5"7;^\S[*(28Q.HE;?5&0<;1%F.M_\,;J>%*]\&Y"WY[!
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MP-?G-WE%D=K?W86]>32_;QVZ*GL&VK]E/?J'TA3+^M=X#\7SRC8I]J2;H>Q
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MRUL_3?;8A,4:"HF'XMU;,0?\F\XG,2TY+T&)%F;Q\?Z=,H24*#?]7NX>R_R
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M;DJ(N]@#T[) ;N^(;J/T !SMEJ)<=#?\$,UGGA>UH@K+J0U#+:[,T.,I\IY
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M*2U16+-*#." GFT1MJ[:\&.$D5Z]-9U3C1@4J8;: +1S7*ZL'H631V_.:(1
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MS2J4>1U3()C3P_J3,;]OM%G%XVL*U2%T6&@E,9:A(28F_T:\&=__^LLS(#/
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MR9IXOU]N/RP)G*.[0"A?X91U8O<Y>Q,+O$\"',F5F=#5BG*:\$TZ.;[!-?0
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M$NF%V'=MB[;,\0I:4FX'(TE2T@^$K75]T]W=<UN,*ZX_B^L)8\5V#H<]<3:
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MZ0.8;/7B,1G ;!NM<O%[W,7K(UG%K'XTU;-Z!MPW, ';\@\J  S<@R$7;YU
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MZ^CKF[&EM_?09S+_"%?]GO*K7@+Y_%[#1A<L0.B80QDL Z\6'6]-S1CFSI-
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M_;%UY>-N_M0!'>:A<7Q3SVCP@(58XEC49Z\* *J4E% !5R#2-3N@3;Z==S
M$F.!FZ].@JD,;AGIGFNCED2'Q'?&1T1#;N(R3@$%>,4 8%S;7%I*8KF"6&0#
M)21"I_(U!73RW]M);B!Q9,L5A&R,40N9!MXW=?7Y<_A5FY.FZ?;2/%%9F6>
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M>6&VE]O&?3/K7=32:298TBMK!+?>##/]IM&/W3A2ACW#/3,F[!YJGXFET_\
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MO2]+ET:*!'=]/01Q(\$QFME?<<97:J"3@$@EV.<9QZ>:'K0 E%%)0 4M)2T
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M"QS@#H*93<T *34B^?>W,<89I97(C3<W7L!DU#5G3IDM]4M)I6VQQS(S'&<
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MC-)10 N:*2B@ HS244 &:*2B@ I**2@ I,T&DH *2BD- !FFTM)0 F:2BD-
M"4AI:;0 4VE-)0 AI#1330 4AI:;0 4VEI#0 E)2TE !3:6DH *2BD- !112
M4 %%%% '_]E02P,$%     @ 2#%O4ZFN8B632@  QE$  !D   !G,C,P,#8U
M9S$Q,#,P-S W-3DQ-S$N:G!GG'P%6)3?\O!+2XD@2(-T"4AW2TMW*"+=)1U+
M(T@CH'0LC2#= H)T@R#=($AW[GX+J/?>__U]SQ?+P[LGYDR>F3-SV 7Z [H
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M8X_<\UM[,.3Z8MV:0^%@Y?<\7$S+0,=5T7?.TF#^^SG&<:1R)WSWSJ/+':!
MY%$I7>(.T2DS?7Q%H+_8#Z:^OB+%V'<!U>N9OIE$,]U'94H0W!-8[2.F-WBY
M(7*69'?%L(T%\:])/QV! OM<36O=UX?GP[?/B?CCS?F^ 2BP=08%9%JA0)!
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M*X?$V6(L7+_&QV#E^=Z#0))TR76(&;XD(^(/8=,[%?V5N31#4*7R_=5_%0^
M">[6/PS2B/QW\>%+E97^!^+YGS5#" P,?VLB\%\CL,?^ RBB:;+J@[_5@P#P
M+^,$)UF-O(D*N> N,"'ISW\A34%H3.-VX565"0702J6@0$;.Q%KSE8(]%#!7
MX7_Y*,O%+)9(XB7,4FA%L!,\(W7P^@@V3;Y7^,;N FW6QPH*M ]?9TOW&6A^
M7#%-LIH +:J;0X$CO/JK"2@06L+3(4PR<B6TDI/ZO7VK/]B,4=T3 TY+B5C.
M425R2PF+,Z6!)"8W*?J/!!;84.!.+N</V$F&!?]6B(#_5@=P+PV.39LZY:%
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MXQDT$I\H\J<P_6A>1-A+OSJ(@T !GK-A*'"/+@BT'@=#- X%EHKB+A6CS,Y
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MIS?)3V<_A.!J\)\R'6%J[UZ1T\&#$O@FA"7^U2?[45\\4EQ*T'OM;G%[L[R
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M\A67C\*YX>EJLI)>BT>4*Q=)[-X*-+AP44LXR(GV2J+!C9/"/TNE]EFO_%E
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M='A@!#IYET8TS!3SAS=,W,2)=C6=HR6VDSO'IRSJBL*-('G;M6G?TX9(GJ-
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M@BOY#*&8[E0X<;3\CY!WGDH>G3G(9+XGBL-2OUM+J^FMKGRG,UI=?9Y RKC
M81@%.2,;%Z#IBN9O[5K&_N+1SEH9&C)'?!Q5>@#L+3QTUJO,%_*=LBE7U#Y)
M-Q/S2#9\[C.-Q/8<<5RE[<?;+ZXN=FSSI&DVYSC)SC-0TE !2444 %+244 +
M2TE+0 M+24M "TM)2T **<*;2B@!]**:*6@!XI::*=0 ZG4P4X4 /%**93J
M'TX4REH ?5BSNGLKN*YC"EXVW ,.*K4HH V#X@O&MX8&$12*)XE^4Y(;J3SR
M1GBG-KTDELT+V5H3(J++)A]T@7& ?FP.@Z 5CTM &Y+XA,]@ED^FV9MXR3&F
MZ8[">X)DS^'3VJ,:Y(\7E7%I;7$(50(Y-X *\ Y5@<\^N*R*=0!H7M['<6]M
M##'L2(,2,<;B><9)..G6J5-I: '4M-I: '44VEH LVMW):-(T84EXS&<]@?Z
MU>GU^]N"2XBR41.%QC:<@]>OK6310!KS:YYZ!'T^S\OS/-=1Y@WMC&2=^?R(
MIUYK[WT<22V-KF$!8GS*60>F2YS^.:QJ6@#5EUIKE66ZLK6?DE2V\%,]<;6'
MZYJOJ-VEW<*8P1&D:HH8<X%4J,T +1244 +13:* %I**2@!:2DHH *2BDH *
M2BDH *2BDH 2DHI#0!;L]3GL%80A/FD23+ ]5SC\.:M/XCO7N?/=(6;SFF(V
MG!W+M*]?NX]*R*0T :SZ\'E@9M,LMENNV*-3*H3G.<APV<GN:==>)9KJ_COW
ML;1;M""9E\S+8&,$%R/QQGWK%IM &M_;$5P81?6-O(R;5-PN_P W8#T #A2<
M<<BL^_NC>W\]TPP97+8^M5S2&@!*0T&DH 0TTTIIM !5VPU:XTU2L 3_ %T<
MV6!/S)G Z]#N.:HFFF@#9;Q->O<B=T@=O/DF92IPWF*%9>#]W QQ@^](WB'?
M/;R-I5CMMDV01JTR"/YBV05D#9R3R2:QC24 ;MUXIGNM3CU)K"R6]5MS3+YF
M7XQA@7(Z=\9XZU"NM0W+VXU#3[>0Q[%:Z3S/.V+CC&\(3@8Y'Z\UCTE $]_=
MM?:A<7;C#32-(0.V3FJU+24 )1124 %%%% '_]E02P,$%     @ 2#%O4R'Q
M-N0A3@  X%8  !D   !G,C,P,#8U9S$Q,#,P-S W-3DV,#@N:G!GG+L%6)1;
MUS!\P] @*(+2J("4=.> 2DM+2@H( ](-XH (*-*IH( TTDK7$ *"E S2(=W=
M-?SW@'K.\[[/]?W?_^-U9O9>]]IKK[7VVJON.6>#9[^ RXJR"K( !@8&8 +^
M \Y&@'L '@X.+@XV'BXN+CX^'@$1V24B0D(B2M*K)&2T5/1TM%0T-#<8.9EO
MW+K#0$/#(L1ZAYN'GY^?GEE$0IA7G)./GQ=-! ,?'Y^(D(CBTB4*WILT-WG_
M/_^=U0-7\##X,/4@&+< S"L8D"L89U\!>@# P,8X_P-^_V%@0K"P<7#Q\ D(
M0832RP F!@2"B07!QL;" I_Z@,\!K"O8I#=YI'&NJIOBWG(DX_6+_(C'<+>X
M@5SCQP8CWV.G%_@$UZY34%(QW69F867C%Q 4$A81O7=?1E9.7D%1\Z&6MHZN
MGKZ9N<432RN8M;.+JYN[AZ>7_\N P*!7KX.CHF-BX^+?ODM(34O/R,S*SOGT
M^4M):5EY16558]/7YI;6;VWMO<B^G_T#@T/#DU/3,[-S\PN+2YM;VSN[>_L'
MAT=HN3  ",:?O_\JUQ50+DPL+ @6+EHN#$QW-,(5+.R;/#BDTNJXIHY7;_'Z
MX9'=C?Q8W(#/P*>Q0?[8Z0?!-4;^2:9-M&CGDOW?"?;B_Y=D?P7[1ZYA@ B"
M 1X>Y H !;:L63)2,..BXGP)]%FM@(Q4]$#1(07S/2NVJ"^!NE06 8#-038I
MA<V2HM&#H9(:0P  &1D9F+Y$&C^4@@%61Z5@?4!17U\?>  "I/"##32F0M0P
M'\>35:21 6_3R)9XI"YE-'.R- -,MUD'0=BH>K#K;18,\/&*NA11,]F*AAK$
M44$U/05'XW&R @AADHPF SHT-'/P4G >1X&@*[U4/OP]$%C)-OB8'ZF:S@^T
MWU/ACP&&;85[U2 PUCYPJ.C*!# Q<9Q_D $QZC( 68FZ%*$,60F 9@P4H@30
M#+AQ(4^J+]G#_AX%5V?R&D5]!9I;?J,)KW1D?N5VLBMO<M2BBAUG1D:>W#\=
MD9RG=WF6LH]ZB#%NHT\7[CAYJGG_<U%9^,,?ME.Q66$"I \<X]L@S&=  7O
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MKV_]W3$+YOBJ/&:X-\0D@D3B>#H#T*S<$/@8>,H_<;G!)QNV8#3WTW9(T&_
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MB$3YI($X-M]SWWF+5#BM@N4"L!Z&J1$<M7SJ+LX'VX'&4JM^/,D=/0-*\LZ
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M_GP+'T%#U%KX^PYH6(L&%3QN_)PE,\PL7'J_3G>:>U;H^-HN?^.%-"U>)C(
ML"E_70J[':9=H?S-8!/+1,0TD!-SLHV&="A==!=)#\7?FV23+[])1M%(Q)8"
M(9 (PH6$L;,% P-T#'TG9X!09]#;DT*NE1^>C]SM6N/+[8V\7%,\@AYNS=US
MH>ZR='L22MG@&#C\U<))6/C6YP!A-4QD@""8&?0MV8KZTJID(K,Q^B;[$U5H
MK3 :WXMJR@B[I&"#UU=8#9(#8T7#6%-!;+#JXT"7?1R L+I4ZD6R<"V8)848
MV0#F7<3V1PLVV07&%^/]3E?RK;>(Z>]]1^^Y-FXND*G+.%,'.$N"?BS"#%[#
MGEE@UCRQ101=#UX DS8JR4SAY%_?>Z;%U.6LV9=)8DE!LEBIP2Q .IA68:$_
M,!-@?4@I?'D8[!+ Q+^3I:FJ".P@@"728:NV<J*05K;GI4-G@&WRX1STIL%U
M?_@,/OUQZ^& DC'KZVBMC*7NC+2[[Q=E2G]0TY]75W?#5S^+WCC)I0MN_1"_
M:VT8&K[:=-H 'N<S!43<7OMH96->DW68O[^AH>-S,4KDQ[VW< 9#81$A(\E,
MW>#+ 93"!4'8ROQ+L,)L20=89H(C6/:9@6D,8A+^-XTAV5?V @OO,V &P^(,
M,(@_U(E.A!-+9N7&PDF- L?(U(WP5P-N+BK)>ZGA)J'+-74;U"&8R[34XDX)
M';TQWN_>*I04^%^)3<GY>^G8._@T\5?2/[]*>X*1?N-#FOA[8A46C!*=5-32
M_2^VG'N4,V&$V3L[Y7J0' +!V-&T^24?=R'R]SV=S&]VVNP9W#XP^-DE:74Q
ML[D%,8>V$@X@DW8P6H(="J7H1Y@?4!Z;;MXH/P-L5F]Q"</K:WTV5[4S^7S2
M2PO@7Q[$TP\_X=J5*2,Z?#L]0'<JDD(BB/;TCLEO(W<H0;-1_Z<W\>&?(5B:
MIV#][HDX_&W= /^"_M/*6@#()O_5BZK_T[WIP?SO1#1Z??]T;Q0Q?S>0T-W?
M/\TD=[K+&WM!N4-V?5C?;T^1_RPB*28/]=I,HX-1]6:P%?P0]E,R0IP!!,=-
MM$GPXQ6PT. Z83\#P-+A^<74Z0R J8,#DFW^(]!O@U<Y<H:L=!FQ47C"<WH<
M?KSR UQ]!C31;_=.HX[3CA7#+0_@;WVTX3_!ZF-+6L9-DK=GQ_!:VR.5[81[
MMW+%RJ2P]LB_/?O#M.%#]I82SU0+[9B<:GE%?8._3;2_S;8R/BI6F,/_:A8"
M*S7T9\ -4 _/!M0-6E_RG"8-H@X+DNHTKY]X>B5K!J"P?#"#60K,',#;!E[+
M2^!U6UQ^N^D&_:("KV-/(SRQ.GH[!??GNA>R*L/5%OX_6WL#_?1L@L'_.IC#
M/PSY4LK\TZ;\VY/SI5;XVYRD^-,^3,'1T/S;YU3XR[HM?]_;O^W-R7_HRL/^
M]E#3_] "N)&JBO\T_'JOTO^&NZ.(07_":*QYLIQ18-]P@&I^0\L+_^ 2NZ6;
M/*W4=Y0'W3!#NQZ3I^0M'NLHZ1_P =.34#?7%H]E^J$?YA'BDSW>5$N@QZ*3
MS)+D.B#=$::"Y>#]92OB#]O&#Y]54F8F1/SAWNX?E6 R'V?6PL\+S\\7A>>W
M][>1VQ<4"@TW$">^=Q#+46< VY:S_61KWZY3X912STAJ,'N#1%&Z!"N,1!'8
M1KR:6+*%3H"IWE$MX12G>.Z#*$GGGB<51'^:;[O_N &TAOZV"Q=#0T[2(]=X
M#%LO#Z,+-'U%?4!=\\V[@*RA>U.D*%,U7(X03!^/[CD?:P)]P)7EO 34#!",
M48,L-B8JLOQQ[>BO#V"].*F,KE#(4J- A !A31E17QIVQ(;ER0OXKR<U)SHI
M!WPH:<CIMI$=[(3DW<(LO/605G9ZR6K41YF)?+NUCO-\K#JO( ,X20J!1Z,/
M*D$+Y=I*'#OD,8*2]D=5<6T7<+L4IK:#V=.V.%'WP<1-&(S5YH?X) P&1I*!
M_QE)+IV/"V- \Z4SRNJ;A/N12(&Z>SO*'K\9=.(/__6X*GCVQ!2\!1,'% 4A
M7)MI2V:O442UQ'RE9&ZI=46':NE@I&5)K0)OKX?@B%&17E>J2<3N743[YUQ]
MLM@YF,K[3\8QTXOLO8A)[:8)7?K]M? #K2)X#UB1W!R #BRXGQ >U70+I!<J
M@;[\$>XI]AFPV:YZH%5V!NR J<(W%Y_G0?!ZR4*^3E;VS$V=0-MG8C3/M38K
M(T>PL.N-4;7. DC%/.O6!&K*KO<IJ^BRE/TN5F923 FRUU>"I&%B"Q*TA+;8
M3@\QE)2CC^IV05R=TM43F->7I:(SH"$\%2RZBP0)IL7=01D'$<M%*-EJT7_/
MJHK@K>$YW6]06+7$F.ABVV8I//XR4IGU=T@ZKZQUP7, 8]+T^KZR-^YY2#+[
M/X<D34@7"BPT<TK.[8QM>VF''G3F2QP71EH7_[<>,57.X$<W%&7(U#!4((S$
M(KO\PTZKHT*DU\4C>!VEJ/V;^(1B-B:&E.U03XY?6@Y=C\.P'5+SNK(OW?WT
MI^4/3AUM?]4P^2<VOOEDV:UF[$2!;8#?<@2/O_YJ[D*D?(2^4C8AQ)ZI,C0_
M@M>>IBV9.^BQ5/?8+[,031V-HN"C;@T%<^ZA0[<<0K;7%E)9WA'XA -^W48U
M5$#.&8#75W$5;J5'S4#_;J^C;?9TM=KQB]O*WLAZ;_H9\%)[D^I^U%2_B+]\
M\?V.D:Q!7D53QQ S2@:)3_7]_.$K$RL^^XC'6P<56U<[)N9PCA,WRR'TWA*G
MG[[6,2/7.$DWIZL45O6-O[20*U9]]JT>N9%#,0]F]+XBBNKRK.U2XK[/2P#P
M9A$CSMM58-IW_IT": 88?NXMO727CRGI ^-"%E9+GH/UQ F#_OPIAAUB'?E0
MM$BE,_6G2*E+B)\*>3XHQ#@8B*5LDH]W^N"-$F#TZ:&;1YT*<-FJ'L:/T[7[
MO(MC;2S%#2I-/H* 9<5$9J9RFK5;3PER,5J&E.A+%3=F@';BL=(ZB:5D1PIK
MH^_T\9O#Y,TLG MV\O$(U*4<T=VW;>BT"M%%2TT*VXL$S)\N0R<$YH]_=_AV
M2'#>+T)"GLW5C"(/Z/E^@-<W?$O4BR6USF6_$9T"JK8@ML" 6?;F9/D-+7OI
M9M;)BR/+??2,B.>"Q)%X(;BRO@.,IUL$K"/_T8D46$ARB"GY']U)C&$/*$H:
M5('A)5?R#@_Q>14[GN,F0XEGF5P'6[N2680G>%[89.H&+9,&B!#H#.49 "'O
MT^&;6H$_$91U:*SB1K2$YX0Q'_#N""?U:983^?R[/>ICNI5FE65'/XINZ/[>
M$$#V5H.!G+3J/A8-O?ZO-Q<KJKL):18V-H.WMHTGN321H.3!I\3AW?''<^&2
MQNNE<C(>UR6ZM :CN^-17@)TSQ 3 K1D!B(Z9F&;A8)%T6> A$U806M+T+6(
MS>3Q@9L73=S"M.]POVU)."\*^LV"Z7<76>'W,ZE?E,H2;,J_&>4O:D7S: 7I
M$:<&[[PP8AS:5:4_5T/=]9J>XC#\K[M(U@I"$:&C?=ZE%Q4(6M SB7(=+4$C
M"WK!V7O8!KA[^(Q-+O:)Q]'[ \0OI9Y?RH))!A=-VF@P3ST?U&4?.H%EVTW'
MOWW:S3\CX#5JL=#D/)S!+\+9==,2U"J:8:/_VR#WCP.IO3K%B9W_A1R7U"SY
M8Z'D^$5C_U_)+D-ZCE#AR;8QVEQX7C'?P-@IF'YERW3^W@G=+E>2!^L2&19T
MZ22LT0O&-H<L=+22X)O,&"V+<VZ[:G*8?F4PA& G?'6(9]_F.XH.K9%I%!@'
MI V[K0^?V5C7A*<UJ;]<D&ES$3@#RAE1J_0C47"WSRP%1FZVZ(H OCH$K38(
M#W=E77<AC'7[:EU)(&%C5(F@0+>4UT_;AU\FYM(_E%$DFU91Y@QZQSQ&MJF>
M-49V=-0T)T?@RJ\1#/B %PDZ<P4T3('YT@4C\'Y$R)T0#20FP"%S7B+&FR@Y
M=1DRG:ZD _ +H^T #)#PO1_P#X[W,MR2!$%DG=,2XWD#M45CN5B0QIP'9?)F
MW;T<6$DI>%U*2F+4<.U_K1_BE)^Z"/3I</P=#K0_!F\GE^:2 Z(^*$5=AKS#
MCKSCH!HE'8K:*$BH3+X._\:!&"?_$8#B]WG@2-\0__'K[ZJ+@)4E!=@I. ,:
M$5NX@34G.X528(KK][&02P!%NBLAGGM0V#,!'NI\MPM+:K")8QVHN'!Y^'+A
M3H%H-0DUO+6$?K>_XNCH03EXT^>_<$V_5I!A<G^/H0Q:0%8&X,4,:@/WHBPS
M& !=#.[UBQ*-Z36*OU;U4],9@"/I)T.FC=-@H!,.G:$E.76C_S9@ TY43Y0^
M@ME5TR&8K<'_)FM7E?E+D&!N5A$SK*G,#_2#F5A0X\0_;P",UQ+VN CAWQ#_
M+\%.#3?Y_'69V._795[T7^T/ML$(7X#H&4C205I,K"T<CK8>K"@JZMNZT]Q$
M][NQ_Q;#'"[Z3T+-G"VM.2^U#A<^FV!*<\6G:VCY]3"N;8<!TE\YW/]E(.O+
MYT>NY>7NX?!HL< )XLW D1>X<\0DMWSYL$43V*PX+<M\]K85KD:&_BC6#&_T
MI6!MS(<_M8;O7 $=$F(5Q3^9]Z\)QN@SJ*NRH--7D@FZK$$=<[LI6CVY:2/>
MJKD\?\)/1GX+G/0GL#-@9+CU%-L>L7'S#&BIJ1JR+\V>[ZQ<_-'A\T& V##<
M[-C<>,*X*[RT^73W9+E5MCH/WJ-]? 9@@FN;#/NA"^P^8(I&@A)(WE-$F:FN
M&J\E->Q]0]0A]G^:>)3ISO1P[GU.CDX1J+_DCF[=Y.^CL* 'O1_LM4W]/QE%
M>/D[G '36D3Y=Q4-1JZ*=R=PBE?':*X%1VA%YEH;[UQ&2]*)XD_3[D,LW 1S
M&7CBB4V_>&JIL%;RJJT2ZL5UX_U#1$O\\2-UD'; P"G*?C.%H+$6TM#+9G4&
M\$#F!9KA-M;0G<M5%X1V^UVEN 78ZR6R[#<+GFK3CS1%[8DZ5(2;2GH;[&JZ
M7UY:@E))#EW?']@NO(,:_@E=8/($-QTY@<E^^03O4=Q&@1[@8  7+2KB6.<X
M*\>G@&N]<%YNY"8*=,(36K,3(Z)9IUB%T/5C>"C77A>874BS=Q^C)J;EP#4F
MJ)^HQ3Z/WH<^C.0F<*]:DEI'_XQ'HG6939>RQY+SP".#6UO3@P6!ZX6D/8V3
MIR]%N)R[OP[L;<^7!I>4VAQKJIT!R<>%QR=HDIF@L4/WSW501>Q4RJ&'ZNN#
MSJ.603:%#GZ<YF3#NW<OE$+\I9$X)Y/G,>[Z)1?9M9L_8YX+S)EI]_G6]W'6
M[[U#J]!8$U1AZ,3I&6"_6<A6H+=Z&S2#)8V.VO=D(FX27*N1<!^XJ.3 N6[X
M40-]9\ "@_N%<N!E M CO#%0 7M@! A?B3T!TW#K,\!EI[!,YA2,"G6Y29OF
MKV_'-.O2OW41^/X?)ANDW?>JH8^SN_\)N+;*TY*QK[+L=J9%-RZ=8?N'[%SC
MX82@$S"VPR? "H<*6BI <HBZ.$R!I21UC>#R<RE/SZ5,/Q?_Z$+\'FS-WNH)
M(OF<-.E*7^'%A.E_K^5'#!]%4%#]%K? 0)MZ^8IZ;5@>)\.@0ON !/?85]&J
M\)9P-/<GRV!L^0\!55=#55$OA.#[IXB6"OAGG6W:B6'$F(30JN.YBH9(]@=0
M1X6\J,%_V0^TS%7U"-\(?DX "J[!W2O<5WG3$E9HB:&-Y5D;7NJXZUCJHQ#4
MF6V8G <R.+%J*(>"KR'6M^&A7A36=(W)3&N>!PFHX6=[Q1J).M!25WJP]/XM
M3?)P53BHI+$+)2V(M+L@>T'W;+T$_6M,,,1_X "K)_2W,@.NS4'F)$Z74X0<
MB0O2-@M9J;JRTR :-9!A-Q#G7KXU8N=J[?DQ"<P^_$XV-PM:!++C\$;:]^*E
M,^#IF^/EPQ][%>!E_^ )W1L'4S!IL8D3// @1.?0$R5P M_,1K49=^B XJKJ
M'9M#)XR/ERK. -JJNG?XVKC[31_W!-KA=J"Q[)"!.]4'H=^6VNCG$@EF><C5
M@/MFT)0/=:HFFHE6AI?X!W'.$L!R6W7^\0:@6$?QIUAV9P#ZQGD%O57G#P0E
MMUGZQ\"2AX^2_V( :O JFX$3/C:YR6.:HNZH&LOAFO+_L/TLN+T-8&(]4$_\
MM@*^6?# "#0-Q;WBGP%?3XV4A_<EWOZ';31W(="YMC[ZQS28QN YE^\F'Q&B
M?X<#UH&ACG#SPCDQ>"F\REMUY!;J".7B\YE^O?!TUXCMF70^O,?H[[+)F_V(
M!9YL^/DR^B'VPZ#3W%-DX<&K]CWM9MTK<WN2+35[)=2&_32FNX_FZ (GNW<S
MX4^7DG=(:R[.9V%RX9CJ67SE_&-V;^OW>\5WHPK_X[F^][NU]&W.VU&6+4+R
MS6&2F>7<-]&-TXS,WAY,9$Y)";#$>M'"1;\*_IEK80%S3)OHZH8.K_[4>PA<
MQ8[U7%.5'&Q]MAFKKRU:]+FHLN08.Z_QEZTG(Z]=BS1@ZR#,(,$"D1UH3/"M
M0.JC>N>H'U6^X/-\&H!QPTG7Y&H2Z\:B_M.J$T'>.YMR-^JO&,DX*5T]W0%8
M]AJ@23:W![0JRY+:I=2;$]=?TWK@BHBTX"\N:^?O5JRZ,M:"I9><]%;F8O!:
M]_C<@_G-UE) %\G_7:Q3<$GN*N6TC@4KKZ-?A'C>==,E6>!3F:A,\Y'L!K^'
MYTMFQI.7+Z3%7>JAL:(<-BO+S)%90\WL=OB\01P4IB]P=/TGUC$]EQ\@2[T_
M"+*__8BG/2DH.1E5M[S@& GZC]Q:S$?L%K&%'!9FMUH>AS__U2%$_ E7]9[.
MW$9/THR<C3.,>+215(_:)>K6B_F/D.A1OV;=VDW.=ZY["O?=[3F*B8*/RPJN
M9Q+EX75)+A4B2TT;\D;K?W#K#J5YTES#C?H%2?+)QD0NI(X/S\E5*+QXE-?3
MAB&F>YVPZQ=)H:F>0)I]@0+974H.CH);E_$(%&HP/^[/L]7/2^XFK=#)6LA(
MJ=SE=*AK8DSNZ,'J?TT3K\XX4E-F0FW#EMQ90:_YZ(N'M?>;@\G>U0)*JAMK
MNH>?@I+$OQKF"2])QOK9<[]PB6FF^:CRP(DHUYM&:\CU36 2I:E\_DL6#>$I
MK$_^ ^NDJD8S/=B;:4TXK^SL4MX:VKN8>U=,LI80/5^-=Z;S(GB=]_2^Z-/L
M[<]='9_7S55D12T#:'89?^KN<E<Y#2F9V?*F\3&&F1-E%+^W-1$C3NEKU=,N
M+_-=+'MDVR7[K*E:PCE^/6QPKQE0R(%%2F<_:K#3%WA'-J<'R6:<#E(/I/OU
ML,C#;ND^!T=S;540ZSNE75Q[&<V^A.[J/KK5J5LLO\+(1V@<+:U#YBN9MP40
MIE.EVQ;>F[?X9(MSRHB$:9W+[HM #;S5L-DE:$2J@F5?IY,2>KS_@C61I/K@
M%^"MH3!Y2#K1I;0L(AV:KB7[K,*X-B1[<3W\:9^S]8^6#4**=V;!LC%W:F:B
M6SSG,3\JZ[N$"3?*O7P]18F;YKK>[WM5O51)#$ED$1P@^YW.4PV>KQ>OV)79
M7_2-E#_4W/.V.,LP/C-DHNC3_O K!)Y^U[C(0\ BI&X.,(O0#?]&4.+:S_OZ
M>0.L)BO^YNG\N@Y%TZ6#DV(ITO!+8\(!4TG#NIE=0UION2#BL]*T8L%=5251
M/2V?8T<7$59=4OLGGS8VR8=;-N7(:QP^!^C^5&& '%>*G+1]$AKH71**,E0N
M$=LEX,;M];V1'],[F2RWO3K]8<TI!2O2?%1AL5AV]BBZ\_'/[9SD8H$2M[+-
MZVJ?%?W**^@JA4]\4RY1PXD-[CV[U6<[=Y^[)'?[E?0-2^I1$^^^*T-ZB@/?
MCV<\S+BH\MIN;2XM<<,Q#G[J"NA-5?+)1QH\X6),]_750<[>0)4RU>7%=8J$
M*W_Y^KTH!^:05D$/W>X$'@S[Y/RX-/K86,0QBDD.E_E]:DC6SW !\K(WSFZW
MK)(X/M\T^?J>B,9DLS_-]L%I:/YT:7F0!\&6++6SW^!,Y"&&)FRXK\PAXPM;
M*2*!\2E)<EC]D1I6:"J_3ERQ0-_5O [G6?M?K/-B,0\_6]U]O"WC:4DD]JP^
M;$TQTP'_4'4VRMI0SN!+DF5%^?5+#C\HFKY75X*A48X!,K&15[@J<I(9_M3#
MZCZS?\]S"2M,FUJ^%;<H_O J\^3O[?0QH97?I@42]57SQ8O;HX=&'C":G &"
MFR5^(:%Y4(-^"X"#+$8-)[(HV)!SW$;=D:,CZNV08,C5D$FI-K"@9YM%!#$'
M[G[LRY^5N4RI,W\Y4-RQM@77R$9D]\;PX\'3L%&VLG7^ZQ/)QK7AO:\$]%(K
M81EA[*&;G@^B7F 8'^#CEN<#NDK4K#('IUL*F-=#[^?<V@PKP*$N-)$L4<@:
M/@-,3PMXN-YG2$LZ"8LLQZK'@(DXG36+@'GYL13Z")9+7O2>I/4\0Q?MU$OF
M0Z4EVF4]ZX "HVFY,"U?E-P,-J!@FVIH>"@K].;IZQH>,[\N;H_EA/CCJ^UU
M):_74I)$7C]^/-%8.-XU2Q>8F+D<-21#7A),-?2$M RWN]7$&8G8S?6*J[04
M_]QMQTDU.<5S&+6V!A^._#8=AO!-P3/O>3:VW>IM@?7H?C7E:,R]GN08E%2T
M%I<+HFBH6G[H'2>1'*P]@HPFC&\\531]CAD\!H\XAH:%6K'=G/3^<8_,L*GV
M?E.&=QBVO]),B$+S),3F?'F7YMYA71=*,JQ_HB&,Z1+$?#K_Z[F6?%]_.:LM
M ]]P@U,>MX;)X-&L/,-VRB61&B$?QH%\"Y@K4VFU0R>A15 9[NVH,^#!ER]%
MI1%Y'V?O6\)+OWXU-Y^BP3GI5$O6K$IZ%'0G=\\7\BF[!5=*@G5[*=<1BY4S
MV;J;]!.^\XTG6BO/GSV74L-N0=ZYKJ/D."].0B#_<8WA9924>/6EM,('5%F.
M&6? U_&YKJ&W>.6\^'[:)C@^HE/IR8^4W@3$*;/5^U&$6ZX[2"UVG;R0>/6I
M5:M"-+OON:J( ;<A@@M)]W;*ES,KT.[!+06[U9MW G[25#[&7&,(N'&9Q,NB
M+I*V)2;,(I RV:5%[YVO;DS  D:7@D2U]DLCYK)$Y:K 0\MM2W<W>7>LQUXN
MD5+ ]*=RQ=;JG^YMMT8R;W 3NA*+$' [-RS)GUIA3IPP<)'WL7+,EF1;AK%J
MX]BVTVQXJHG0OUICYQSN%=G-?CI8%+IV[9;T/';QX<_(PC'\87M.VA;Y]!9D
M2.N^]_&VUDQ?ZUZ(4)'>HT=M5U\+MIBS=1 [N?- (\F HD6XE7>\S5O;_%\^
M@7K[9LS"%%J,22367YPG;>^.=(Z:FM+<-4B[6D$JBTN31#+[ #6F9D$_)$CW
M()VO\4&&$M$DHM^<3O[7]'"&ZG5K^1_%C]S-W[83WES#&VDX3F.&C/ORK-LF
MM6\]@E'J33W.TQ3^=O3S.5^WRLZA.<P"1C/[-DJU5I:8@DY89.:)KRA[(7'>
MYA#<?&1,Z<Y:>SOCHX#Z%FH7,\*!6!&&S8S2C8$( >R?MIEZ^1_(U<:84DQ&
MZFQ["_ ./5KU.ZKZS1.$TU[T#W<)SVZ7U>>_.'G6ZF@O73\]'#6A[Q&W:F?+
M47AM229*6G)SFVA+D/<,\.C!/ UNVZ$LO%* _=6=D)IU6(T=9S%,]R0M271G
M76-9W^+#AX#\SM0.\7X+6V3ZDE0+\0R%AI/3.T;'9;7;GXL7G08+$BW+%+ "
M[YK?H;"D;PW#8(C<[92!YPK,?AYIM;2%859&M-I1$\U@1%>^7A E(K$&RJ\'
MK#/!OCC:TJBS%;\;*HME,68@4*"6R_0D*[:*'%HJOS*N=*GO6O^$E?,5A_Q8
M:AQYS3:+7"JYX/&?*ZDU6-(PLM?4]5D=WXDP'994@/HFUE:X_E'=%TN'\C>F
M-),%L[*Q<XQQ!'5KK7&,OXH71%+PX9/$%=O/BC_!JL%*X@OY!#/IGFIEW]'.
M=!0[LUJQDI*$I-8=HZEKGA@, )C%G9!I14ZQ%SO/O_HUMO?#)S2+NM4.X;Z[
MG\W\$X7,;+;D",@59],6"_G&J&9020^WUY;0]N6#L:2C?TX==?&.2E]?D06C
MKR2F!"B9?)!!AM'7FC;(/Z#=R^] P;\PRZ=HD!U9]CZB4H*:A@@N&GG"A=6_
M1P+S)O.+\4G5_;'GJZ\Z_FQ0&(,GA#AI]XUSGK(DD<TLWPA'2:O_''8+B8HP
MX>'#,J_5SOS8S@JFFF7[+ZQ=F#=M6T.<O% N&%[(IK)]&(S*FF3O>X61[N-C
MZ/>M.(HG8RUN>SA904W7XDF<(JW#48&Z!E]&3%@)OJXTD3:QR8D]CTT:9ZBE
MLBT-H;X51J%_:^3*^[7'*A0%LU@TETF$<U9K]')D'.<5VVX2G %NC,H=:ME/
M&D]F+ ^^3/3[<G'Z9W"^V6NM2VQ/T/W*>YJX[R_6H)&XMPO,NZNV)UI,2CLS
M;BBX]71$U[#HF>'?-+[;BR-YK%7<;#:ZK+,/F^WD/33)P8N\Q;;:Q4T&2&XN
M+FLV34EHX'J2>NR7A-[>>R%H\63I82R3\VHP4(6BN<<^\LA(?, QW6[SK6"(
MY'B08Y<0T0:;_8&LK?[]%QSJ25/RX_(#*P=W/^G2E*WQE40VY(W0NBTAU:-.
M7T=-?N3!^:;&6RU=3_,+SF:1],4=YFXK6F%_D\@ZG:3".1)9IRKAF7*I\H0Q
M8J+)9J\M<E"^UR=US)0MY^2>\R__P2C<BH_B'$^1)M;>J3=L(Y^]@-"<Y#U;
M3=E\C]E*K@AZ426)/J%K@C 8V[4[QX^9]MUNFFDQ%*IY]5TY\%<+_2YKJRDL
MIMUU.27L)><HI%N]$U#(7=Q<W-O[!&PKR7_F9B;2*M9[D5F%J*P=V7OMOGJG
M:182)R(AL40 N!KUQ@WMLC!4&_94V]K)MWAO/L064<"Z["!WRU>4^<>M8);5
M-9)HWG=,"6J$Y*$>% :^3M)@51HWT;2'U,<)<W-]GQ7-UUH:0RK='LBP*Q Q
MW'D\D;_<736I^61.YD8!SPN>%Y*I[X?'4[H1W83M$:0":H);W$ ]7:,OQ]!"
MD7+6Z>>IW8_AC)<CUL6YZ<?IQW-)/>SX'(H>&1\6SK\RJ'E$[L2+)U8Y/4">
MZ%A@?5W=4Z,]R=A<7AV8H0O&=6!%# ^,?#^<X8E0E%>3-.$F454$BC\M1L"F
M;@?NB?D>8N&$?)[N8ZAHG=;[*3"V,Y"7SUN/=P8DJ3%Z'JU"H*$Z*;@_T/_C
MCXX,3K09\YZW1 >>Q1OGQO$G\^([-^7IWQ8XY;TYCMBHB)X+<&MQ"\,&[ L#
MHSPZ5ODC92^3FI9SYK8X?45\U[+LS1OO97[A_BC\\V$+E(MMD)FQ;(VD".>-
M_16VH</K<3"7IC4^O T<'O\89M3AC7[+O8 NCVB*5XV2ZHU>:CCY81]L7&UL
M7&=1:[Q3"W;BO\SIK9_J\Y-^>[T7^"A(55AZ=A;3,O-TJ$L"0?4]$#4W/FQC
ME<%.U$3*B2O NWP]Q[ILF>VE>@D]J[O?8C5U\>I[-9R _M?T>S'J,LSQ-&N3
MLJ,KPY(UR#.@Z$[@K^'WB9']@I@C4#Z7ULYNA&I+MERA-8_=B*C%:[$0%OEN
M7*R0\,84T0^33V[;Z?WL;A<-"\H K&4FOW+SQU.]5/O0E4V9!JQ.,SOGG/CE
MW>+^:DY#EUK 6>A17/.TYUM!\ZLXO FLW999,3B1%DT/]JK@N$CZASG#-C*.
MVZ.1T2,93V&;L 'M_L>&@D-$70M;N/$WL+L<$90G[ 3MZRM.U10GS1Y#E,XA
M_@K7/CICRA:WE9HQ1=B"/-'U8:2ZZ,ZI];NKLKAP4-6(*8$6.B[ 6$<?*'+S
ME7%<E/+7*?I8K>>;7>M(^ECUHI_SQ97E\4S-=>L<3CCX^ZWY]TZSW)B"U06I
M2!5ITT+>)Q=.2U'AIPYWI'JLSQPSQZT9KFY,PX#0CZ_6E[41126;60TW:R)\
M4M6*VF:>?;W,3>ENXCQQ^\OD)O:H#@G?X=.6:Z_)S63N=VN6<"(/G;7F^KFR
MS&&WZ1F"I(H_!3!D A20L \L$'TN0GST:X6R,-/0MELWIH6_8=Z=\7FH9;PB
MG#ZZMQ^VT=+UN;JI_,F/I,0PZ1,V[$WBS$]WNWR3" _Q*T)F,$><P2J,>^G+
M/0MO.XS;*Z&K2?7S6;6 U:,#+^IH(O6)\F'SUT\&30[O1D'?N!MY/4Z/;KJ2
ML31R6J"[>27.N.1NT6? \4=ZJ^2,MFU<J:NE-WG+_<3+]Q_Z\OJ7JUHG;!MN
M<TXGM?2+:6NQ'<J/=&"= 9<?:C$LE6"X00FE[S1?U\#6]:/Q;V-3H,7?]@J7
M&=/3GTW7%DU\]+5:2\NY37PZJ:08]#X!W[_V+SA78)>^PI;\)#BI6M&L45V=
MM.>6-+G_;?1:/7V[[XWTU"A??I=$*WO]N2$D'S]3RM,D2L_6.EGKV?YHB\MF
MXN&VM)]EH_EA<]7M38PF11":??)0>V>!#QWNER7;S$2TZX6AH:K7BGVPOV[G
M97>+C+'$,4;J[G;U8UENI%QZ-$$B9Y]53$HBR!0E&P$YKB?PY4F2W.4EN?3H
M6UR=6_H/B2XL:XY]0!%W9NV7<\CV3MYDP1+[[6T'FMG7I+(%Q&N56)?EBM,3
MC?JRDD32*W#D1YRN4/EF87AAA/D2  CZP,F*)#[BCXG: 1DP<YG00&H8A27A
MP,^@G;Q\[18)R>VVX"6Q&#8*4=[WEL7#';P2KU,YC/8@E&$67ZV^??J1RZKA
M)(UE&JCBV:E=5>F=$_+YCF)K=C!3*'P]%G@>@X&?F:!O"^ DCOO+6T'RDZ60
M:7V%O6*)>N)%U1Q!'ZIXS:7;;D :& +7U8P/M-F5):>.E%Y'JD7Y<<"=6CW5
M_+[/NU.V$./F/Z;5WE]U-O2<J$O$E!VL^>6/I%A*V\H7*[PJYYV>Z!TJ*<+9
M;GM\#^] [$O%\W4/R9'-;I4^( $5:@9C.BF[3OS=UNE6U+4W&$)V+?UWE,Q@
MN#>>"]RI4GY;'JT>-B'X1:_%1'G53XPVW5)$F&T^6;$I6:.ZXE@^SG8"%J$D
MU(XS1]FPV#HN(0$KS#&L2Z1[C[QJ0Q,H$PX)E-@>. /ZK2 IQ1L_WRPIDPR/
MSPRWWZI^_9&G0-Z^HN&U"<$^X</59WQ[^:HK<)O!2S57U[>VP[E;>$+VMD7W
M6VNUHK]6E8124\<0A2*<&JCBGUZ)O^DTC[4UM&3UYNMP:6W5/?)VMFPU"FFZ
M+;(7*66C$7@46#W8ZP>R*XQE"K:[,,.,L">O]9%V#Z3BL-:%L8A)F/L(PI:;
MKNC#<)8,5;"K+C-.6/+>YZ7 )'N^_7R%;@$7-^GE[.U<;]+[KP6O,46JV=+@
MX]"7.\ ;/W 6>PH$#RN:1 FH^8T/\]U0[\$77*]?',BB98%(HC,T](\O,8,O
MLC3TAZTH^K>>P8!#%H&%L!I.>>!KXZNP$-$W,=#L@L]\9'?7U5Y'/R^TX6$1
MS=8=;-OY[G>@D]P;#"S3-RUPK'$VO^RTLC6QHE4RG7GL]R)Y"NH=YJBO'QA
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ML[P1KW/F^PH\_%S_Z]B_4$L#!!0    ( $@Q;U/6E<TP*54  ")@   9
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M!A0V:6GI $!*2_%7M->-Z.@@>53%7S&$+[UN$KY,"& 3Q@X "83Q&DFR% (
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MPH'9R%J=A#!8C,,PS -TEQ 5.O3W &TB0&1KP:Q0&LZ[V+^1ZB)+H^8;67&
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M<6-Z\L_W #G!S[4 49GWS.X55W,3A!@#Z>U1UL_\(MJ_F;/)@Z'+_:XMBD$
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M2;#P\?&)"(FHB(FI^._1W>/___Q!?P?(;F!)7-/'QKH/7"/#PB;#0K<"$ #
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MRG\^9ABQD&+#JLD%!VA@NRB'>;)EXIJ':Q=>/8/B'%'G+P;1JK5!*>*!;I4
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MKX^=NY/PP4F$_[W!GR9#\L.W>D45\R1%]?^E0?CO$]S!?//<&FWB<.0&>+O
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M?L"H(][VT0:KJ?,^:FY7==?++13V*UU3QNCCB3((?TSEJI ATWJ2 FXK]U>
M'KBW0@[CT%&XN-.5 5T3=U32^-= ;3453$N-#;2Q-$!>R=XX]*(',?S8!BP'
M<!22[;6NVIZ07=XU&1H&:C00D]QSN82,\&."N]9[M3A$D4^X2B/6 R+\*, '
M1%-G10.G7YL6H)I'FO(^BKD4$:=JW(P!PX])><[>H0'(2<9.]5$)3QWLK6J=
M9M4R:?0Q5&6I"IS]\MA4\R4:\'IW^'3W]!W9L#V,"V//NY\=B%RB ]]\ZWM8
M@6&GE6)U:<465?P0%E:>=^L=U-!,Y&>"JF3'Y40UW\0A6BM1?@L0!W$RY*;V
MXY/IS3YBT?>8_+-\I)2_+Z>2P(34BTWLDB:](TJV+5\KIX6T"X3;(,**9 C8
M?R2#?(B.79Z9+1./0%,);-Q.PURMBJ>R9X.<AV+3%N2YFNH4KU+9L-U^P _H
MHRZ'3=(S/.L[_FZD9G@V>@FBH)WG1.5G$+X14/R"3(HNZ86"8::+-Q\8GBW"
M$-2L:, %7FRCF_0.NFR9<=F&JDPSU0M!$060)K7!:4RR5.6YW>D65"?#, &-
M%S1!6^F,L6H'0HP)XP9O7#IX-BJ2(?5]R[?80!<K_98M.ZQU@/-6:\8!00T:
M\*S:PE3Q,=7*'.0C>=.7Z=[!*Q2;\A?9B8WUB'M\\MP40$+APKCEN)F5*",3
MS<]B>FR47'0 \;-W**(&XC_FVJ,*M_:VU%9X/]+<QBX9U(([8J$!KB04@O(]
M9*9 K_NP?'V6)N%$&%X5BCPTO5@&!Y B5IM..[_XLJV9GQ?SM-=MO;['2;Y&
MYU^YW/@@737J)C73\W(%:)HOX66+B=MB!H(XZGR5LXG;<5R113S^WL.#G-L@
MU3EG_$&>@KGP'M)*/H+B3-C=\56AEVUC-N\@G2MV6^0C>.V3+)RCH).B*;F:
M8K)Q&;S@?(ZG *>!_N'/#;JA]:*H"ZT,"^?"QWLY:D([:."7-!AI,]V?P,W.
M#%$ORS0O"V%_!*C8!"?;E9KN2Z=E&MA6*_2HO56_;PZYJ->+]J <?]/:_LV1
M.[Q((X'3S8/&+C_5KG+(3#@%)C@L0V-"\R^[IP/-W*T%?L _ :^'QY1:1.WH
MO4R!4_HRG.@A63>EP]A*V8Y>Q31NY.4Z?[-[N=($NK]E1@?4 BJA7<]FGQ0E
M*]RT ]DPL@I0P+N<9>VU:)IE8F9FSRTICU8!LQ>@9&SR0E5<Z/WT>V%50\<L
M5_]]D61UH'_F[EI!L<N3"JSAK4.9*NT?2='3]>>OD]C, Z8T(E&OUPHJW9YH
MRI!JU:RXG0TWPW8@?3D4"S*DW? 7*(\-$_HSCWP'7Z,[O' F_F^XEHPCGJ4"
MI;9[M9Q93Z-?^">@=-:LA0I4R%YX2NP),AIH:8$P)PA6!17X)>.T$XS"(7+Y
M\ $M6'=U_0:TT?8P%X5 ;G6=7\)7)=! >;89Z-FSA^'KH$DF0/8^'>V>$T!7
M#&?=,^:@:0Q7)<2T%-E\F7$K=%_DI> <Z8;6#/-17'=1=!!<?#Z817H!N36,
MM%2U%7F=FI:P4G@J[T<=H#^:/SUS+(GTH!J,#?<C?Y4Q?6GWO> 4:A"N'>*5
MRO01MA-8D8EIF^5E$H/;I11?]C;R+VCP-0^8/.3%1P.=GM!3-5_[@$G$]/ 9
M&F!<Y^^?]^_0E*=<30_2!A&9\3ANA\;,)^GM'Y**TGK0^Z?G8X':%P6'Q:3D
M\,X6D8OWEP[BC:6$2*IS"&\82K!!T0KZ#2YN5'H*6U/+*PE.]=2[:"JF-@J8
M&TM1G02C3 L$1.@Z/,UI[ Z&:!+C#?W'&".I#*(Z!0PL3F62JG]5P1ACDJMS
M!LE:6]>S1< -KA9Y#/O&/GJ\UD68@-K=4L L!J9(M:8[J,J<S 345#!A9,,6
M?X4[*8+DX=D85<9\S\ <,=+V/#T.Q*FVQ47%)D)@\ZFF/$60 X@[K\5P8EM+
MFU.+I@9?1K#M@<$AZ?DJ"$LQF_W!YH]PK(_4L)V,OCCVRV'$D);>8(8D#T8;
MN=UP=Y1[?#Q 7@-E1VXU[CDC7UITG$8=ED*E. <D:4$)E-# ++2O_N?X&>?(
MT=>F):A<7G88YUJ4-^B<@([].\B7I="M]W".@R!M6P34X#B*S"UG)NK<?*Z[
M/NE,WF\"ULS8UALH&J8"=SO.7X'6P,6)!<>_^-R/S9B&I@G&HQ:0ZQ@,!M*!
M?!N?.?$.A&_WM\,OBXN$I49P^9C8/V'Y7Z//*YD1QZ\"!PS''5:8-7Y+WP-M
M1&'JLN7_!D4)]LL6Q# MSA[?V= 0S988[J \!:"G[)AK8+(^UC[*&+L1)$)Z
M$I7,U5,M;2)N5BJV:_2K6+2R</NWP>0LK;<JFUZR8&LX5A]^_R=( F R5G%Q
MXTMN>C?[_0->AM&6QNTS:N+?WI*ZQ+:;!J-]GUZR*%F8\N4](W><72N"!')*
M:F 'L68*SA>OPSELK>GQD1O-*1<=AYG7)^=FH E^(F^@R]@6:,!(#Z$7X>2\
M"^EK2 +-#JL,#91P(HNZ>IM"(=JCW4WO>.7L03^$<_(CC"V3Q*T=<@#4HP'7
M^EJ*;3I(=X/B/P\:J*NB/J \CJCU]C(*%U:;VDR"JZJSD(7-,+# %CF-6E,G
MFIL%C20TD4WW")H@R@X6+*NH?>2&'*97AK;Q%HY#V3+DF\/PK9WQCV>/XTH4
M8V'=5ZV^U8P.!.1A(AQ[51S<C>#1M8^LTX+GEADOAK%_(A7P]XE^0;XWC957
M9<@A=)/>=C'<2\*)B@&CXY5D&.C=^ MZ<G;@LCS#H%)$,*LJK!Y#T]SI%K>E
M0P]R,%VT*2,H=Z?G'M TP!</U!$QW@ :$)_Y B6"=]*09J$\:DT9WZ*X&O2/
MX^$AD$<4FO+FMI3O%DT1.-/P.D./=XO:$2SSH"<S&$3=OU^Z-Y>UUDDRV(PL
MG,*HX6;5X"&D+ZWF/*,/$T*%P=UJ5IQ#NI.X+Y<00T[.VH@!+$R[0O"F0BWN
MPUW]"W W'CF9L1XU_##?EEM(:E_:A:8(B/;@$@C*YW#/-%.6 %4"MNQH8GB-
M0Q]2 W_L#1ZR'%6Y'G5*[#,7AD\ST,QX:H$8STF$T]-1)^U11V"FC\,(*N$&
M]T:YIV!LHC1'VML)HQ*U@H&A'8S&(GK!#0U@$Z2Z0Q.\4"14@Q;]($Y+<,K-
MD!V')6B@&4.#HS8=?O;"7S7 5#E1 D?B*FS9C=ZGH&O*)(H" U7G_5U4K<A!
M*>ND)[B:;\=;^#*9%VAO*0B]N)WG 4N(\;IX)+FDT?C2VR&,C<IB"A=KC#WD
M76W*Z$ A 3R5?,S1%"1B=O6QMJD>S$H&]WXQMB;JX^U"EAU^Y8#8G:4U]U>V
MB@W<_PO,\]9S;2:A#0D@QL^C0/_1+747$T#M:'>2S7R<6^^JYSD&P3H=(CDP
M2/"$WE2F26O$A]PKN5*)QS$5Y-0[0R "#7A'IQA>%!SD1RMJJD]C;%<PUC=U
M7+];$/-+.E!X6\1V4B9<4XGH^PN!37L^X_P4Z=A&>MOK>P1%%-5D@JR\K!]R
M#Z?- .@M&;KXJD,9BEZBF!UJXTV%P/AF8[UWDU9E,3RK^DP!"LK<J!>_WD;F
MT&,AO$]*GFA<"WN1)1O38[%7$ +;1<4#DR=PT/JN=:!J2@]*:2<SYBXY)R3Y
M0'=)RWN^W-1=GSIUYG(L951T%GLD_"D[; _V'.,N5Y$@O.\2-IUR]L3MA!U#
MJ."=N+N7W8<4.I/2\*'&8 [4K6-)R7'0S1F\R+%' _"C@NNFNZB$38:G!)HJ
ME/"F<^U7I:=H0 68VLM AC*B ??Q?-:94L&]3,A4S$+Y0?KHAMVIPYH;; D9
ME=D#?7E(+T^AE^R+A0F& ?RP&KN7JX%,H%=]8WIZYWS,MAA&!I)R?*+:Y_[O
MI[;TO_-BYCZO9]UC7/=OY#P;.KZIJ?X#LXT<PLO=H6\D+NQ^6@OPAG.M!9?3
M)A5@%\EWQ6%#$6,KS\XL4#(# :2'Q=T(.L5]J\W^+SE(MO.[X%G?DOD"O07O
MO+]T.3G]3VTL:O].(24\E%<NR/0;NYT&S^!A8'R-Z6Y@ A@4B;/30E"G&PIW
M+N;R /X*00B"N/ELE(X77'1@X#O-"-7SX^VGYO!@7CE_D?V<35])$'9J43O#
M1<O]A<_D*;2P2J^P!E\6A&YE')<^^A.)6&/MZE!/";]_@YXR[$J\W*L2@[G(
M,!_"2S0P%'=5!C%BHB ]*.33Q@+$^#79)? PYKRA*)DRL[4XY-;_!FO;)F6+
MI B<&?@X"TIG1=0H )RW8;I@/F9QM8E"J5=P)$3O @WD"7Z^VH+1P?]\E$E,
M"A*@SAXKU#Y*H2$,6FL"7?C>M!>K_ZS\D&&VO>$5^ 37$:FS[C=ANI?QZ9PM
MNSYGB$#A(C\19*GY>(E(6300G59]\:9FV#BC%2 I<(Z+BCXI$?T,!Y?[]!T-
MU+4B4IWWE_EC<S%FS!X.K+L9V[!-JABH -?%DSGMYQXZI-V=E7]!E,%SGR^:
MQ(@-Z]OM-=&C3*(P38-O^6&"ZY+K)4,KNI[52?:4$_?#E])S2J5'X]FPY$6U
MY44UKHV7>YNB9(1-C[O@"=Z]?B(8]H1E!7J=)-#KI,!)I N*$N#D)F]F*#1-
M\+=#*#1EZ.;"H<M87J@5']> 09.<)0@",$8#M29&&>YZ U:F/P(+0I/1 *4O
MN7:(<"KGB&39CW@M DT9VEER4-)E^$[R4>M%Y:K)K;];(Q>5A[4%^RC% :N,
M[XA(T")[I8!\Y5-B:4S$^GX( ]_K;&&]=#/=TG]5@01I&R-1Q@[O\9?N?X<"
M!DD/^[AY[55,1K#6I:G V04A<L@MUS_^#07^D8QG7X]MQC11% $W03+Z+E,7
M\JYIF<P%M>VDR_I7S4'Q[/U(6%-+4M;:UJD\MY#T>H'>> 83A::RS'5;6],#
MVN#]+^<# TW+(GA+_V[EC_^3E8^#5BX,W0+#_/J_-TL5N5!B&-[WX2B^8MA4
MP7^/1H6=&+BW8?(2#(6(:_+'(*=#'@FM,Y" @C"9:O\_&G/&37@GR]:5+;-L
MFY3_RY:7&XIFN@/Q&7@<]A_)J0DNJ0EMI2L-8RJ"6'D+I0CJYTVST,[Q,L53
MS@Y_(5"IW$D7'0B:$S;4BC=U];Y>UJX5O#DP9ST[["!*B1T,! :@T7Y@,-PG
M1,EZHH$=FB4U,!# ESF=06/I=1G].PB@)%_GYH$)5;P*QD0Y?3L,JX>/%J,[
M7HQSO53IG&^]\6(J:),4"&3YP^Y'D/!Q@,G0P4Q6^:NG8X:)WY)ZS0+-^5Y&
MMF3TE=EF!S'I?F\?A6K"2%'=*)V;!01 '/R"$Z%7AO%E_\%B]?Z[Q;Z"=DOK
M((N&,8[^_N7<1<)*UZE\ *X.F#MZZQ> 0C^ G^@=%."A 2LXQUOM$-_0#RJ0
MRP1DH1P:^-J4H, ^@M6TH-!7"P'\"S)+56%U)A8+, 1)&VJC5!U69RJ1#(<L
M!^#J(TD_;() 'QX@P/"MC=B EL>D0ONT%JWD>Z2=#8ICY5Y7T]EZ)Z$4J.'3
MH&%7'GN;SBL.(/SU]O,VH1@QM7:O-F'%[4ZW='HUG/;LH@BAS6Z+/5 O<&72
M;ZHY23&)3_4YS71I3.E_N)G(3&-9@LP4?VL'$X%7.]"98ELT0$:F-Q\8FIZ#
MS%DQ[4YK J7[+'21G69JXA^]C09^EZXHH %0"?F#,B1S&,7#Y9YO:1"17%ZW
M'HL,1@/W:J T_\:KAC#)#ICG>?A_/.8"EY410BV42NR+M5</0&8BFPR.%"_>
MU&^U00[ ;*'J3UY%-_^S*<C2^4H\M:L5E94Q$*A# Q.FW5=GK*6E<2UI'EF$
MT N81[DK-6%2G+.C4ID]+^1+,*QZ@P3S4,!TOE1[J!L-A%^2)((4-UUJ/CN,
M#9NU%7* _PWDY&H@)S_=/]4[*-7;)Z61G[MT=5XQ49O\Q[G+8Z1[,G2U ?D'
MXR4^]Y.NMF2',8',837 WMNQ?-&0!T!$/019$B,FY<'<1"3^GRG/?-/_D?)P
MGP5Y;E8AL2_*1_S&&4Q!+1>5GH&F>D\5?KX*3W-I;\S!1NW>6G5IZHC^4_#D
M#LEYTCR*A#'7"$$-V\QKWXSY)7PJ+.BW<_GD&9DTU.^02[YY6+-VD>5*ZI30
MJQLT5GG/K KZ/.GWYSQ=KCVLY0'<]B8BW!]VY'VT-M4C3%4P;N$=&8GSF,C&
MXUZ=HE[U"\V)DYZ/+!-I=7TNZ96Z00R?6BWAXMX1#7BK'!PO,O$EJXX@'THM
M]SIHB*/10+XJLJC=3Z_<&X,UZ'$;/,%'K'IO:=.W5F^?>=UQ4)YR/OT7F.!B
M]9ZUH&3NP'?T/C Y5KR BA^A 9 W73L$\UR#?R)"2#*<TO?6C:GAXP),\2E$
M5.^3S^MLX:-+NQ]@87]/G0*K84&'T?B]=&@#YMK@$/+/)8+K?[M$*'@[DG&S
M)VJ'%\Q>GCL_1(R%OH,O/TO"W.]]Q-SOX?QUOY>;0CL0Z%X'%A[T&%2=B!1L
M*;1WP,92Y %?R!O1P6+4%57"B%R%!N0,*P]$HQ9[1C/T%<\TCQ[*4^BRO'PZ
M>Q]TR$:@_QOKM?!^CWKH!=D9JV@4E(>]3/=].Z6(?5CPW!DVE@.2)H>M_ECZ
ML@:\-85V4,P*#>PJ<#T#&O*88AE8DV]O,3T>2NY%H- ;UC/^(Y$6.(UT06[!
M3(&V]O^,(.]&TIRC$)C+ LZK.[PH! E\BL\D4A_I%LR/PHK#+*&,*=1R,13)
ML_T(DL:"*81C@RAR+#(Q]P9>-%SP7<B:B;^O7N:9"$HF!@W4P]-\/I;NZ15N
M6,'; T-5P?C9S["'.=&815X$]@P:N(HB%[3846,-%JVF!WAU?X'*3^^O/&3Q
M;3[F!,$"DH:;8E*['&8!JG_XL>,Z5!P,.5A%"Q7/%@VY0+R>G@C])KOLWI\C
MAG?V_HLJ_4.,3/\#,7JH-9G7"%W[N+MK!$^<#3ZD'$>"7C@ZK_K2#=I7,WD>
M3GI1#_O8C@88Y.HQIIO_@..%K2 (GW?R%!I8NDWE.VVOYJCH# 40#JSFTWM0
M1H2.P8;@1O'\WLZ&<_'/(A_*[]7,U=MJ\Y$?NJ9)#8#NQB'GBM&(DGF^4";V
M:5)&:CR\5_RBDJ/BZY5;*0^M!!^8*+J/W]EU)S)#OE7 =15//3HI\0RBT XA
M+*=[TU]60,H[V"0.<$[47^49D/-%,,]P/@V,0(Q_/;,!0?04#:3_]WN"$NOZ
M,NGU4NU].#*(%W3SDKT^]A23HLY]_TH_W@^\*" 0@.0$NF<6Y 1Z@-E'=KP&
M@:_(FGHW6,C0!F*HU9$I2*V.,$2+8NJR[C;614'Q_^(Z[A_@I!@$,DU=Y1[]
MTR89$=8K4K2'I44@#[\F'=JSV!3!J\EN%PA30&ZXIH,"/NQCYK4W C?C;L6'
M4<(1A!!$[VW2K.+)'WL=R)>9'5DHC[K_< T0 9K:=<PU@-#?-8.ALT%*:5R?
MH8!!]5RU%$5BQ' CN,X6"";R,-,X<'9IL+F.59F3">]T(FW_9 7NK)@8I_1D
MF@HO:^N_$K(.D(&)H8'G;;X25S=Q:4U3_FN73S?^P=-[974$.&4N1I>8J#3I
M"&5?GTMCT<8(]FS#)'A^#G%-$31AC[4U:W&1-9"Q3</-%:,P\+)V0%)N^NJ;
M[F=D#8$>\K"C'A03L/0.1<F<PH^[FA)\6.V/2\GH;$]M4!\QV<?U!^#)_AV1
MZ!1H[ KQ,4K-[0!7]%V+5;#+S[V< ]4ZC=$M2-LR$-1?_D7;ZH6J4>2&7-BG
M4=K_,XV__I_2>- P;]'J'LM"$UP2)I&R4R<7QA,7Q<-[)2)79CIB!I]9]!^3
MN%PT'9<55XG#/!RFA;2D^HWK=PK')H+N1(.=P\'68'&3C2)H2%0&5ML&\"=6
M549P=(^-%GSUZ7RSL6UUZZ;737[J%[A8S?-KE>8:UX9#,'_#8C(([AWX!3H5
M2I1LO4%#2HOK?5MAL6<9S-[]?Y1R"NF]#H#I<7BF-A!/<F![4&WV( 9//C75
M-Z5Y&\5*E5C"Y!^>? )]5E,:Q/[]Q19BL.ONJL(=D-69_@F98A R6OON;U&0
M>H[OR-"L4F[8-\[9[M'")NV67OI-WH='"VH%!,>D#UX48/[T1@3)#$;B=30P
M([2Q<>K0@V22&;< $V_\4M4[-_!F(6G^)]8II046Z_QC":0?I2CQ)K-1YRCW
M@,_07=XU$R^F2)0E#(.8J&U-N ]<7*'V77S$%F)X)=J-L;?^,7PQ.PE56PHF
M*(/[[&@@+-;Y?+5IK-QA\T53<U36(57IDNJ(!S<SY8!;9$XE"!S@"'8%E[FK
M^VN\-Y9/!KD/9.9/3XN#W3":&.\:?^\!9NQ%V>-?H[)9LS,OGIC.FO9%52I>
MKB"W&)1IW.[[MNU#D*]*0(('K92_/$9NL;:2YR:KM8_A+1\7L\L79G,(=?9+
MP<!,OA!,:0)<#LP'E>4!;MLS^-7O3]9C2:$@BQ8A'?CWN^PDR$S!$T)QK(B6
MPQQ0T "X.$)=-T N]FH'\']VL+X<[79?#V1Y2VVF!W20XTZX^-'MVK>O1$K7
M3 (6LTFJ;HA=#H#YCU7AY\TU$O/AS)\&*@:. 62'S<KRS)B4)Q1$%%;;%:)L
M\GQ)@].TY:*82#]@.)Z;O"_F6KO:OG]@D^T3\8A%$>^:XM5A>!PB8Z5F_[-A
M>+W%_ 3@ Z8$A@B]6-)OG&-"""VUVX<.V!>)N]LFC\4)3OES1YB\:XOJ%RF&
M5=5*GQZ\%AQ6L2,&*9\-2L&!]S3J0.BW"QBOFHC @_DK8 78R-1,0\7WW)[,
MZ#AUU"54?&K2:OL?IF'*%*7Z\=:0R(P0Z60.Z@#E_F;U/E\#7-P_EL32I[05
M!OK>"C3@T93GXC&!E+L[9W#S(:UAP8*158 PWN4L=%Q[=7^N(^EX0$6%G?/+
M,H$*6^:U#+H(BD(..O$'5M*O,>3?\,G8E-;['L.GCC'Y=LMD-FLQW^)BX?<Z
M6+YNL-M>FQ:/V*Z7%76R>D1/:7@MEZ8]!PU R^%S.@IAP #JUPA\[<3Y8K/
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M@"LD4 :2Z[JP,A&I70,ARY$K?,>G-5))I9BIED9RJA1N.< =JAIU #A3JUK
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M\=-IXJA_96F76IWMK';+ MB^]R)6)DB7.[.3UZ=/6@#F;R_N[^17N[F6=U&
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M% "TM)10 ZBDI: %I:2EH 6EI** 'THIM** '4HI** 'BEIHIU #J4&FBEH
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M9O@8A=L./JR$.&[_$7O&@HMZ"V PH7>U9TE>.=?'8YE\4 =1S%4LA+[\>C-
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ME?W=[5+<QTP35 N>D);7E!F<)0YB>XJ/_&G@9 7^Q4:V1[[CO5Z; #T%RQ;
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M[3W>9YK@[>' UFVFR95+2K9^DL\(^ZE0QUK$.[S<(H-;['%S/DW^ZPS3GVD
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M0,=T<Z)#2IF71K+[F_N:L,Q7IIO1,R/O>(X_4XMOU+]0A:M\EFJ=I),)+K^
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M4X'( U8@FZ=W>>?FWUY$STD>1U:+CI2#5"!>L-G9/K%:WU#\O8]H?->XU?*
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MO_Y%@Q1?QID<5#FBPRM)S.KU;O@)(U?"[A# 7.1_+\5QLR6MN@+$AC)WUO>
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MK;Z091[G%2.%90=D_ O@^8\Z(6+FOP%02P,$%     @ 2#%O4\:M-P/</0
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MN,OD'561&R5#X"/%#MLZ.YFC7)1JW@_%)$989A+>3;N?V2D;H&:JHXJ61-M
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M4$L! A0#%     @ 2#%O4QAV.1T1X@  GXD*  \              ( !,*0
M &0R,S P-C5D,3!Q+FAT;5!+ 0(4 Q0    ( $@Q;U/2= E:Y <  '@I   1
M              "  6Z& 0!D,C,P,#8U9&5X,S$Q+FAT;5!+ 0(4 Q0    (
M $@Q;U,)Q853^ <  -\I   1              "  8&. 0!D,C,P,#8U9&5X
M,S$R+FAT;5!+ 0(4 Q0    ( $@Q;U.S?!UT"@0   (,   1
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M."YJ<&=02P$"% ,4    " !(,6]3D%BK!8A-  "85@  &0
M@ 'J2@( 9S(S,# V-6<Q,3 S,#<P-S4X-S$X+FIP9U!+ 0(4 Q0    ( $@Q
M;U.IKF(EDTH  ,91   9              "  :F8 @!G,C,P,#8U9S$Q,#,P
M-S W-3DQ-S$N:G!G4$L! A0#%     @ 2#%O4R'Q-N0A3@  X%8  !D
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=,S<T+FIP9U!+!08     $P 3  ,%  "I0@0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
